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ABSTRACT
Background: People with multiple sclerosis (PwMS) are less physically active 
than the general population. Moderate intensity exercise is likely to be safe and 
may provide an effective intervention for improving health outcomes for people 
with mild-to-moderate disability from MS. A robustly designed trial, using a 
pragmatic approach constructed to be cost-effective and elicit long-lasting 
behaviour change is required to influence health care practice.
Objectives:
To determine the feasibility of a pragmatic exercise intervention for PwMS and 
to determine if this type of intervention can provide a cost effective solution to 
improving health outcomes and increasing exercise and physical activity at up 
to nine months follow-up in PwMS compared with usual care alone.
Methods: We initially conducted a feasibility randomised controlled trial, 
recruiting a voluntary sample of 30 PwMS (male n = 4, female n = 26; mean age 
40 years; range 24 to 49 years; Expanded Disability Status Scale (EDSS) 0.0 to 
5.5). Results from which informed the design of a large-scale randomised 
controlled trial (RCT). A total of 120 PwMS (male n = 34, female n = 86; mean 
age 46 years; range 19 to 65 years; EDSS 1.0 to 6.5) were then recruited to a 
three month exercise intervention (two supervised and one home-based 
session for first six weeks; one supervised and two home-based session for the 
final six weeks) plus usual care or usual care alone. Cognitive behavioural 
strategies were used to promote long-term behaviour change. The primary 
outcome was self-reported exercise behaviour change (Godin Leisure Time 
Exercise Questionnaire (GLTEQ)). Secondary outcomes included clinical, 
functional and quality-of- life (MSQol-54) measures.
Results: The feasibility trial demonstrated that attrition was low (6.7% at 
immediate follow-up and 20% at three months follow-up) and compliance was 
high (>75% of all sessions). The main trial reported significant improvements in 
self-reported exercise behaviour (p = 0.01), fatigue (p < 0.0001) and many 
MSQol-54 domains (p < 0.03). Only the significant improvements in overall 
quality of life (p = 0.001), and the sub-domains of emotional wellbeing (p = 0.01) 
and social function (p = 0.004) were maintained at the nine months follow-up. 
The probability of the intervention being cost-effective was 0.75 at the threshold 
of £20,000 per quality adjusted life year (QALY).
Conclusion: This pragmatic intervention was not only feasible, but outcomes 
from the main trial suggest that it is highly likely to be cost effective, leading to 
improved self-reported exercise behaviour, fatigue and a sustained 
enhancement of health-related quality of life. This provides a strong evidence 
base to influence the prescription of exercise into the treatment pathway for 
PwMS within the NHS.
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1.0 INTRODUCTION
1.1 History
1.1.1 General History
Multiple Sclerosis (MS) is an autoimmune disease that is typically progressive 
and involves damage to the sheaths of nerve cells (demyelination) in the central 
nervous system (CNS) (Dorland and Newman, 2000). MS symptoms can be 
categorised into eleven key areas; mobility, hand function, vision, fatigue, 
cognition, bowel/bladder function, sensory, spasticity, pain, depression, and 
tremor/coordination (Kister et al., 2013), with symptoms dependant on the CNS 
pathology (Doring et al., 2012). Symptoms present themselves either in acute 
attacks or slowly progressing over time (Lavery et al., 2014). The condition was 
first defined as a unique disease by neurology professor Jean-Martin Charcot in 
1868 (Kumar et al., 2011). However, much of our early understanding of the 
disease, it’s symptoms and pathogenesis, has come from the personal diary of 
Sir Augustus d'Este (1794-1848), which formed possibly the first case study of 
MS (Landtblom et al., 2010). In the last two decades our improved 
understanding of the disease, earlier diagnosis through technological advances 
and new disease modifying medications have assisted in modifying the course 
of MS, with the life expectancy of someone with the condition now near normal 
(Asano et al., 2009). MS is the most common cause of disability in young to 
middle aged adults in the developing world (Koch-Henrikson and Sorenson, 
2010) and because of its progressive and unpredictable nature has a marked 
impact on the quality of life experienced for People with Multiple Sclerosis 
(PwMS) and their families (Benito-Leon et al., 2003; Mitchell et al., 2005). The 
high incidence rates and longitudinal nature of the condition has a substantial 
economic impact on both the health care system and PwMS and their families
(Naci et al., 2010). While treatments are now available to improve management 
of the condition, there is still no cure and the fundamental cause is still 
unknown, so symptom management and maintenance of function is crucial. In 
addition to drug treatments, therapeutic investigations such as exercise and 
rehabilitation are increasingly being recommended to better control the 
condition and assist PwMS to better self-manage their care (Jelinek and 
Hassed, 2009).
1.1.2 Exercise History
Historically, exercise has commonly been defined as “planned, structured and 
repetitive bodily movement” (Caspersen et al., 1985). However, this definition 
fails to recognise muscle activities of a static nature such as maintenance of 
posture and other activities of everyday living that expend energy. Therefore the 
following definition of exercise has been proposed by Winter and Fowler (2009) 
to encompass all types of activity, 'a potential disruption to homeostasis by 
muscle activity that is either exclusively, or in combination, concentric, eccentric 
or isometric'.
The beneficial effect of exercise on health is not a new concept and has been 
acknowledged since at least the time of Hippocrates, circa 400BC (Porter, 
1999). Research into the use of exercise as a therapy for the treatment of MS in 
comparison is relatively new, with PwMS previously advised to avoid exercise to 
conserve energy and prevent increases in body temperature that could worsen 
symptoms (Uhthoffs syndrome) (Petajan and White, 1999).
Early research focused on rehabilitation-based physiotherapy treatments (Solari 
et al., 1999) and water-based exercise (Gehlsen et al., 1984); these studies
generally had small sample sizes and lacked the robust design of a 
randomised-control trial (RCT). An early review (Ponichtera-Mulcare, 1992), 
reported that exercise 'seems to improve cardio respiratory fitness and skeletal 
muscle function' in PwMS. The first RCT to explore the possible benefits of 
exercise for PwMS was conducted by Petajan et al. (1996) and reported 
increased aerobic capacity, strength and mobility, improved bowel and bladder 
function, decreased fatigue and depression, with no increase in the number of 
exacerbations. Research in the area has since gained momentum, with the 
Cochrane review on ‘Exercise therapy for Multiple Sclerosis’ (Rietburg, 2005) 
recognising nine RCT’s of high technical quality, concluding that exercise is 
efficacious for improved outcomes in MS. However, it was recognised that 
further research of high technical quality is required. Further reviews by Heesen 
et al., (2006), Dalgas et al., (2008), Motl and Pilutti (2012), Latimer-Cheung et 
al., (2013) and Sa (2013) supported these findings and concluded that 
supervised exercise (aerobic and or strength) training is beneficial for people 
with mild-to-moderate MS. Moreover, a recent review on exercise safety for 
PwMS suggested that exercise causes no increase in relapse rate or the 
number of exercise-related adverse events reported in PwMS (Pilutti et al., 
2014), indicating it is both a safe and effective treatment strategy for this patient 
group. Current evidence suggests that exercise does more than improve 
function and better manage symptoms in MS, but may slow down the disease 
process, with some evidence to indicate a possible disease modifying effect. 
This indicates that guidance for long-term prescription is required (Dalgas and 
Stenager, 2012).
Despite the suggested benefits of exercise, PwMS are often reported to be less 
physically active than the general population (Motl et al., 2008), with symptoms
being linked to physical activity levels and partially accounted for by low 
exercise self-efficacy (Motl et al., 2006). This low physical activity can lead to 
secondary complications such as obesity, cardiovascular disease and 
osteoporosis (Petajan and White, 1999; Heesen et al., 2006; Doring et al., 
2012).
1.2 Brief overview of gaps in the literature
The current body of knowledge suggests that supervised one-to-one, facility- 
based exercise benefits people with mild to moderate disability from MS 
(Reitberg et al., 2011; Latimer-Cheung et al., 2013; Sa, 2013). However, long­
term this approach is unlikely to be convenient or cost effective for both PwMS 
and healthcare systems. To date few trials are of sufficient quality (Doring et al.,
2012) or have included: statistical power calculations to determine sample size 
(Sa, 2013), long-term follow-up (Doring et al., 2012; Latimer-Cheung et al.,
2013) or cost effectiveness analysis (Reitberg et al., 2005). In addition, further 
information is required on optimal dose (Reitberg et al., 2005; Sa, 2013) of 
exercise required and the benefits of exercise for those with greater disability 
from MS (Doring et al., 2012; Latimer-Cheung et al., 2013).
In conclusion, there is a need for more high-quality RCT’s that are statistically 
powered to show a clinically meaningful difference in outcome measures 
(Doring et al., 2012; Sa, 2013), with interventions that are MS-tailored and 
provide evidence to guide regular exercise prescription (Asano et al., 2009). 
There is also a need for more information on the exercise dose required to 
achieve optimal benefit (Reitberg et al., 2005; Sa, 2013) and a need to assess 
the efficacy of a pragmatic, tailored and cost-effective approach.
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1.3 Purpose of Thesis
The purpose of this thesis was to determine if a pragmatically designed 
exercise intervention would lead to improvements in physical activity, function 
and health in a large population of PwMS, up to nine months of follow-up and 
whether this would be a cost-effective treatment strategy when compared with 
usual care. In addition, exercise preferences and dose-response relationships, 
between physical activity and health outcomes for people with mild and more 
severe disability will be explored.
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2.0 LITERATURE REVIEW
2.1 Background
2.1.1 Disease Epidemiology
Epidemiology is a study of the prevalence and distribution of a disease
(Koutsouraki et al., 2010). MS is the most common cause of disability in young
to middle aged adults in the developed world and has undergone extensive
epidemiological research (Koch-Henrikson and Sorenson, 2010). The
prevalence of MS across the globe is variable, with differences most commonly
explained by exposure to environmental factors such as; sunlight, diet and
infectious diseases, or ethnic differences in susceptibility (Milo and Kahana,
2010). European prevalence rates published by Puglialti et al., (2006) and
Koutsouraki et al., (2010) suggested that 83 people per 100,000 have the
disease, with an incidence rate of 4.3 cases per 100,000 per annum. Higher
rates are reported in northern Europe and the female to male ratio is 2.0, with
the highest prevalence rates occurring between the ages of 35 and 64 in both
sexes and all countries. European figures show that there are nearly 700,000
people with MS across Europe (The European Multiple Sclerosis Platform,
2016), and in the UK approximately 100,000 people have the condition, with a
lifetime risk from birth estimated at about 5/1000 in women and less than half
this figure in men (Alonso et al., 2007). There has been an increased incidence
in the condition over the last 10 years (Koch-Henrickson and Sorenson, 2010
and Koutsouraki et al., 2010), thought predominantly to be caused by increased
incidence of relapsing remitting MS in women and an increased prevalence due
to patients surviving with the condition for longer (Koch-Henrikson and
Sorenson, 2010), with the women to men incidence rate reported to have
increased from 1.4 in 1955 to 2.3 in 2000 (Aivaro and Hernan, 2008).
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2.1.2 Disease Aetiology, Risk Factors and Pathogenesis
Aetiology is the study of causes of disease (Kent, 2006). Extensive research 
has been conducted in an attempt to ascertain the exact causes of MS that 
would enable population based interventions to reduce the incidence of the 
condition. Despite these efforts, precise aetiology of the condition remains 
unknown. The majority of current data is based on epidemiological studies that 
have highlighted that both genetic and environmental factors are both 
associated with the incidence of MS (Milo and Kahana, 2010).
Genetic risk can be examined in terms of familial, gender and ethnic variations
in disease prevalence. The familial risk of MS is low, with first degree relatives
having an additional lifetime risk of 2.5%, above that of the general population
irrespective of gender (Nielsen et al., 2005). Risk increases dependant on the
amount of shared genetic information, with a first degree relative reported to
have between 10 and 25 times greater risk than the general population (Wilier
et al., 2003), with monozygotic twins carrying the highest risk (Ramagopalan et
al., 2010). This increase in risk is suggested to be genetic rather than
environmental (Lindsey, 2005), with monozygotic twins having concordance
rates of 30-40% compared to only 5% in dizygotic twins (Wilier et al, 2003). In
particular, certain patterns in the major histocompatibility complex genes, which
control a large part of the immune system, such as HLA DR15 are reported to
carry the highest genetic risk (Young, 2011). Ethnic origin is also thought to be
important with some ethnic groups such as African Americans, Native
Americans, Mexicans, Puerto Ricans and Japanese having much lower risk
than Caucasians, with virtually no occurrence of the disease in people of
Chinese and Filipino origin (Ramagopalan, 2010). It is well known that MS is
more common in women than men, with the female to male ratio in Europe
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reported to be 2:1 (Puglialti et al., 2006). It is suggested that this increased risk 
is related to female differences in physiology (Ramagopalan, 2010). In addition, 
the last 10 years have seen an increase in this ratio, with Canadian research 
indicating an increase to a ratio of almost 3:1 (Orton et al., 2006), leading to 
suggestions that changing environmental factors may influence women more 
than men (Koch-Henrikson and Sorenson, 2010).
Although research has reported that genetics play a part in the development of 
MS, environmental factors are thought to play an important role in determining 
overall risk. Viral infection, lifestyle, latitude and vitamin D exposure at present 
appear to have the strongest links (Ramagopalan et al., 2010). Epidemiological 
studies have often reported a link between different viruses and the occurrence 
of MS in particular Epstein-Barr virus (EBV) (Wingerchuk, 2011; Young, 2011; 
Ramagopalan et al., 2010 and Ascherio and Munger, 2007). The majority of 
PwMS (>99%) have been infected with EBV, compared with only around 94% 
of age-matched controls. Moreover, MS risk is about 10 times less in EBV 
negative individuals and 2-3 times greater in those who develop infection later 
in life (Ascherio and Munger, 2007). However, association based on 
epidemiological data, does not necessarily mean causation and further 
clarification is required as to the role of viral infection in the aetiology of MS 
(Brahic, 2010).
It is often reported in epidemiological studies that latitude (distance from the
equator) plays an important role in MS risk, with incidence and prevalence
increasing with increasing latitude in areas of temperate climate (-1 to 21
degrees Celsius) (Ramagopalan, et al. 2010; Ascherio and Munger, 2007).
Duration and intensity of sunlight exposure has one of the strongest correlations
with latitude and thus sunlight exposure and its links to vitamin D levels are the
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most commonly sighted explanations for the latitudinal gradient in worldwide 
MS incidence rates (Young 2011; Ramagopalan etal., 2010; Ascherio and 
Munger, 2007). This link was noted in early studies with US war veterans which 
reported that average yearly sunlight exposure and winter solar radiation 
exposure at place of birth demonstrated a strong negative correlation with the 
incidence of MS (Acheson et al., 1960), indicating a protective effect of sunlight 
exposure. However, people living in the same area may share many other 
similar characteristics and thus, this explanation is not definitive. To overcome 
this bias further research has explored the risk amongst matched individuals, 
with different habitual levels of sunlight exposure, such as outdoor workers, 
reporting that working outdoors was significantly correlated with reduced MS 
mortality rates in areas of greater MS incidence (Freedman et al., 2000). For 
most people sunlight exposure is thought to be the main source of Vitamin D. 
However, dietary sources have also been reported to have an impact on the 
condition, with studies in Norway demonstrating decreased incidence rates in 
coastal communities that have greater fish consumption and hence Vitamin D in 
their diet, than inland farming communities (Kampman et al., 2008). It has even 
been hypothesised that Vitamin D may reduce the risk of EBV infection (Grant,
2010). This link has led to suggestions of possible supplementation at a 
population level in regions of high risk, in an attempt to reduce the risk of the 
condition in these areas (Ramagopalan et al., 2010; Ascherio and Mungar, 
2007).
The increase in incidence of MS in recent decades, particularly in women 
(Sellner, et al 2011) has led to an increased focus on lifestyle related risk 
factors, such as smoking and obesity that have also increased in this population 
group over the same time period. Smoking has been consistently highlighted as
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a potential modifiable risk factor for MS (Sellner et al., 2011; Romagopalan et 
al., 2010; Ascherio and Mungar 2007). Early studies have linked cigarette 
smoking to aggravation of symptoms after smoking (Perkin et al., 1975 and 
Emre et al., 1992), with further research linking smoking to both increased risk 
(Ascherio and Mungar 2007) and accelerated disease progression (Hernan et 
al., 2005). Mechanisms suggested for this increased risk include both the 
neurotoxic effect of tobacco smoking and its impact on respiratory infection 
rates which have been linked to increased relapse rates (Ascherio and Munger 
2007). The obesity epidemic has also been linked to the increased incidence of 
MS in women (Sellner et al., 2011), with analysis of the Nurse’s Health Study 
suggesting that obesity at the age of 18 (BMI > 30 kg/m2) more than doubles 
the risk of subsequent diagnosis of MS (Munger et al., 2009). The link between 
obesity and low levels of vitamin D are also currently being explored as 
potential mediating factors in increased MS risk (Sellner et al., 2011). Existing 
epidemiological data suggests that modifiable environmental factors such as 
vitamin D levels, smoking status and obesity may impact on MS risk; however 
the underlying mechanisms are still unclear.
Research has suggested that environmental factors in early years are 
particularly important in establishing risk in later life, as if an individual migrates 
after adolescence (aged 15) they are reported to maintain the risk of their 
country of origin, whereas before this age they adopt the risk of their new 
country (Koutsouraki et al., 2010). In addition, month of birth is also reported to 
be important, with babies born after a winter pregnancy reported to be at 
greater risk of developing MS in later life (Wilier et al., 2005; Bayes et al., 2009; 
Salzer et al., 2010) This risk is hypothesised to be due to lack of sunlight 
exposure (vitamin D) during pregnancy, although further research is required to
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further explore this link (Salzer et al., 2010). However, research now suggests 
that in North America and Europe latitudinal gradient may be of less 
importance, with studies needing to focus at a population level on western 
lifestyles that have changed (Koch-Henrickson and Sorenson, 2010).
Stress is often suspected to have a negative impact on the occurrence of MS 
relapses (Mohr et al., 2004), and has been proposed to provide an increased 
risk of onset of MS (Li et al., 2004). Although research to date cannot rule out 
the involvement of stress in the appearance of MS, there is no strong evidence 
to support this hypothesis (Riise et al., 2011).
The causal pathway for MS is complex and it appears that both a genetic 
susceptibility and exposure to various environmental factors, particularly in early 
life lead to the development of the abnormalities that lead to the incidence of 
MS. Further research is still required to enhance understanding of this pathway 
and thus advise public health strategies on the reduction of risk. However, 
research is still a long way from fully understanding the complex aetiology of 
MS and with incidence rates (women) still increasing, optimising strategies to 
better manage the condition are still of utmost importance.
2.1.3 Diagnosis, Symptoms and Prognosis
The diagnosis of MS is often complex and can take time to confirm as no one 
symptom is unique to MS, with other similar conditions such as neuromyelitis 
optica needing to be excluded before a definitive diagnosis can be made (Kelly 
et al., 2011). The UK National Institute for Health and Clinical Excellence 
(NICE) recommend that from the initial referral to a clinical diagnosis of MS 
should take no more than 12-weeks, six-weeks to see a consultant neurologist
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and a further six-weeks for the diagnosis (NICE, 2014). MS usually presents 
with an acute occurrence of neurological symptoms. Diagnosis is clinical and is 
supported by a range of tests to look for evidence of MS, with the clinician 
looking for evidence of two or more lesions that have occurred at different times 
and on different parts of the Central Nervous System (CNS). Clinically the 
neurologist will be required to take a detailed medical history of symptoms and 
timing, alongside a neurological examination to help determine the cause of 
symptoms and what additional tests may be useful. This clinical assessment 
can suggest MS as a possible diagnosis, but this needs to be supported by 
additional tests which may include magnetic resonance imaging (MRI), analysis 
of cerebrospinal fluid (CSF) from lumbar puncture to provide evidence of 
chronic inflammation of the CNS and evoked potential assessments to indicate 
nerve damage (Tsang and MacDonell, 2011). The use of MRI has led to the 
currently accepted McDonald criteria for diagnosis (Polman et al 2011).
MS can be categorised into three main types; relapsing remitting (RRMS), 
secondary progressive (SPMS) and primary progressive (PPMS). Despite this 
the effects can still vary greatly from person to person even in the same 
subcategory. The most common disease type at diagnosis is RRMS (85%), 
although after 10 years 40-45% of people with RRMS will have progressed to 
having SPMS (Tsang and MacDonell, 2011), whilst approximately 15% will 
experience PPMS from the outset (Wingerchuk, 2011).
People with RRMS will have periods of increased symptoms, called relapses or
exacerbations that are suggestive of an acute inflammatory demyelinating
episode in the CNS, lasting for at least 24-hours. This is followed by periods of
remission, where the individual may recover completely, or retain a mild
increase in symptoms (approximately 40% of people) (Tsang and MacDonell,
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2011). Approximately 80% of people who start with RRMS will progress to 
having SPMS over there lifetime (Tsang and MacDonell, 2011), as this occurs 
the frequency of relapses decreases, whilst disability gradually gets worse. 
Those that have PPMS from the outset will experience a gradual increase in 
disability from the start.
The progression in disability experienced during the course of MS is monitored 
clinically to assess the extent of symptoms indicative of neurological 
impairment. The Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) is 
still the most commonly used assessment measure. Other tools used clinically 
include; Guy’s Neurological Disability Scale (GNDS) (Sharrack and Hughes, 
1999) and the MS Functional Composite (MSFC) (Cutter et al., 1999). There is 
considerable variation in the rate of disability progression in people with MS. 
However, it is reported that without treatment the median duration from 
diagnosis to requiring a cane is 20 years and to needing a wheelchair is 30 
years (Brown and Kraft, 2005). The disability caused by MS also has a notable 
impact on employment, with two thirds of people with MS unemployed and 75% 
of these attributing it to their disability (Brown and Kraft, 2005).
The symptoms that an individual experiences will vary depending on the part of 
the CNS that has been damaged and can occur in many parts of the body. 
Fatigue is the most common symptom reported, affecting approximately 70% of 
PwMS (Brown and Kraft, 2005). Other symptoms include;
• Muscle symptoms such as poor balance, spasms, poor coordination, 
weakness, and tremors.
• Bowel and Bladder symptoms such as constipation, urgency and 
incontinence.
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• Eye symptoms such as double vision, discomfort and vision loss.
• Sensation symptoms such as numbness, tingling and pain.
• Other brain and nerve symptoms such as cognitive difficulties, 
depression, dizziness and hearing loss.
• Other symptoms can include sexual problems, slurred speech and 
difficulty swallowing and chewing.
2.1.4 Current Management
There is no current cure for MS, treatment focuses on managing symptoms, 
reducing the number of relapses and maintaining the best possible quality of 
life. MS treatment has three main components; disease modifying therapy 
(DMT), relapse treatment and symptom management.
2.1.4.1 Disease Modifying Therapy
Current disease modifying medications work by reducing relapse rates, 
therefore they are only useful for people with RRMS and SPMS, no current 
disease modifying therapies are available for people with PPMS. It is currently 
recommended that patients with RRMS benefit from early intervention with 
disease modifying drugs to limit the effect of the disease on disability (Brown 
and Kraft, 2005). Commonly used approved drugs are outlined in Table 2.1.
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Table 2.1. Common disease modifying drugs used for the treatment of people 
with RRMS and SPMS.
Medication Brand
Name
Mechanisms Administration Side Effects
Interferons 
Beta la  
Beta lb
Avon ex,
Rebif
Betaferon
Beta Interferon is a 
cytokine produced 
during viral infections 
and is suggested to 
work by healing the 
blood brain barrier, 
preventing cells of the 
immune system from 
entering the brain.
Regular (l-3x  
per week) 
self-injection
Flu like
symptoms and 
skin reactions 
at injection 
sites
Glatiramer
acetate
Copaxone Synthetic peptides 
made of four amino 
acids, which are basic 
models of all proteins 
in the human body and 
is suggested to work by 
changing harmful 
inflammatory cells into 
the non-inflammatory 
healing cells of the 
immune system.
Daily
injections
Injection site 
reactions
Natalizumab Tysabri Tysabri is a drug that 
blocks the passage of 
inflammatory cells of 
the immune system 
from entering the brain 
and the spinal cord.
Intravenous Long-term 
effects 
unknown. 
Occasional 
infusion 
reactions. 
3/3000 may 
suffer serious 
brain infection.
Fingolimod Gilenya,
Novartis
Causes lymphocytes to 
be retained in the 
lymph glands, 
dampening the 
immune response that 
causes nerve damage.
Daily tablet 
taken orally
Headaches, 
liver enzyme 
increase, flu, 
diarrhoea, 
back pain, 
cough, slowing 
heart rate, 
swelling in the 
eye.
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Dimethyl
fumerate
Tecfidera Activates Nrf2,
decreasing
inflammation
Oral capsule 
taken twice a 
day
Flushing,
Nausea,
heartburn,
abdominal
pain and
diarrhea.
Alemtuzimab Lemtrada Binds and kills white 
blood celles stopping 
them from entering the 
brain and attaching the 
myelin sheath
Two courses 
of infusion in 
hospital
Headaches, 
rash, nausea, 
fever and 
infections.
2.1.4.2 Relapse Treatment
The primary course of treatment during a relapse is a course of high dose 
corticosteroids, although there is no long-term evidence as to the effect of this 
treatment on prognosis (NICE, 2014).
2.1.4.3 Symptom Management
The goal of symptom management is to improve and maintain function and
preserve quality of life (Crayton and Rossman, 2006). Symptoms are often
interrelated and can be identified as primary, secondary or tertiary (Ben-
Zacharia, 2011). Primary symptoms are those directly caused by demyelination
and axonal loss, such as weakness and sensory loss; secondary symptoms are
those occurring as a result of the primary symptoms, such as bladder infections;
whilst tertiary symptoms are those related to the social and psychological
consequences of the disease such as depression. MS symptoms are varied
both between individuals and within the same individual across time, making the
need for its management a complex process that needs to be individually
tailored and multi-model using both pharmacological and non-pharmacological
therapies to ensure the best patient care.
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A variety of pharmacological therapies are used to treat the symptoms of MS 
such as, Baclofen and Tizanidine used for the treatment of spasticity and 
Gabapentine and Amitriptyline for the reduction of pain and tingling.
Non-pharmacological treatments include physiotherapy (balance, fatigue, 
walking), exercise (walking, balance, fatigue), cognitive behavioural therapy 
(depression, fatigue), functional electrical stimulation (foot drop), speech and 
language therapy (speech and swallowing problems) and occupational therapy 
(fatigue).
However, optimal treatment usually involves a combination of strategies, for 
example it is recommended that the management of fatigue may involve 
medication, exercise and the use of energy conservation techniques, whilst 
depression may be treated with a combination of psychotherapy and medication 
(Ben-Zacharia, 2011). The National institute of Clinical Excellence (NICE) is 
currently updating its guidelines for MS, with new recommendation for health 
care professionals including; ‘considering supervised exercise programmes to 
give relief from fatigue and to increase mobility (NICE, 2014). This 
recommendation is supported by MS Charities (MS Society, MS Trust, 2015), 
providing information to PwMS about the benefits of exercise.
2.1.5 Economic Impact
The cost of MS places a meaningful burden on society, with the highest costs 
primarily associated with a decreased work capacity (Kobelt and Pugliatti, 
2005). The introduction of DMT’s over the last decade has also led to an 
increase in direct costs and more intensive management of PwMS (Rotstein et 
al., 2006). A review by Rotstein et al., (2006) concluded that, costs outside the
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healthcare system surpass all other costs and that all costs increase as disease 
severity increase as measured by EDSS.
The economic impact of the condition is particularly significant as the majority of 
PwMS are of working age, costing the UK economy approximately £1.4 billion 
(McCrone et al, 2008). In a review of current literature, Adelman et al., (2013) 
reported that MS is the second most costly chronic condition after congestive 
heart failure. There is currently no cure for MS; however, disease modifying 
treatments exist that can reduce the number of relapses and slow disease 
progression (Brown and Kraft, 2005; Tsivgoulis et al., 2015). The cost 
effectiveness of these treatments in the current economic climate is being 
questioned, with some studies reporting DMT’s to meet the current threshold 
and some reporting them to be well above the acceptable level 
(Manouchehrinia and Constantinescu, 2012; Phillips, 2004). Therefore if cost 
effective treatments (pharmacological or non-pharmacological) that help 
maintain function and reduce the number of relapse can be developed, this 
would be of notable importance in reducing the economic impact of MS on both 
the health care system and people with MS and their families.
2.1.6 Impact on Physical and Mental Health - Comorbidities
MS is a neurodegenerative disease and as such can lead to PwMS 
experiencing a wide variety of physical and mental symptoms that impact on 
health outcomes. Comorbidities are common, with an increased prevalence of 
many physical and mental health conditions when compared with the general 
population (Simpson et al., 2014).
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Less than 20% of PwMS currently meet the recommended physical activity 
guidelines (Klaren et al., 2013), with more severe disability reported to be 
correlated with less physical activity (Kohn et al., 2014). Mobility and walking 
difficulties are common, with 40-50% of PwMS reported to have an EDSS score 
of 6.0 (requires a walking aid) within 15 years of disease onset (Myhr et al., 
2001), rising to 60% by 20 years (Coenen et al., 2011). Comorbidities such as 
hyperlipidaemia, hypertension, arthritis, irritable bowel syndrome, osteoporosis 
and chronic lung disease are common in PwMS (Marrie and Hanwell, 2013). 
Simpson et al., (2014) conducted a large study into comorbidities in MS, looking 
at 39 different comorbidities in 3826 PwMS, compared with over one million 
controls. This research reported inconclusive evidence on the increased 
prevalence of cardiovascular disease in PwMS when compared with controls, 
sighting constipation as having the greatest increased prevalence, followed by 
visual impairment, chronic pain, migraine and epilepsy.
Mental health problems such as depression are reported to be one of the most 
significant predictors of patient quality of life in PwMS (Wynia et al., 2008; 
Goksel Karatepe et al., 2011). Depression is often cited as the most common 
mental health condition in PwMS, with a lifetime prevalence of 50%, followed by 
anxiety with a prevalence of 36% (Marrie and Hanwell, 2013; Simpson et al 
2014). Moreover, problematic drug use has also been reported to be higher in 
PwMS (Simpson et al., 2014).
Physical inactivity is one of the leading causes of death from chronic diseases 
in the world (World Health Organisation, 2005), with physical activity having well 
documented benefits for improving mental and physical health in both the 
general population (Pedersen and Saltin, 2006), and PwMS (Giesser, 2015).
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Therefore, exercise interventions that promote long-term improvements in 
exercise and physical activity participation are required in this population group.
2.1.7 Outcome Measures
Reliable and valid clinical outcome measures are essential when determining 
the effect of an intervention. The number of outcome measures used in the 
reporting of results from MS research is vast, leaving it difficult to compare 
studies and build a consistent evidence base. Recent reviews have stated the 
need for a more consistent approach in the reporting of outcome measures for 
both pharmacological and non-pharmacological clinical trials, if they are to 
provide robust data sets that can more successfully inform future clinical 
guidelines (Cohen et al., 2012; Noble et al., 2012; Paul et al., 2014). In addition 
outcome measures are required to cover a range of symptoms and disabilities 
(Cohen et al., 2012).
Historically, the Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) has 
been used as the ‘gold standard’ measure for assessing the outcome of clinical 
trials (Brown and Kraft, 2005; Cohen et al., 2012; Uitdehaag, 2014, Bermel et 
al., 2014). The EDSS has long been popular with neurologists; however it is 
often reported to be of limited value as an outcome measure for clinical trials 
(Cohen et al., 2012; Potter et al., 2014; Uitdehaag, 2014; Bermel et al., 2014). 
The EDSS consists of a non-linear scale that is heavily reliant on walking ability 
(Bermel et al., 2014) and is not adequately responsive or sensitive to changes 
in disability from MS (Whitaker, 1995). A clinically meaningful change in EDSS 
is reported to have to be at least 2 levels (1 point) to be considered meaningful, 
this change can take time and most studies last less than a year, which will only
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show subtle differences (Brown and Kraft, 2005). However, it is recommended 
that this popular measure should be upgraded rather than replaced as a 
measure of disability to ensure its continued acceptance (Cohen et al., 2012; 
Noble et al., 2012). More recently the Multiple Sclerosis Functional Composite 
Scale (MSFC) was developed by Cutter et al., (1999) as an alternative or 
secondary measure to the EDSS (Kurtzke, 1983) (Cohen et al., 2012). 
However, it is still unclear as to whether this is a suitable replacement (Cohen et 
al., 2012). Despite the limitations of the EDSS (Kurtzke, 1983) and MSFC 
(Cutter et al., 1999) there is an obvious link between scores for both 
assessments and patient relapse rates (Goldman, Motl and Rudick, 2010), with 
both of these measures frequently used in clinical studies and considered to be 
valid despite their methodological limitations (Meyer-Mooke et al., 2014). The 
research conducted as part of this thesis collected both of these measures to 
report impact on clinical outcomes.
Since the introduction of DMT’s there has been much discussion over the most 
useful outcome measures for assessing their impact. This has led to numerous 
reviews being written looking at clinical outcomes (Amato and Portuccio, 2007; 
D’Souza et al., 2008), quality of life (Benito-Leon et al., 2003; Bandari et al.,
2012), functional (Bethoux and Bennett, 2011; Learmonth et al., 2013) and 
cognitive measures (Scherer, 2007). However, studies have often focused on 
specific symptoms of MS and do not represent the wide range of disabilities 
experienced (Potter et al., 2013). Recent reviews have recommended that there 
is a need to investigate developing a comprehensive package of assessment 
measures to cover the wide range of symptoms and disability experienced in 
MS (Cohen et al, 2012, Noble et al., 2012).
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The views outlined in clinical trials are mirrored in research on outcome 
measures for exercise and physical activity interventions, with reviews often 
highlighting poor quality outcome measures and the lack of consistency across 
trials as one of the major flaws preventing advanced statistics from being 
carried out (Rietberg et al., 2005; Asano et al 2009; Dalgas et al., 2008). At 
present research suggests that exercise is beneficial for PwMS, however the 
diversity of measures used makes it difficult to compare studies and build a 
consistent evidence base. Potter et al., (2014) reviewed 63 different outcome 
measures and looked at what measures were appropriate for different levels of 
disability from MS and in different practical settings, concluding that Patient 
Reported Outcomes (PROMS) such as the Multiple Sclerosis Quality of Life-54 
(MSQoL-54) (Vickrey et al., 1995) and Multiple Sclerosis Impact Scale (MSIS- 
29) (Hobart et al., 2001) and Time based tests such as the MSFC (Cutter et al., 
1999) (9-hole peg test, paced auditory serial addition test (PASAT) and the 25 
foot walk), as being highly recommended for people with mild-to-moderate 
disability from MS. However, this review was aimed at determining what 
measures had clinical utility and were both reliable and valid for use in a 
practical setting. The review was not specifically aimed at clinical trials. Despite 
the recommendation by the Cochrane review in 2005 (Rietberg et al., 2005) for 
a consensus on outcome measure for exercise and MS trials, it wasn’t until 
2014 that a group of international experts met to discuss this issue. The 
resultant publication (Paul et al., 2014) recommended a range of measures 
covering MS Symptoms that are most likely to be influenced by exercise. These 
included PROMS, time based tests and objective measures to provide a 
triangulation of methods as recommended by Schaffler et al., (2013). The 
assessments suggested were all easy to deliver and were already in regular
use in exercise and MS research. The PROMS assessments recommended by 
Paul et al., (2014) included measures of Quality of life (MSIS-29 (Hobart et al., 
2001) or MSQoL54 (Vickrey et al., 1993)) and fatigue (Modified Fatigue Impact 
Scale (MFIS) (Fisk et al., 1994ab) or Fatigue Severity Scale (FSS) (Krupp et al., 
1989)), timed measures for exercise tolerance (6-Minute Walk Test (6MWT) 
(ATS Committee, 2002) and muscle function (Timed Up and Go (TUG) 
(Podsiadlo and Richardson, 1991) and objective measure of body measurement 
(Body Mass Index (BMI) or Waist Hip Ratio (WH)). It was also recommended 
that these be supported by qualitative measures and assessments of cost 
benefit where possible. The research reported in this thesis followed these 
guidelines utalising MSQoL54, MFIS, 6MWT, BMI and WH, supported by a cost 
effectiveness analysis and qualitaive report.
In summary, MS is a complex condition with varying degrees of disability and 
symptoms. There are a large number of tests that are used across the research 
literature, but the tests used to measure different symptoms are not consistent 
and often focus on individual symptoms. Moreover, measures such as the 
EDSS used to assess clinical disability are not sensitive or responsive enough, 
but at present we do not have a better alternative. A recommended battery of 
core tests now exists for exercise and MS Trials (Paul et al., 2014), however 
only time will tell if this is adopted by future research in the area, enabling 
provision of the data required to inform clinical guidelines such as those 
produced by the National Institute of Clinical Excellence (NICE). Moreover, with 
a condition as varied as MS it must not be forgotten that there can be large 
variability in results from day to day. Therefore, pre-test controls are of 
particular importance to ensure that participants arrive as fresh as possible and
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that results represent a typical day. This would enhance the reliability of results 
and decrease the measurement error.
2.1.7.1 Physical Activity. Exercise Tolerance and Walking Mobility 
Definitions
Exercise, physical activity, exercise tolerance and walking mobility are all 
important measures in the assessment of exercise and physical activity based 
interventions.
• Exercise can be defined as a potential disruption to homeostasis by 
muscle activity that is either exclusively, or in combination, concentric, 
eccentric, or isometric' (Winter and Fowler, 2009). Exercise is often 
planned and structured activity designed to improve fitness and health 
(Bouchard and Shephard, 1994).
• Physical activity is often referred to as exercise that includes activities of 
daily living such as household jobs, walking the dog manual labour etc 
(Bouchard and Shephard et al., 1994).
• Exercise tolerance can be defined as ‘the point at which a participant in a 
physical activity attains the limit of acceptable effort before succumbing 
to weariness’ (Stedman and Thomas, 2011).
• Walking Mobility can be defined as ‘as the ability to independently and 
safely move oneself from one place to another’ (MS Trust, 2011)
In addition, to the core outcome measures recommended by Paul et al., (2014), 
interventions that have the primary aim of increasing exercise and or physical 
activity would benefit from more comprehensive measurement of this variable,
as it is important to determine not only has the intervention had an impact on 
MS, but also have PwMS become more active and fitter because of it. Within 
this domain it is important to not only examine physical activity, but also whether 
fitness and walking mobility have improved. Walking mobility is particularly 
important for PwMS as it is reported to be one of the ‘most visible 
manifestations’ of the condition (Bethoux and Bennett, 2011) and has a further 
impact on Quality of Life (LaRocca, 2011).
A triangulation of methods as recommended by Schafler et al., (2013) is 
suggested, to ensure that a clear picture of the impact of exercise interventions 
can be determined. Measures should include PROMS such as the International 
Physical Activity Questionnaire (IPAQ) (Craig et al., 2003) or the Godin Leisure­
time exercise Questionnaire (GLTEQ) (Godin and Shephard, 1985), alongside 
objective measures such as accelerometry and timed functional tests such as 
the 6MWT (ATS Committee, 2002) as recommended by Paul et al., (2014) to 
assess exercise tolerance and walking endurance and the 25 foot walk as 
recommended by Potter et al., (2013) to assess walking ability and speed.
Patient reported outcome measures (PROMS)
Probably the most obvious assessment to measure physical activity for PwMS 
is the Physical Activity and Disability Survey (PADS-R), which is specifically 
designed to measure physical activity in people with chronic neurological 
conditions (Kayes et al., 2009a). However, this test as yet has had limited use in 
the MS literature and does not provide results that are comparable with the 
general population. Currently the two primary measures utilised for measuring 
physical activity through self-report, are the GLTEQ and the IPAQ (Craig et al.,
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2003). Both of these measures are quick and easy to complete and there is 
strong evidence to suggest that they are both valid and reliable for assessing 
physical activity in PwMS (Motl et al., 2013; Weikert et al., 2010; Snook, Motl 
and Gliottoni, 2009; Gosney et al., 2007; Motl et al., 2006a). The GLTEQ in 
particular has shown excellent correlations with physical activity (Gosney et al., 
2007) and good test re-test reliability with PwMS (Motl et al., 2013). In addition 
to this some studies have used the 7-day PAR, which has shown excellent 
correlations with physical activity (Motl et al., 2006a). However, this is 
administered using an interview, which makes it more time consuming for both 
the researcher and the study participant. The GLTEQ and the IPAQ do not 
correlate well with walking mobility and should only be used as a physical 
activity outcome measure (Snook, Motl and Gliottoni, 2009; Motl et al., 2006a). 
In both the feasibility study and main trial reported in this thesis, home exercise 
compliance was also monitored via self-report exercise diaries that were 
reviewed weekly by the practitioner. This type of approach is simple and easy to 
administer and enables the client to benefit from self-monitoring of their 
exercise programme. However, it is noted that this method could lead to miss- 
reporting, with more objective measures such as video monitoring or 
accelerometry potentially providing more robust data.
Accelerometry
Less than 20% of PwMS are reported to meet the current physical activity
recommendations in the UK (Klaren et al 2013), with 41% of PwMS reporting to
have difficulty with walking (LaRocca, 2011). There is therefore a need for a tool
to better understand walking mobility, exercise behaviour, and the ability to
determine time spent participating in physical activity of at least a moderate
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intensity (Sandroff et al 2014). Accelerometry provides a possible solution 
enabling a more objective measurement of these variables to take place, in a 
community setting and with minimum participant burden (Motl et al., 2012). 
Moreover, accelerometry has the potential to measure walking mobility, which is 
of particular significance to PwMS, due to its ability to offer insight into both 
disability and disease progression (Pearson et al., 2004).
Research regarding the use of accelerometry as both a measure of physical 
activity and walking mobility is variable, with the use of accelerometry for 
measurement of physical activity coming under scrutiny. Kayes et al., (2009b), 
suggested that caution should be taken when using with PwMS, due to poor 
test re-test reliability at low levels of activity, whilst several researchers have 
reported it to correlate better with walking mobility than physical activity (Hale, 
Pal and Becker, 2008; Weikert et al., 2012). However, other researchers have 
suggested that it can be used to measure both variables (Snook, Motl and 
Gliottoni, 2009; Weikert et al., 2010). Its usefulness as a reliable and valid 
measure of walking mobility and exercise behaviour has gained momentum 
over recent years with many studies supporting its use (Hale, Pal and Becker, 
2008: Snook, Motl and Gliottoni, 2009; Weikert et al., 2010; Weikert et al., 2012; 
Motl et al., 2013). However, it has been indicated that there is a significant 
difference in results between different types of accelerometer, which may limit 
comparisons between studies (Coote and Dwyer, 2012). The majority of studies 
have small samples sizes and have only used a single type of accelerometer, 
so may not be able to be generalised across the MS population and when using 
different types of device. Recently Klaren et al., (2013) and Sandroff et al., 
(2014), have reported recommended activity count cut off points to take into 
account the increased energy cost of walking in this population group. The
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study by Klaren et al., (2013) used treadmill based walking, whilst the more 
recent research by Sandroff et al., (2014) had the added advantage of 
measuring in the real world and also developing different activity count cut 
points for people with different levels of disability from MS. This offers the 
potential to provide a better correlation between accelerometers and physical 
activity measures and to provide a good indication of whether PwMS are 
meeting current physical activity guidelines.
Walking assessments
The most commonly used timed walking assessments for MS are the shorter 
25ft walk or 10 metre walk (Cutter et al., 1999) and the longer two-minute or six- 
minute walk test (Butland et al., 1992). Whilst the most widely used self-report 
test is the Multiple Sclerosis Walking Test-12 (MSWT-12) (Hobart et al., 2003). 
The longer 2MWT and 6MWT have been reported to have better test retest 
reliability Feys et al., (2014) and perform better when detecting improvements 
after physical rehabilitation (Baert et al,, (2014). With the 6MWT recommended 
in reviews on outcome measures by Paul et al., (2014) and Potter et al., (2013), 
alongside the 25ft walking test and the MSWT-12, which were also 
recommended by Potter et al., (2013). However, the six-minute test is time 
consuming and tiring for the participant, current research indicates that the two- 
minute test correlates well with the six-minute test Gijbels, Eijnde and Feys 
(2011), and has recently been shown to responsive to detecting improvements 
Baert et al., (2014). This indicates that the two-minute test may be a valuable 
alternative to the more commonly used six-minute assessment in future MS and 
exercise research trials.
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Aerobic Capacity Assessments
V02max is often considered to be the best method of assessing endurance 
capacity in the general population (Stickland et al., 2012) and has been 
suggested to be feasible for use in PwMS, with a ten percent day to day 
variance (Langeskov-Christensena, 2014). However, the exertion required for 
this test can be off-putting, particularly for PwMS, where fatigue is reported as 
one of the most common symptoms (Zajicek, 2010). Exercise interventions in 
this population have therefore focused on walking based assessments (Butland 
et al., 1992) or sub-maximal protocols on cycle ergometers usually starting with 
the bike unloaded and proceeding at increments of 10-15 watts per minute until 
volitional termination of the test (Sutherland and Anderson, 2001; and Motl and 
Fernhall, 2012) in order to reduce the level of participant risk and burden 
experienced from the research assessment process.
2.1.7.2 Fatigue
Fatigue is poorly defined in MS, yet is often reported as one of the most 
common and disabling symptoms (Flachenecker et al., 2002). Some reports 
show that 80-90% of PwMS experience fatigue (Krupp et al., 2006; Weiland et 
al; 2015), with approximately two thirds of PwMS describing it as their most 
disabling symptom (Branas et al., 2000). Exercise interventions suggest that 
improved fitness may positively impact fatigue (Carter et al., 2014), with 
rehabilitation interventions such as exercise and education reported to have a 
more significant impact than pharmacological treatments (Asano and Finlayson,
2014). A variety of PROMS are used to assess the impact of exercise 
interventions on fatigue in PwMS. These include the Fatigue Severity Scale
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(Krupp et al., 1989); the MS-Specific FSS (MS-FS) (Krupp et al., 1995); the 
Fatigue Impact Scale (FIS) (Fisk et al., 1994ab) and the Modified Fatigue 
Impact Scale (MFIS) (MS Council, 1998). The most frequently used fatigue 
outcome measure in exercise interventions is the MFSS (Asano and Finlayson, 
2014). MS fatigue is generally considered to be a multidimensional construct 
(Kesselring and Beer, 2005), with some fatigue scales measuring different 
aspects of fatigue which are poorly correlated (Flaschenecker et al., 2002) and 
others providing a single (unidimensional) fatigue score (Elbers et al., 2012). 
There is a need for a multidimensional scale to be developed that covers all 
dimensions of MS fatigue if we are to provide a robust assessment of the 
impact of research trials in the future (Flachenecker et al., 2002). It is 
recommended that based on current available measures, a multidimensional 
assessment tool such as the MFIS is used to determine the impact of exercise 
interventions on fatigue (Paul et al., 2014; Potter et al., 2014). However, it is 
suggested that should only a unidimensional measure be required then the FSS 
is sufficient (Paul et al., 2014), with well-defined cut points available for sub­
group analysis (Roelcke et al., 1997; Bakshi et al., 2000).
2.2 Theoretical Underpinning
Current research suggests that there is an increased interest in using
behavioural interventions to improve long-term physical activity in PwMS (Ellis
and Motl 2013; Motl, 2014). Behavioural interventions including theories such
as the Social Cognitive Theory (SCT) (Bandura, 1986) have been reported to
have a positive impact on physical activity behaviour in PwMS (Motl et al., 2011;
Dlugonski et al., 2012; Pilutti et al., 2014). It therefore makes sense that a
combined approach using an exercise intervention alongside a behavioural
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intervention that is theoretically underpinned may have a greater long-term 
impact on physical activity behaviour (Coote et al., 2014).
2.2.1 Psychological approach
Pharmacological agents are only moderately effective in managing MS 
symptoms. Physical activity is considered to be an important self-management 
tool for PwMS, with increased physical activity linked to improved health 
outcomes such as quality of life and fatigue (Reitberg et al., 2005; Heesen et 
al., 2006; Dalgas et al., 2008; Doring et al., 2012; Latimer-Cheung et al., 2013; 
Sa, 2013). Despite this PwMS are less physically active than the general 
population (Motl, McAuley and Snook, 2005), with symptoms reported to be 
linked to physical inactivity and partially explained by low exercise self-efficacy 
(Motl et al., 2006b). It is reasonable to hypothesise that this could be linked to 
MS symptoms and their ability to impact on physical ability, self-efficacy and 
intentions to engage in physical activity (Plow, Finlayson and Cho, 2011). It is 
therefore important to consider strategies to enhance self-efficacy and 
intentions in the design of any pragmatic exercise intervention aimed at 
promoting improved long-term autonomous physical activity behaviour for 
PwMS.
There are many barriers to changing complex health behaviours such as 
physical activity (Sallis et al., 2006), with early exercise and physical activity 
interventions for PwMS (Petajan et al., 1996; Sutherland and Anderson, 2001) 
predominantly focusing on the physiological content of the intervention. 
However, a psychology based approach that is theoretical underpinned is 
required to promote long-term behaviour change and enable interventions to be
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replicated. Contemporarily, the most commonly used theories in exercise and 
physical activity literature to date have come from pre-existing approaches to 
behaviour change developed in the social psychology arena (Buchan et al., 
2012). These include theories such as Social Cognitive Theory (SCT) (Bandura, 
1986), The Theory of Planned Behaviour (TPB) (Ajzen, 1991), The Self- 
Determination Theory (SDT) (Deci and Ryan, 2002), and The Transtheoretical 
Model (TTM) (Prochaska and Diclemente, 1983) (Nigg et al., 2008). A practical 
yet tailored approach to exercise intervention design is required that follows a 
model with structure that enables it to be repeated if successful. One such 
approach often used to inform physical activity behaviour change is the 
Transtheoretical model (TTM) (Prochaska and DiClemente, 1983).
2.2.1.1 The Transtheoretical Model
The TTM (Prochaska & DiClemente, 1983; Prochaska, DiClemente, & 
Norcross, 1992; Prochaska & Velicer, 1997) focuses on an individual's ability to 
make volitional decisions about their behaviour and utilises existing theories to 
underpin its approach. Subsequently, it's a comprehensive theory of change 
comprising of 4 key constructs; stages of change (SOC), decisional balance, 
self-efficacy and processes of change (Prochaska and Diclemente, 1983). The 
model seeks to explain how individuals make positive changes to their 
behaviour and features the SOC as one of its core constructs (Figure 2.1).
The stages of change offer a temporal dimension looking at change as a 
process containing five (Oka, 2000) or six (Horiuchi et al., 2012) stages rather 
than a single event, with individuals going through a series of set processes of 
change to move through the stages.
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Table 2.2 outlines the five most common stages of change. However, recent 
research in adults with physical disabilities validated a four stage model, 
combining the later fourth and fifth stages into a single action stage (Kosma and 
Ellis, 2010).
The TTM also includes measures sensitive to progression through the stages 
such as decisional balance (weighing up the advantages and disadvantages to 
change) and self-efficacy. In addition the ten processes of change are divided 
into two main sub-groups, cognitive and behavioural, which help to explain how 
changes occur. Interventions designed using the principles of the TTM take into 
account the varying needs of individuals, tailoring the intervention to their stage 
of change and accounting for both forward and backward movement between 
the stages (Khatta, 2008).
Table 2.2. Description of stages of change as linked to the TTM (Horiuchi et al., 
2012).
Stages Of Change Description
Pre-contemplation No. I have no intention to begin in the next six months
Contemplation No. But I intend to begin in the next six months
Preparation No. But I exercise irregularly
Action Yes. I have been practicing for at least six months
Maintenance Yes. I have been practicing for at least six months
Termination Yes. I have been practicing for more than five years 
(termination stage)
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This approach was originally used in helping to prevent negative health 
behaviours such as smoking (Prochaska and DiClemente, 1983). However, 
over the last decade it has been used to promote positive health behaviours 
such as physical activity (Fahrenwald et al., 2004).
A recent Cochrane library systematic review (2014) reported that current 
research utilising the TTM in physical activity and dietary interventions is 
reported to be of low quality, providing limited evidence for its use in physical 
activity interventions (Mastellos et al., 2014). This highlights the need for more 
'well-designed RCTs that apply the principles of the TTM SOC appropriately to 
produce conclusive evidence about the effect of TTM SOC on lifestyle 
interventions' (Mastellos et al., 2014).
The complex and varied symptoms experienced by PwMS are reported to 
interfere with their intention to be physical activity (Plow, Resnik and Allen, 
2009), with constructs of the TTM such as self-efficacy reported to be mediators 
of intention to engage in physical activity in this population group (Motl et al., 
2006c). Research into the TTM and SOC with PwMS has suggested that this 
approach is worth exploring in exercise interventions with PwMS (Plow et al., 
2011) and has the potential for motivating PwMS to exercise (Levy et al., 2009). 
Moreover, longitudinal changes in the TTM constructs have been linked to 
changes in physical activity behaviour in PwMS, suggesting that long-term 
maintenance of autonomous exercise requires cognitive change first, before 
behavioural strategies are introduced (Kosma, 2012). It would therefore seem 
valid to utilise this approach in future exercise interventions for PwMS.
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2.3 Trial Design
2.3.1 Randomised-Control Trials (RCT)
The National Institute of Clinical Excellence has defined an RCT as; 'A study in 
which a number of similar people are randomly assigned to 2 (or more) groups 
to test a specific drug or treatment. One group (the experimental group) 
receives the treatment being tested, the other (the comparison or control group) 
receives an alternative treatment, a dummy treatment (placebo) or no treatment 
at all'.
RCTs are often reported to be the most robust method for assessing the effect 
of a treatment and its cost-effective ness (Sibbald, 1998). RCTs also include 
double blinding where appropriate and intention to treat analysis (i.e. analyzed 
in the group that they were originally assigned regardless of adherence to the 
intervention) (Sibbald, 1998). The most commonly cited limitation of this method 
are with ethical and practical concerns regarding the withholding of a treatment 
thought to be beneficial to the trials participants (Edwards et al., 1998).
2.3.2 Mixed Methods Approach
Outcomes based research has typically utilised quantitative approaches to
determine the effectiveness of an intervention. This method does not enable the
researcher to fully understand many aspects of health care research such as
patient perceptions that are crucial in determining the effectiveness of a
pragmatic intervention (Curry et al., 2009). Therefore for pragmatically designed
trials a mixed methods approach is recommended (Creswell et al., 2011). Mixed
methods research can be defined as research that; 'focuses on questions that
call for real-life contextual understandings, multi-level perspectives, and cultural
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influences; employ rigorous quantitative research assessing magnitude and 
frequency of constructs and rigorous qualitative research exploring the meaning 
and understanding of constructs; utilize multiple methods (e.g., intervention 
trials and in-depth interviews); intentionally integrate or combine these methods 
to draw on the strengths of each; and frame the investigation within 
philosophical and theoretical positions' (Creswell et al., 2011). The use of a 
mixed methods approach is becoming increasingly important when designing 
pragmatic research trials, as using this approach enables us to gain a much 
broader understanding of real-world interventions and the context in which they 
work (Albright et al, 2013).
2.4 Barriers to participation
Current knowledge suggests that people with MS benefit from taking part in 
regular and appropriate physical activity, despite this PwMS still engage in less 
physical activity than the general population and even those with other chronic 
illnesses (Motl et al., 2005). There are currently only a handful of papers 
exploring both, what factors help people with MS to take part in physical activity 
and what creates barriers to participation (Kayes et al., 2011a). Understanding 
this is crucial if we are to design interventions that help to promote autonomous 
long-term participation. The complexity of MS in terms of symptoms and its 
unpredictable nature suggest that it may have a unique set of barriers.
The majority of research has explored the facilitators and barriers to physical 
activity participation utilising questionnaire based studies to determine which 
variables correlate best with amount of physical activity in PwMS (Motl et al., 
2006c; Motl et al., 2009; Vanner et al., 2008; Kayes et al., 2011a). Numerous
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studies to date have reported the importance of exercise self-efficacy in 
promoting participation (Motl et al., 2006b; McAuley et al., 2007; Snook and 
Motl, 2008; Motl et al., 2009; Stroud, Minahan, Sabapathy, 2009), with people 
with greater self-efficacy reporting more enjoyment and greater adherence to 
exercise interventions (McAuley et al., 2007). In addition, the importance of MS 
symptoms and there management in terms of promoting exercise self-efficacy is 
also noted (Motl et al., 2006b; Snook and Motl, 2008), indicating that monitoring 
symptoms during exercise and maintaining a flexible approach to exercise 
prescription may help to promote self-efficacy and exercise adherence. 
Moreover, the importance of designing programmes to limit fatigue and the 
provision of education around the benefits of exercise on this variable may 
enhance exercise self-efficacy (Stroud et al., 2009). More recently Kayes et al., 
(2011a) explored the facilitators and barriers to participation in a large group 
(n=282) of individuals with MS, reporting that the most frequently cited barrier 
was being ‘too tired’. In addition this study supported the notion that physical 
activity participation is significantly correlated with both self-efficacy and the 
number of perceived barriers to physical activity participation. Importantly the 
study highlighted potentially modifiable factors such as self-efficacy, mental 
fatigue and perceived barriers to participation that could be used to improve the 
design of future exercise interventions.
Qualitative studies are capable of providing a more personal and detailed 
insight into exercise participation. However, only a few studies have used this 
approach to explore the barriers and facilitators to physical activity participation 
for PwMS (Kayes et al., 2011b; Brown, Kitchen and Nicoll, 2012; Learmouth et 
al., 2013). Kayes et al. (2011b) highlighted that the decision to take part in 
physical activity is complex amongst PwMS and there is a need for a highly
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individual approach to barrier management taking into account personal beliefs. 
Studies by Brown, Kitchen and Nicoll (2012) and Learmonth et al., (2013) 
explored barriers and facilitators to participation in specific types of group based 
exercise programme (aqua fitness and leisure centre). Both studies sited that 
knowledge of MS amongst staff and lack of opportunities as key barriers to 
participation. Moreover, knowledge on benefits, inadequate transport, lack of 
one-to-one support, participation fears and accessibility were also highlighted 
as potential barriers to aqua fitness (Brown, Kitchen and Nicoll, 2012). 
Exercising with healthy people, the perceived attitudes of others and MS 
symptoms where additionally reported as barriers to exercising in a leisure 
facility (Learmouth et al., 2013). However, both groups were small and covered 
a limited range of abilities and activity types, with a potentially biased sample of 
participants who were already engaging in an activity based intervention. More 
detailed research in this area is needed if we are to gain a full understanding of 
the unique set of variables that may both facilitate and provide barriers to 
physical activity participation in PwMS.
2.5 Scoping review: exercise and physical activity interventions for the 
treatment of Multiple Sclerosis
The purpose of this scoping review was to map the existing literature on 
exercise and MS in order to provide a general update on what is currently 
understood about exercise and MS and provide reference for the discussion 
and conclusion in this thesis. A scoping review was chosen as a recognised 
method of summarising research findings and identifying gaps in existing 
literature (Levac et al., 2010). This scoping review followed the framework
recommended by Arksey and O'Malley (2005) (figure 2.2).
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It is recognised that this type of review generally fails to evaluate the quality of 
the literature or provide any synthesis regarding intervention effectiveness. Due 
to the volume of information available, it was decided to include an element of 
quality review in stage 2 (only including RCTs) in order to select the most 
pertinent literature and some synthesis within the narrative in stage 5.
2.5.1 Research question for scoping review
What is currently understood about the impact of different exercise and physical 
activity intervention on functional and health outcomes for PwMS?
2.5.2 Scoping review methods
Search Strategy
Literature searches were conducted using Scopus and PubMed from 1996 to 
August 2014. Only articles printed from 1996 onwards were included as several 
previous systematic reviews (Rietberg et al., 2005; Asano et al., 2009; Latimer- 
Cheung et al., 2013) have reported Petajan, (1996) to be the first published MS 
and exercise RCT. Research published from this thesis was excluded from this 
review.
Inclusion Criteria
The review included studies containing PwMS of any age, gender or disease 
type that were not experiencing a relapse or exacerbation. Studies must have 
been published in an English language peer review journal and be an RCT 
where exercise training/therapy was the main treatment. Where exercise 
training/therapy is defined as “a series of movements with the aim of training or
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developing the body by a routine practice or as a physical training to promote 
good physical health” (Webster’s New World Dictionary, 1982). Randomised 
controlled trials, with both wait list control and cross-over design were included 
as well as the standard RCT.
Exclusion Criteria
Reviews, editorials or notes were excluded and used for cross reference only. 
Interventions that were only behavioural, balance rehabilitation, qualitative or 
utilised vibration therapy were also excluded. Non-English languages were also 
excluded due to no translation service available.
Search Criteria:
A list of keywords was generated based on keywords and search terms used in 
existing exercise and physical activity literature and reviews. The search criteria 
used was; ("exercise" AND "multiple sclerosis") OR ("exercise therapy" AND 
"multiple sclerosis") OR ("physical activity" AND "multiple sclerosis") OR 
("physical therapy" AND "multiple sclerosis") OR ("training" AND "multiple 
sclerosis") OR ("rehabilitation" AND "multiple sclerosis").
Date of search 28/08/2014
2.5.3 Process
The search yielded 1876 papers (SCOPUS), 1956 (PubMed). The titles and 
abstracts were then screened to exclude non RCT's where exercise 
therapy/training was not the main treatment. The use of the Physiotherapy 
Evidence Database Scale (PEDro Scale) (Verhagen et al., 1998) was
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considered as a method of rating methodological quality of the RCT’s and 
eliminating further low quality studies from the search. However, it was decided 
that based on the low quality of many studies and to remain as inclusive as 
possible this search would be based on the primary PEDro criteria of an RCT, 
without looking further at the additional sub criteria.
75 (SCOPUS) and 52 (PubMed) articles were retained. Duplicate articles were 
removed and the remaining 83 articles were obtained and read. Following this 
34 papers were deemed relevant for inclusion in the review. It is recognised that 
the ideal scenario would have been to have this process carried out by two 
independent reviewers; however this was outside the scope of this thesis. To 
minimise the impact of this further checking was carried out by cross checking 
the references from five previous MS and exercise reviews (Rietberg et al., 
2005; Asano et al., 2009; Doring et al., 2012; Kjolhede, Vissing and Dalgas, 
2012; Sa, 2013 and Latimer-Cheung et al., 2013) to determine if any further 
relevant papers needed to be included. This process revealed a further, eight 
papers that needed to be included. In total 42 papers (38 studies) were retained 
in the final review. Figure 2.3.outlines a flow chart of the review process.
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Articles/studies included in final 
selection (n=42/38)___________
Articles/studies selected for 
inclusion in review (n=34/30)
Initial search using keywords 
Scopus (n=1876); PubMed (n=1956)
Articles retrieved to review full text 
(n=83)___________________________
Articles reviewed for duplicates 
Scopus (n=75); PubMed (n=52)
Articles removed due to duplication 
(n=44)_________________  _______
Articles excluded (not RCT or exercise 
trial)
(n=49)_____________________________
Review articles cross checked for 
additional studies 
(n=8)____________
Articles excluded (not RCT or exercise 
trial)
Scopus (n=1801); PubMed (n=1904)
Figure 2.3. Flow chart outlining the review process.
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2.5.4 Interventions
2.5.4.1 Aerobic exercise
Eleven studies comparing aerobic exercise (Table 2.3a) with a usual care 
control group were included in this review; three of these were feasibility or pilot 
work only. The studies included 342 PwMS, the majority of which were 
individuals with mild-to-moderate disability from the condition. The largest study 
so far was that of Petajan et al., (1996), leaving most trials inadequately 
powered. The modality of exercise used in these trials included arm, cycle, 
combined (arm/cycle) and rowing ergometry, treadmill walking and water based 
activity. Sessions lasted between 30 and 60 minutes, and were carried out for 
two to three times per week (except one which was five times per week) for 
between three and 20 weeks. The intensity of the sessions was generally light 
to moderate and included both continuous and interval style training. Outcome 
measures were generally assessed at baseline and immediately following the 
intervention period. Only two studies (Van den Berg et al., 2006; Ahmadi et al.,
2013) included a follow-up, but neither of these would be considered to be of 
sufficient duration to be classified as long-term. Retention on the trials varied 
from 57.9% up to 100%, with the majority being between 80 and 90%. 
Compliance to exercise was less well reported with only three trials reporting 
this measure. Most of these were supervised sessions and reported good 
compliance of between 90 and 97%.
Outcome measures suggested no negative effects of mild-to-moderate aerobic
exercise and several positive outcomes for PwMS. Most studies reported
improvements in aerobic fitness as measured directly by either V 0 2  peak, V 0 2
max or anaerobic threshold (Petajan et al., 1996; Mostert and Kesselring et al.,
2002; Briken et al., 2014) or indirectly through the walking distance covered
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during a six minute walk test (Ahmadi et al., 2013) or as maximum walking 
distance (Dettmers et al., 2009). Walking speed has been commonly measured 
either using the 10 metre walk test or the 25 foot walk test. Results on the 
impact of exercise training on this variable are mixed with Ahmadi et al., (2013) 
and van den Berg et al., (2006) both showing an improvement in walk speed. 
These two studies used treadmill training only for their aerobic intervention. 
Thus, indicating that specificity of training may be important to gain an 
improvement in walking speed for PwMS.
The impact of aerobic exercise on fatigue was less conclusive, with some 
studies showing evidence for improvement (Sutherland et al., 2001; Ahmadi et 
al., 2013; Briken et al., 2014) and others failing to show any significant 
difference (Petajan et al., 1996; Schulz et al 2004; van den Berg et al., 2006; 
Rampello et al., 2007; Dettmers et al., 2009; Skjerbaek et al., 2014). This 
difference may have been due to the different outcome measures used to report 
on this variable. The majority of those reporting a significant improvement 
utilised the Modified Fatigue Impact Scale (MFIS), which is a multidimensional 
tool. Whereas the majority of those that did not, utilised either the Fatigue 
Scale for Motor and Cognition (FSMC) or the Fatigue Severity Scale (FSS), 
both of which are uni-dimensional. In a recent review of outcome measures for 
MS and exercise interventions Paul et al., (2014) recommended using the MFIS 
as a measure of energy and drive due to its ability to provide a multidimensional 
assessment.
Health related quality of life (HRQoL) was assessed in the majority of studies.
Different measures used include the Multiple Sclerosis Quality of Life-54
(MSQol-54), Multiple Sclerosis Impact Scale-29 (MSIS-29) and the Hamburg
Quality of Life in MS (HAQUAMS). The majority have shown some
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improvements in various sub-domains and overall quality of life (Petajan et al., 
1996; Sutherland et al., 2001; Mostert and Kesselring, 2002; Schulz et al., 
2004; Rampello et al., 2007), but there is little consistency over what domains 
are impacted most, or evidence to describe what it was about the intervention 
that caused that impact.
2.5.4.2 Resistance exercise
Six studies (eight articles) were included where the primary exercise 
intervention was resistance training (Table 2.3b). The studies included 227 
PwMS, most of which were individuals with mild-to-moderate disability from the 
condition. The majority of studies had small sample sizes (n=27 to 36), with the 
exception of one study (n=71). As with the studies reported into aerobic 
exercise this leaves most inadequately powered. The type of resistance 
exercises used ranged from home-based functional body weight and resistance 
band exercises (DeBolt and McCubbin 2004; Sosnoff et al., 2014), to resistance 
cycling (Cakt et al., 2010) and gym based (machine/free weights) (Dalgas et al., 
2009; Dodd et al., 2 0 1 1 ) work. Sessions lasted between 45 and 60 minutes, 
and were carried out two to three times per week for between eight and 2 0  
weeks. Where recorded the intensity of the sessions was between eight and 12 
repetitions, at between eight and 15 repetition maximum. Retention to the trials 
was good at between 73.3% and 91.6%, with reported compliance to the 
intervention varying from 68.3% up to 99%. No long-term follow-ups were 
reported.
Outcome measures suggested no negative impact from this type of training for 
PwMS, with several positive outcomes. In those studies that assessed muscle
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strength or power as a main outcome measure improvements were reported in 
the intervention groups (DeBolt and McCubbin, 2004; Dalgas et al., 2010b; 
Broekmans et al., 2011; Dodd et al., 2011), suggesting that PwMS can improve 
their strength through appropriate training. Several studies used more functional 
outcome measures such as the timed up and go test (TUG) (Debolt and 
McCubbin, 2004; Cakt et al., 2010; Broekmans et al., 2011), falls risk (Sosnoff 
et al., 2014) or walking ability (Cakt et al., 2010; et al., 2011; Sosnoff et al., 
2014). DeBolt and McCubbin et al., (2004) reported no difference in TUG during 
home-based resistance training, despite improved leg extensor power, whereas 
a significant improvement was seen following cycle resistance training. Sosnoff 
et al., (2014) reported home-based exercise to be sufficient to reduce risk of 
falls. With regard to walking mobility, walking speed as measured by the 10 
metre walk and the 25 foot walk, was reported to be improved following home- 
based (Sosnoff et al., 2014), cycle resistance (Cakt et al., 2010) and gym 
weights (Dalgas et al., 2010c), with only Broekmans et al., (2011) reporting no 
significant improvement in this measure. However, the exercise training used 
was very specific containing unilateral leg raises, with and without additional 
functional electrical stimulation and may not have been targeted enough to 
improve the strength, balance and coordination required to walk faster. Walking 
endurance as measured using the six minute walking test (6 MWT) and the 2 
minute walking test (2MWT) were reported to be significantly improved by both 
home based exercise (Sosnoff et al., 2014) and gym based exercise (Dalgas et 
al., 2010b; Dodd et al., 2011), with the study by Broekmans et al., (2011) again 
not showing a significant difference.
Three of the included studies measured self-reported fatigue using either the 
multidimensional MFIS or the unidimensional FSS. Gym based (Dalgas et al.,
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2010b; Dodd et al., 2011), and cycle resistance (Caikt et al., 2010) training both 
reported improvements in fatigue, suggesting that resistance training may have 
a positive impact on this variable.
Only two of the RCT’s included in this review repored the impact of resistance 
training on quality of life. Dalgas et al., (2010b) utilised the SF-36 and reported 
improvements in the physical component of the QoL score following 12 weeks 
of progressive resistance training. This was supported by Dodd et al., (2011), 
who utilised the WHOQol-Bref and again found improvements following 
progressive resistance training, in the physical domain. Findings regarding the 
impact on this variable suggest a potentially positive impact on the physical 
domain of quality of life, but not enough research is available to conclude the 
impact of resistance training on the various domains of health related quality of 
life.
2.5.4.3 Combined (Aerobic, balance/mobility and resistance) exercise
Seven studies (eight articles) were included where the prescribed exercise 
intervention was a combination of either aerobic or balance and mobility and 
resistance training (Table 2.3c). The studies included 341 participants, the 
majority of which had mild-to-moderate disability from MS. However, 
Learmounth et al., (2012) looked at community based resistance and 
mobility/balance work in individuals with moderate to severe MS. The structure 
and content of the interventions was diverse. The modality of aerobic exercises 
included varied from combinations of, treadmill and cycle ergometry (McCullagh 
et al., 2008; Sangelaji et al., 2014), cycle ergometry (Bjarnadottir et al., 2002; 
Mostart and Kesselring, 2002) and aquatic exercises (Romberg et al., 2004;
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Surakka et al., 2004), with resistance exercises varying from gym based to 
resistance band work, with sessions taking place both in the community, at 
home or in a more structured gym environment. Sessions lasted between 20 
and 90 minutes, and were carried out between two and five times per week, for 
between eight and 24 weeks. Recorded exercise intensity was generally fairly 
light to moderate (40-75% APHRM). Retention to the trials was good at 
between 70% and 96%, with reported compliance to the interventions varying 
from 59% up to 98%. Two studies reported long term follow-up data of three 
months (McCullagh et al., 2008) and one year (Sangelaji et al., 2014).
The majority of studies that measured aerobic fitness reported improvements in 
this measure (Bjarnadottir et al., 2002; Romberg et al., 2004; McCullagh et al., 
2008; Sangelaji et al., 2014), with only Learmonth et al., (2013) reporting no 
change as measured by the 6 MWT and Golzari et al., (2010) as measured by 
V0 2  peak. It is unlikely that the study by Learmonth et al., (2013) contained 
enough of an aerobic stimulus to improve this area, as the exercise intervention 
focused around mobility, balance and resistance work, whereas the study by 
Golzari et al., (2010) although containing an aerobic component, was only 8  
weeks long and fails to provide detail on exactly what the aerobic component 
involved. The evidence for the impact of resistance training on muscle strength 
when combined with an additional aerobic component is less convincing with 
only Golzari et al., (2010) demonstrating an improvement in absolute muscle 
strength, although Surakka et al., (2004) demonstrated an improvement in 
muscle fatigue index in women (but not men) and Romberg et al., (2004) 
demonstrated an improvement in upper body strength endurance. It can 
therefore be suggested that providing an appropriate aerobic component is
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included in a combined intervention, aerobic fitness can be improved. However, 
improvements in absolute strength may require a more targeted approach.
The impact of combined exercise on fatigue is sparse, with few studies 
reporting this as an outcome measure (McCullagh et al., 2008; Learmonth et al., 
2 0 1 2 ). Out of these two studies only McCullagh et al., (2008) reported an 
improvement in this measure. This is likely to be due to the much greater dose 
of exercise in this study, which also had an impact on fitness, unlike the 
Learmonth et al., (2012) study, which failed to report a significant increase in 
exercise capacity.
Quality of Life was also not frequently assessed in this section of research, with 
only the recent study by Sangelaji et al., (2014) assessing this variable and 
demonstrating improvements.
2.5.4.4 Other exercise programmes
Twelve studies (thirteen articles) were included where the prescribed exercise 
intervention contained training that could not be definitively defined as 
containing either aerobic or resistance training (Table 2.3d). Types of studies 
include those looking at pilates, yoga and tai-chi. The studies included 694 
participants, the majority of which had mild-to-moderate disability from MS.
The majority of studies had small sample sizes (n=10 to 42), with the exception
of three studies containing 69 (Oken et al., 2004), 90 (Storr et al., 2006) and
314 (Garrett et al., 2013) participants. The type of exercise interventions
included contained home-based exercises such as walking, physiotherapy and
indoor aerobic, strength and balance exercises (Wiles et al., 2001; Geddes et
al., 2009; Conklyn et al., 2010; Miller et al., 2011; Plow et al., 2014;), supervised
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exercises such as aquatic (ai-chi), yoga, treadmill, horse riding and 
physiotherapy (Oken et al., 2004; Storr et al., 2006; Kargarfard et al., 2012; 
Ahmadi et al. 2013; Garrett et al., 2013; Bayraktar et al., 2013; Garpoulou et al., 
2014;) and mixed supervised and home-based interventions (Straudi et al.,
2014). Sessions lasted between 20 and 120 minutes, and were carried out 
between one and seven times per week for between four and 24 weeks. 
Intensity of these interventions was poorly recorded with only one study 
reporting intensity of between 50-75% of maximum heart rate reserve 
(Kargarfard et al., 2 0 1 2 ). Retention to the trials was again good at between 
77.1% and 100%, compliance to the intervention was only reported in one study 
at 58.3% (Straudi et al., 2014).
Aerobic capacity has predominantly been assessed using the 6 -minute walking 
test, with most studies (Ahamadi et al., 2013; Garret et al., 2013; Plow et al., 
2014; Garpoulou et al., 2014; Straudi et al., 2014) demonstrating an 
improvement in this measure following the exercise intervention. Only two 
studies (Wiles et al., 2001; Geddes et al., 2009) failed to show an improvement. 
Wiles et al., (2001) utilised a physiotherapy programme and Geddes et al., 
(2009) a home-based walking programme. The exercise interventions that were 
successful in improving this area reported a greater aerobic exercise dose.
Fatigue was assessed in seven out of 13 studies and improvements were 
reported in 5 of these. Both- of the studies that failed to show an impact also 
reported no improvements in aerobic capacity Geddes et al., 2009; (Straudi et 
al., 2014), indicating that the aerobic stimulus may have not been sufficient to 
bring about an improvement in fatigue.
As with the mixed exercise group quality of life was not commonly assessed.
However, in the two studies that did assess this (Kargarfrad et al., 2012; Straudi
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et al., 2014) a positive impact was reported. However, Straudi et al., (2014) only 
reported this after the supervised portion of the intervention this along with other 
measures, was not significant following the home portion of the programme, 
where compliance was much lower. This suggests that to sustain impact 
following a supervised programme, a different approach is required to ensure 
compliance and impact.
2.6 Current physical activity recommendations for people with Multiple 
Sclerosis
2.6.1 What is known?
The current evidence base is sufficient to suggest that for people with mild-to- 
moderate disability from MS, supervised, facility based exercise is safe and can 
improve aerobic capacity and muscle strength, and may improve other health 
outcomes such as fatigue, mobility and quality of life for PwMS (Reitberg et al., 
2005; Sa, 2013; Latimer-Cheung et al., 2013). It is recommended that exercise 
is promoted for PwMS not experiencing an exacerbation (Rietberg et al., 2005) 
and that exercise twice a week at a moderate intensity is appropriate for 
achieving improvements in fitness and health outcome measures (Latimer- 
Cheung et al., 2013).
2.6.2 What needs to be determined?
MS and exercise research is generally of poor quality, leading to insufficient
evidence to provide accurate information for individuals with different degrees of
disability from MS and different types of MS (Doring et al., 2012). In addition,
evidence on the short and long-term impact of exercise on symptoms, and
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information capable of providing accurate exercise prescription to guide long­
term exercise participation is currently unavailable (Doring et al., 2012; Latimer- 
Cheung et al., 2013). Therefore the challenge now is to assess the efficacy of 
pragmatic and cost-effective ways to implement exercise interventions for 
PwMS. Although one-to-one supervised facility-based exercise programmes 
can offer more support and guidance to MS patients, over the long-term they 
may prove difficult for many PwMS due to time barriers, transport issues and 
health constraints (e.g. fatigue). Moreover, they are very labour intensive, 
require specialist equipment, and are unlikely to be cost-effective. Hence, the 
purpose of the proposed investigation is to investigate whether a pragmatically- 
designed exercise intervention is effective for evoking improvements in physical 
activity behaviour and health outcomes in PwMS.
2.7 Research Question
Does a pragmatically designed exercise programme enable PwMS to benefit 
from improved health outcomes both in the short and long-term and is this a 
cost-effective approach to the treatment of MS?
2.8 Research Aims
2.8.1 Feasibility study
The primary aim of this study was to investigate the feasibility of a pragmatic 
exercise intervention in PwMS. The secondary aim was to obtain preliminary 
data on the impact of the intervention on key health outcomes by comparison 
with PwMS randomised to a standard care control group.
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2.8.2 Main trial
Primary aims for the main study trial were;
1. Will PwMS who are randomised to pragmatic exercise have increased 
structured exercise and free living physical activity in comparison to usual care 
only controls at three-months and nine-months of follow-up?
2. Will PwMS who are randomised to pragmatic exercise have improved 
functional and health outcomes in comparison to usual care only controls at 
three-months and nine-months of follow-up?
3. Is inclusion of a pragmatic exercise intervention in the patient care pathway a 
more cost-effective treatment strategy than current medical care alone in 
PWMS?
Secondary aims for the main study trial were;
1. What dose of exercise is achievable by PwMS during facility-based 
supervised and home-exercise portions of the intervention?
2. Is the dose of physical activity associated with improvement in outcomes in 
people with mild-to-moderate MS and those more severely affected?
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3.1 Preface to Chapter 3
Chapters one and two explored the current literature on exercise for people with 
Multiple Sclerosis and the current recommendations for trial design. It was 
concluded that further knowledge was required on the feasibility of a pragmatic 
exercise intervention for PwMS to inform a robust RCT that could influence 
clinical practice.
Chapter three investigates the feasibility of an exercise therapy intervention 
designed using a pragmatic approach, alongside principles from the 
transtheoretical model to increase long-term exercise behaviour change in 
people with mild to moderate MS. Permission for its reprint in this thesis has 
been gained from the publishers (Appendix 9.14).
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3.2 Abstract
Background: People with Multiple Sclerosis (PwMS) are less physically active 
than the general population and pragmatic approaches designed to equip them 
with the skills and confidence to participate in long-term physical activity are 
required.
Objective: To determine the feasibility of a pragmatic exercise intervention in 
PwMS.
Methods: A voluntary sample of 30 PwMS (male n=4, female n=26; mean age = 
40 years; range = 24-49 years), with mild to moderate disability (EDSS < 5.5), 
were recruited from eligible participants attending outpatient clinics (26, retained 
immediate follow-up, 24, 3-month follow-up). Participants were randomised to a 
10 week pragmatic exercise intervention (2 x supervised and 1 x home-based 
session per week) or standard care. Clinical, functional and quality of life 
(MSQoL-54) outcomes were assessed at baseline, immediately and 3 months 
after the intervention.
Results: Attrition was low (10 weeks, 13%; 3 months, 20%), with high 
compliance rates (> 75% of all sessions). The intervention group achieved 
progression of exercise volume (24.3 ± 7.0 to 30.9 ± 5.5 min per session), 
intensity (60.4 ± 8.8 to 67.7 ± 6.9 % HR max) and training impulse (min x 
average HR = Training Impulse/load [arbitrary units; AU]) (2600 ± 1105 to 3210 
± 1269 AU) during the intervention, whilst significantly increasing (P=0.050) 
their physical composite score (MSQOL-54) at 10 weeks and readiness to 
exercise (P=0.003) at 3 months compared with standard care.
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Conclusion: This pragmatic intervention was feasible for PwMS, but further 
research is needed to assess its long-term impact on physical activity 
behaviour.
3.3 Introduction
Evidence suggests that people with multiple sclerosis (PwMS) are less
physically active than the general population [1], but exercise self-efficacy has
consistently been reported to influence participation [2, 3]. Current research
supports the health benefits of supervised, one to one facility based exercise
interventions for people with mild to moderate disability from Multiple Sclerosis
(MS). These include, increased muscle strength and aerobic capacity, improved
mood state and enhanced quality of life (QoL), with no evidence of patient harm
[4, 5]. In the long-term, this approach may prove difficult for PwMS and is
unlikely to be cost effective. More high quality randomised control trials (RCT) to
assess the efficacy of pragmatic interventions for equipping PwMS with the
skills and confidence needed to exercise independently long-term are required
[6]. Moreover, given that despite the benefits PwMS appear to find long-term
exercise behaviour change difficult, interventions based on behaviour change
theories are likely to optimise the chances of long term behaviour change taking
place. One approach to this is the Transtheoretical Model [7] of behaviour
change which outlines a series of stages that people move through in the
behaviour change process and suggests strategies or processes that can be
used to facilitate movement through the stages. This model has been applied
to several health-related behaviours, including exercise, and is often used in
research and as a basis to develop health related interventions that are person
specific. It is hypothesised that PwMS will find a pragmatic approach to
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exercise feasible, with results indicating improvements in function and quality of 
life.
Hence, the primary aim of this study was to investigate the feasibility of a 
'pragmatic' exercise intervention that included cognitive-behavioural strategies 
to facilitate long term behaviour change in PwMS. Feasibility was measured in 
terms of recruitment, acceptability of the intervention, compliance and attrition, 
safety and suitability of exercise dose and appropriateness of outcome 
measures. A secondary aim was to obtain preliminary data on the impact of the 
intervention on key health outcomes by comparison with PwMS randomized to 
a standard care control group. In this study 'pragmatic1 is defined as a practical, 
achievable and flexible programme that allows for individual choice and utilises 
behaviour change tools to enhance self-efficacy and promote long-term 
behaviour change.
3.4 Method
3.4.1 Participant inclusion/exclusion criteria:
A total of 30 participants were recruited from MS clinics at Sheffield Teaching 
Hospitals NHS Foundation Trust (UK). All participants were aged 18-65 years, 
fulfilled the modified McDonald diagnostic criteria for MS [8], had an Expanded 
Disability Status Score (EDSS; [9]) < 5.5 and were stable on disease modifying 
treatment for > 3 months prior to recruitment. Participants who experienced 
relapses within the preceding 3 months, had other illness substantially affecting 
their ability to exercise (confirmed by consultant) or who were physically active 
(>2 x week, > 30 minutes per session, during previous 3 months) were 
excluded. Ethics and research governance approval for this study was obtained
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through Sheffield Research Ethics Committee and the Sheffield Teaching 
Hospitals NHS Foundation Trust respectively.
3.4.2 Study design
This feasibility study was a parallel randomised controlled trial (RCT). Following 
completion of baseline assessments, participants were randomly assigned to 
either pragmatic exercise or standard care control groups. The randomisation 
list was computer generated by an independent researcher and was concealed 
from those conducting assessments. Both groups had access to standard 
medical care.
3.4.2.1 Pragmatic exercise therapy intervention
Participants attended two supervised sessions and undertook one home 
session per week for 10 weeks. Supervised sessions were delivered one-to-one 
and led by an exercise researcher, qualified up to postgraduate level in sport 
and exercise science, with applied accreditation in exercise delivery. The 
project lead observed the delivery of the intervention at the start to ensure that 
protocols were interpreted correctly and consistently. Each session lasted 
approximately 1 hour, with participants being offered a range of aerobic 
exercise options (rowing, walking, upright cycle, recumbent bike and cross­
trainer), delivered as short bouts (e.g. 5 x 3  minutes, with 2 min rest) at 50 to 
69% age predicted maximum heart rate (ratings of perceived exertion [RPE] 11 
to 13 on the Borg RPE Scale). Training impulse (TRIMP), calculated as average 
exercise heart rate (bpm) x duration (minutes); arbitrary units (AU), was used to
quantify overall exercise training load [10].
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The exercise programme was progressive and tailored towards individual 
capabilities and preferences. Participants were encouraged to try all appropriate 
exercise options, but were given choice over the exact modality, duration and 
intensity of the sessions. Sessions were then designed and progressed on the 
basis of individual preferences. Each session contained a warm-up, followed by 
an aerobic component, tailored functional body conditioning exercises based on 
individual need (balance, strength and flexibility) and a cool down, with content 
recorded (exercise modality, heart rate, RPE and duration). This type of tailored 
approach is recommended for PwMS [6]. Using the Transtheoretical Model [7] 
as a guiding framework, a variety of cognitive behavioural techniques (e.g. 
consciousness raising, goal setting and finding social support for exercise) were 
also used during sessions to promote motivation and confidence for exercise. 
Exercise researchers were trained in the delivery of the intervention and 
detailed guidelines on weekly content were provided. The behavioural 
techniques were integrated into the exercise sessions and the instructor used 
strategies appropriate to the conversation, the stage of change participants 
were at, and difficulties/questions participants raised during sessions. Full 
details of the behaviour change strategy have been published previously [11].
Home session content comprised both aerobic exercise and body conditioning 
activities, and was agreed with the participant after taking into account their 
needs, preferences, goals and exercise opportunities in their community. The 
duration and intensity of the home exercise sessions mirrored the level and 
progression achieved in the supervised sessions. Home sessions were included 
to promote independent exercise participation following the intervention. 
Participants completed a physical activity diary to log compliance and diaries
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were checked and confirmed weekly, with participants being made aware of the 
importance of recording accurate data.
3.4.2.2 Standard care control
The standard care group continued with their usual National Health Service 
Care (NHS) and were offered the opportunity to receive advice and take part in 
3 supervised sessions once they had completed the study.
3.4.3 Assessment of outcomes
All participants were assessed at baseline, immediately following the 
intervention (week 10) and 3 months post intervention. Participants were initially 
assessed on the hospital site by a neurologist (BS) who assigned EDSS [9] and 
Guy's Neurological Disability Scale (GNDS, [12]) scores. All other assessments 
were undertaken at Sheffield Hallam University.
Height (m) and body mass (kg) for body mass index (BMI) and waist and hip
circumferences (cm) were measured using standard techniques [13]. Aerobic
capacity was determined using a continuous, resistance incremented, sub-
maximal cycle ergometer test. The test was terminated when participants
reached a rating of perceived exertion of 17 (very hard), with time to termination
recorded [14]. The 25ft walk from the multiple sclerosis functional composite
(MSFC) assessment was included as a measure of clinical functional ability
[15]. QoL was assessed using the Multiple Sclerosis Quality of Life-54
(MSQOL-54 [16]), which includes a generic health related QoL instrument
(Rand 36-item health survey 1.0 [17]) and 18 additional items relevant to
PwMS. Current physical activity and readiness to exercise was assessed using
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the Godin Leisure-Time Questionnaire [18] and a visual-analogue stage of 
change ladder [19], with anchored labels for the five items from the standard 
stages of change for exercise questionnaire [20]. Additionally, participants 
assigned to the exercise arm completed a series of open-ended questions 
focusing on their reasons for taking part, confidence, side effects, barriers and 
attitudes towards exercise following the intervention.
3.4.4 Data analysis
Data were analysed using SPSS for Windows version 18.0 (SPSS Inc, Chicago, 
Illinois, USA). Statistical significance was set at P<0.05. Data were first checked 
for normality using Kolmogrorov-Smirnov test and found to be normally 
distributed. Data analysis was conducted using the intention to treat principle, 
with missing data points checked to be random (Little's Chi Squared test), and 
then imputed using the SPSS Expectation Maximization (EM) method. Data 
were analysed using analysis of covariance (ANCOVA), with baseline values 
used as the covariate, to compare differences between groups at each time 
point (Follow-up 1 / week 10 and Follow-up 2 /3 months) [21]. Results are 
presented as mean (± SD) at each time point. As this was a feasibility study, 
changes in outcome data are considered to be preliminary, and a cautious 
approach to interpretation has been taken.
3.5 Results
3.5.1 Recruitment, retention and compliance
Thirty PwMS were recruited at a rate of 1.4 participants per month, of these 28
were randomised to pragmatic exercise (n=15) or standard care control
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(n=13).Two participants withdrew prior to randomisation (increased 
commitments, opted to participate in drugs trial). Table 3.1 shows the baseline 
characteristics of participants.
Table 3.1. Baseline characteristics of pragmatic exercise and usual care 
groups.
Mean (SD)
Pragmatic Exercise 
(a?=16)
Usual Care 
(n=14)
Gender (male/female) 2/14 2/12
Age (years) 39.5 (6.5) 40.9 (8.7)
Height (m) 1.66(0.08) 1.68 (0.09)
Mass (kg) 72.9(13.3) 75.0 (17.0)
EDSS (analogue scale) 3.0 (1.1) 3.1 (1.7)
From the standard care group, one participant withdrew in week 10 (MS 
relapse), whilst in the intervention group, one participant withdrew in week 5 
due to increased work and fatigue. Attrition was low with 87% completing the 
week 10 assessments. A further two participants from the intervention group 
were lost to follow-up at 3 months, when they failed to respond to study visit 
invitations (80% completion; Figure 3.1). No adverse effects resulting from the 
intervention were reported. Compliance was high, with participants attending 
76% of supervised exercise sessions (15.2 ± 2.7) and an average of 75% of 
prescribed home sessions (7.5 ± 2.2).
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Figure 3.1. CONSORT diagram of patient recruitment and retention during the 
study.
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3.5.2 Exercise dose and preference
The mean duration of the aerobic component of supervised sessions 
progressed from 24.3 ± 7.0 to 30.9 ± 5.5 min across the 10 weeks, with 11 
participants showing an increase. This was accompanied by an increase in 
intensity (mean percentage of age predicted [HR max]), with participants 
progressing from 60.4 ± 8.8 to 67.7 ± 6.9 % HR max. Overall training impulse 
(TRIMP) showed steady progress from 2600 ± 1105 to 3210 ± 1269 Arbitrary 
Units (AU). Increased TRIMP was achieved with only small changes in RPE,
11.2 ± 0.8 to 11.6 ± 0.8, excluding the first session (RPE 10.8 ± 0.8) which was 
intentionally light to assess individual responses to exercise (Figure 3.2).
During supervised exercise, the most used mode of exercise was the treadmill, 
with a mean duration of 14.0 ± 5.5 min per session (Figure 3.3). The most 
popular activity for home sessions was walking (68%), although participants 
also used public gyms and swimming pools (14%), engaged in activities of daily 
living (gardening and housework) (10%) and used exercise equipment at home 
(8%).
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Figure 3.3. Exercise preference during supervised exercise sessions, with error 
bars reflecting SD (n=15).
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3.5.3 Functional, Clinical and Anthropometric Outcomes
There was encouraging evidence of improvements in walking speed between 
baseline and 3 months and EDSS between baseline and 10 weeks in the 
intervention group compared with standard care, but with changes being of 
border-line statistical significance (P=0.08 and 0.07 respectively) (Table 3.2). 
There were no improvements in anthropometric variables over the duration of 
the trial.
3.5.4 Quality of Life and Physical Activity Outcomes
The exercise group increased their readiness to exercise (P=0.003), based on 
the visual analogue stages of change ladder [19] (Figure 3.4) and there was a 
trend for an increase in moderate intensity physical activity (P= 0.08) based on 
results from the Godin Leisure-Time Questionnaire [18] (table 3.3) at 3 months. 
In addition, this group also scored higher on the physical health composite 
component (P= 0.05) of the MSQOL-54 [16] at 10 weeks (table 3.3).
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3.5.5 Qualitative analysis
Data are reported as frequency counts for each of the questions asked. Over 
90% of participants felt confident they would continue to exercise. When asked 
about feelings during and after exercise, 100% (n=14) gave positive comments, 
with remarks such as ‘exercise made them feel more awake’, ‘eased aches and 
pains’, and that they ‘only occasionally felt tired’. Following exercise, 36% (n=5) 
reported feeling more energetic, 29% (n=4) reported that they felt tired at first 
but this improved and 29% (n=4) continued to feel occasional tiredness, but this 
was reported as manageable. All participants liked the session structure as it 
was tailored, built up gradually, manageable and they liked having goals and 
targets. However, 14% (n=2) did suggest a wider variety of equipment would 
have been preferable.
3.6 Discussion
This study evaluated the feasibility of a mixed (supervised and home-based) 
pragmatic exercise intervention, designed to promote confidence and motivation 
for self-directed exercise in people with mild to moderate disability due to MS. 
Our findings suggest that this type of intervention is feasible, with excellent 
retention (10 week, 87%; 3 month, 80%) and high compliance (> 75% of all 
sessions) rates, with this pragmatic approach leading to progression in exercise 
duration and intensity over the 10 week intervention period. Our preliminary 
data also suggests that PwMS might experience important behavioural and QoL 
benefits that are retained for at least 3 months. However, caution should be 
heeded when interpreting outcome data from feasibility studies, as participant 
numbers are not powered for statistical significance,
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3.6.1 Recruitment, retention and compliance
Study recruitment rates (1.4 PwMS / month) are comparable a cognitive 
behavioural trial that recruited via clinics in Sheffield [22]. Recruitment to future 
large scale interventions could be enhanced by using a range of different 
methods to reach eligible patients (mail-outs, advertisements, patient notes and 
a multi-centre approach). The implementation of an efficient and effective 
recruitment strategy for patients on clinical trials is critical to avoid expensive 
delays and failures [23].
Trial retention was excellent (87% at 10 week; 80% at 3 month). Previous 
supervised interventions using similar exercise frequency and intensity have 
reported slightly lower retention rates (73 to 85% at follow-up 1) [24, 25, 26, 27]. 
The inclusion in our study of home exercise, individually tailored sessions and a 
framework to promote motivation and confidence to exercise may have 
increased retention rates. Previous home-based interventions focusing on 
resistance or physiotherapy exercises, have reported excellent retention rates 
of 95% to 100% [28, 29]. However, to our knowledge McCullagh etal. [30] is the 
only other exercise intervention with PwMS reporting long-term follow-up data 
(83% retention at follow-ups 1 and 2), which is comparable to rates reported 
here.
Compliance to exercise was also excellent, with 80% of participants completing
at least 70% of both supervised and home sessions and with no adverse events
reported. Petajan et al. [24] reported 97% compliance to a moderate intensity
aerobic exercise programme (3 x week; 15 week), whilst Mostert and Kesselring
[31] reported only 65% compliance (5 x week; 4 week) during exercise at the
individually determined anaerobic threshold. Home-based exercise compliance
rates are also variable, with a physiotherapy lead resistance programme (3 x
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week; 8 weeks) reporting 95% compliance [28]. However, a combined 
supervised and home-based aerobic programme, reported 83% compliance for 
supervised exercise, with no participants achieving more than half of home- 
based sessions [30]. This is much lower than our home session compliance 
rates. However, their study [30] did not contain any cognitive strategies to 
enhance self-efficacy and promote positive behaviour change, suggesting that 
strategies used in the current study, could have had a positive impact on home 
exercise adherence, with 90% feeling confident to continue exercise after the 
programme. This is supported by previous research linking the importance of 
increased self-efficacy for physical activity participation in PwMS [32, 33, 34]. 
Future exercise interventions should consider the importance of this component 
when designing trials for PwMS.
3.6.2 Exercise progression and preferences
This study aimed to progress exercise sessions by increasing intensity and 
duration whilst keeping RPE between 11 and 13 (fairly light to somewhat hard). 
Exercise dose, intensity and TRIMP all increased across the programme, whilst 
RPE remained relatively constant, suggesting progression was well tolerated. 
Motl et al. [35] reported a relatively fast progression rate with PwMS (EDSS 4.0-
6.0), from 15 to 60 min per session during an 8 week, moderate intensity, 
supervised programme. Rassova et al [36] reported progression from between 
2 and 10 min of cycling during week 1 (60% V02 max), up to between 10 and 
30 min at week 10, with progression dependent of disability. This progression 
rate is similar to results from our study, where progression was participant lead.
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During the intervention PwMS were encouraged to try all suitable ergometers 
and provide feedback on preferences, to inform programme design. During 
supervised exercise, the treadmill was utilised the most. Rowing and cycling 
ergometers were also used frequently, but were not as well tolerated for long 
durations, either due to the higher intensity of the activity (rower) or localised 
muscle fatigue (cycle). This conflicts with suggestions that rowing was only 
likely to be tolerated by well-functioning patients [5], as after initial training on 
correct usage all our participants included rowing in their programme. Previous 
exercise research with PwMS has focused on treadmill or cycle ergometry [6] 
and to our knowledge no other intervention has utilised rowing. Anecdotally, for 
participants experiencing muscle fatigue, alternating between equipment using 
different muscle groups was found to assist with more continuous exercise. At 
home 68% of total exercise time was spent walking, in accordance with 
previous research [36].
3.6.3 Outcome measures
Changes in the outcome measures should be interpreted with caution due to 
the small sample size. However, high retention rates in both groups suggest 
that despite the large number of measures, the volume and type of 
assessments were feasible and did not discourage participation.
We observed significant improvements in stages of change and QoL (Physical 
Health Composite) reported. There was also encouraging evidence of an 
improvement in 25 ft walk, EDSS and increases in self-reported moderate 
intensity activity (borderline statistical significance). In addition, participants 
reported that they felt confident in continuing to be active and enjoyed exercise.
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Anecdotally, participants commented on having the energy to do more at home, 
and using walking aids less. This suggests that PwMS can gain important 
clinical, physical and QoL benefits from exercise, with some improvements 
present after 3 months of follow-up. This is consistent with systematic reviews 
of exercise and MS, which concluded that mild to moderate exercise can be 
beneficial for PwMS, without any negative effects [4, 6]. Pilot work by 
McCullagh et al., [30] supports the possible benefits 3 months after an exercise 
intervention, suggesting significant improvements in both fatigue and QoL. 
However, a larger scale trial with long-term follow-up needs to be conducted 
before conclusions regarding exercise maintenance and long-term benefits can 
be drawn.
3.6.4 Study Limitations
Changes in physical activity and home exercise were assessed by
questionnaire, a subjective fitness assessment and self-report activity diaries.
This may have impacted on results given the social desirability response. The
inclusion of an objective physical activity measure such as 7-day accelerometry
would enhance future trials. The current study utilised strategies to enhance
self-efficacy and confidence. However, it is recommended that these behaviour
change constructs are explored in more detail in future trials to gain more
insight into their impact on long-term-behaviour change in PwMS. This study
used TRIMP as a non-intrusive method of monitoring changes in exercise load.
This method does not take into account the limitations of using absolute heart
rate as a measure of exercise intensity, particularly given the cardiovascular
dysfunction reported in PwMS [37]. However, as TRIMP results compared the
same individual over time, it is unlikely to have significantly impacted on the
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findings. Future studies would benefit from using more precise measurements 
of change in exercise training load. Furthermore future studies would benefit 
from monitoring the other services such as physiotherapy that were accessed 
by PwMS during the trial, as this may have impacted on outcome measures. It 
is recommended that this not only monitored in future trials, but also that this 
pragmatic tailored approach could be further enhanced if both the expertise of a 
physiotherapist and an exercise researcher were used in the programme 
design.
3.7 Conclusions
Our findings suggest that this type of pragmatic exercise intervention is feasible 
for people with mild to moderate MS, with good compliance reported for both 
aspects of the programme. No other studies to date have investigated the 
feasibility of this type of pragmatic exercise programme, combining individually 
tailored aerobic (supervised and home-based) exercise, with flexibility, balance 
and core work, and behavioural strategies to encourage PwMS to be more 
physically active. In addition, a cautious consideration of the outcome data 
suggests that PwMS can experience behavioural and QoL benefits from 
participation and that these changes may be sustained for up to 3 months after 
the intervention. Future larger-scale definitive trials, with longer follow-up are 
required to corroborate the results from this preliminary study.
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4.1 Preface for Chapter 4.0
Chapter three explored the feasibility of running a pragmatically designed 
exercise intervention for people with mild to moderate MS. Results suggested 
that this type of exercise intervention was not only feasible, but has the potential 
to elicit long-term exercise behaviour change, with a further large scale trial 
required to support these findings.
The results from the feasibility trial outlined in chapter three informed the design 
of a larger RCT in this population group. The methods of which are reported in 
chapter four. Permission for its reprint in this thesis has been gained from the 
publishers (Appendix 9.14).
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4.2 Abstract
Exercise is an effective intervention for improving function, mobility and health- 
related quality of life in people with multiple sclerosis (PwMS). Questions remain 
however, regarding the effectiveness of pragmatic exercise interventions for 
evoking tangible and sustained increases in physical activity and long-term 
impact on important health outcomes in PwMS. Furthermore, dose-response 
relationships between exercise and health outcomes have not previously been 
reported in PwMS. These issues, and improved knowledge of cost 
effectiveness, are likely to influence key decisions of health policymakers 
regarding the implementation of exercise therapy as part of the patient care 
pathway for PwMS. Hence, the primary aim of this study is to investigate 
whether a 12-week tapered programme of supervised exercise, incorporating 
cognitive-behavioural techniques to facilitate sustained behaviour change, is 
effective for evoking improvements in physical activity and key health outcomes 
in PwMS over 9 months of follow-up. A total of 120 PwMS will be randomised 
(1:1) to either a 12-week pragmatic exercise therapy intervention or usual care 
control group. Participants will be included on the basis of a clinical diagnosis of 
MS, with an expanded disability status score (EDSS) between 1 and 6.5. 
Outcome measures, to be assessed before and after the intervention and 6 
months later, will include physical activity, clinical and functional measures and 
health-related quality of life. In addition, the cost effectiveness of the 
intervention will be evaluated and dose- response relationships between 
physical activity and the primary/ secondary outcomes in those with mild and 
more severe disease will be explored.
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4.3 Introduction
Living with multiple sclerosis (MS) can be a difficult experience, both physically 
and psychologically [1,2], with common symptoms including visual problems, 
motor abnormalities, bowel and bladder incontinence, loss of balance and 
sexual dysfunction [2,3]. Research also indicates that there is an increased 
prevalence of falls in people with MS (PwMS) [4,5] and a high proportion of 
patients who experience debilitating symptoms of fatigue, defined as a ‘a 
subjective lack of physical and/or mental energy that is perceived by the 
individual or the caregiver to interfere with usual and desired activities’ [6]. 
Hence, there is a need to assess the effectiveness of therapeutic strategies that 
could have a long-term impact on health-related quality of life of PwMS, 
particularly given that MS affects many young and middle-aged individuals [7], 
who have a life expectancy close to normal [8].
A growing body of evidence supports the beneficial effects of exercise in terms 
of wide-ranging health outcomes for PwMS [9-13]. However, a major challenge 
is to develop pragmatic and cost-effective interventions that engage PwMS in 
exercise therapy and have a long-lasting impact on physical activity behaviour. 
Supervised facility-based exercise programmes offer comprehensive support 
and guidance but over the long-term they are likely to prove difficult due to time 
barriers, transport issues and health constraints (e.g. fatigue) in PwMS. In 
addition, they are very labour intensive, require specialised equipment, and may 
not be cost-effective. Pragmatic physical activity interventions, involving 
cognitive-behavioural techniques to promote confidence for self-directed 
exercise are likely to be more cost-effective than long-term supervised 
programmes of exercise therapy.
We undertook a small-scale study (N=30) to investigate the feasibility of a
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pragmatic exercise intervention which was designed to promote sustained 
changes in physical activity behaviour in PwMS. The intervention involved two 
supervised and one home-based exercise session each week for 10 weeks, 
using a variety of cognitive-behavioural techniques (e.g. consciousness raising, 
goal setting and finding social support for exercise) and the Transtheoretical 
Model [14] as a guiding framework, to promote motivation and confidence for 
exercise. Outcomes were assessed at baseline, after the 10 week intervention 
and after a further 3 months. Adherence to the intervention was excellent (80% 
of participants completed >70% of the exercise sessions), attrition was low 
(20%) and trends for improvement in key health outcomes (i.e. quality of life and 
readiness to exercise) were observed up to 3 months of follow-up in the 
intervention group. Focus groups showed that PwMS enjoyed the intervention, 
including the structure and content of the sessions. Qualitative analysis also 
revealed that the exercise sessions provided participants with feelings of 
energy, vitality and a sense of achievement. On completing the 10-week 
intervention, over 90% of the participants indicated that they felt confident they 
would continue to exercise in their communities.
On the basis of these positive feasibility data and the qualitative feedback 
received from PwMS, this definitive randomised controlled trial was designed to 
investigate the effectiveness of this pragmatic approach to implementing 
exercise therapy in a larger population of PwMS. The main aims of this trial are 
to investigate the effects of the pragmatic exercise intervention on physical 
activity behaviour and important health outcomes up to 9 months of follow-up, 
as well as cost-effectiveness of the intervention in relation to standard care.
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In addition, dose-response relationships between exercise therapy and the 
primary/secondary outcomes in those with mild and more severe disease will be 
explored.
4.4. Methods 
4.4.1. Patient recruitment
A total of 120 PwMS will be recruited by consultant neurologists at the 
collaborating hospitals and via flyers/community adverts displayed at the local 
South Yorkshire MS Society branches. All patients will be seen by a neurologist 
prior to entering the trial, regardless of their route of recruitment. In total, around 
50 potential participants per week are seen at the collaborating hospital centres. 
In addition, we will have access to several hundred PwMS who are affiliated 
with local South Yorkshire MS Society branches. We will seek to feature the trial 
in the MS matters newsletter during recruitment and aim to recruit the required 
sample of 120 PwMS over 24-months; this equates to a recruitment rate of 5 
PwMS per month. Participant travel expenses will be reimbursed. Ethics 
approval for the study has been granted by the South Yorkshire Research 
Ethics Committee.
4.4.2 Randomisation and allocation concealment
The study is a randomised controlled trial with participants being randomised to 
the pragmatic exercise intervention or standard care control group (Fig. 4.1). 
Stratification will be used to balance the potentially confounding variables of 
gender and Expanded Disability Status Scale (EDSS) score (low: up to 3.5, 
high: up to 6.5). Randomisation will be undertaken by a distant randomisation 
service at the University of York, UK. The randomisation sequence will not be
138
disclosed until participants have completed their baseline assessments.
4.4.3 Inclusion and exclusion criteria
The inclusion criteria for the trial are: clinical diagnosis of MS with an EDSS 
score of between 1.0 and 6.5, and able to walk 10 m distance; aged 18-65 
years; clinically stable for at least 4 weeks prior to entering the study; 
participants on disease modifying therapy (Interferon, Glatiramer Acetate, 
Mitoxantrone and Natalizumab) must have been stable on this treatment for at 
least 3 months prior to entering the study; physically able to participate in some 
form of exercise three times per week; able to provide written informed consent. 
The exclusion criteria for the trial are: failure to meet any of the above inclusion 
criteria; experiencing illness that impairs the ability to be physically active three 
times per week; unwilling to be randomised to either the exercise intervention or 
usual care control group; living more than 20 miles from the trial centre; already 
engaged in purposeful structured exercise or brisk walking >3 times per week 
for >30 min per session for at least 6-months.
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Hme-line
CD O
Agree to participate
Eligible
Confirmation of eligibility
Refuse to 
participate
Refuse to 
participateFamiliarisation visit to the centre
1-to-l 
interviews 
and focus 
groups 
(random 
sample)
Assessment of outcomes (weeks 13-14)
9-month follow-up assessment
Baseline assessment, then randomisation to one of two 
groups (stratified for EDSS [1.0-3.5; 4.0-6.5] and gender)
Potential participants identified by Consultant Neurologists, 
or through community adverts or patient notes
Continue with usual care for 
12 weeks
Usual care control group
Weeks 1 -6:
2x week supervised exercise 
1 x week exercise at home
Weeks 7-12:
1 x week supervised exercise 
2x week exercise at home
Pragmatic exercise intervention
Figure 4.1. Flow of participants through the trial.
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4.4.4 Sample size calculations and expected loss to follow-up
The sample size estimation is based on physical activity behaviour change data 
from our pilot study [15,16] and an estimated post-intervention difference in 6- 
min walk test (6MWT) between the groups [17]. A sample of 50 patients 
randomised to each group will be sufficient to detect a moderate effect size 
difference (80% power and a 5% significance level) of 1.3 units on the Godin 
physical activity scale (standard deviation=2.29 [our pilot study data]) and an 
increase of 56 m (sd=99.4 m) in 6MWT [17] (an increase in 6MWT of 56 m was 
accompanied by improved neurological function after a 12 week aerobic 
exercise programme in PwMS) [17]. This figure rises to 60 in each group to 
allow for a 15% loss to follow-up.
4.4.5 Exercise intervention
At baseline, participants in the intervention group will receive a pack of printed 
information that details important information about exercise and MS (e.g. safely 
increasing exercise over time, minimising injuries, dealing with fatigue, taking 
heart rate and appropriate shoes for exercise, etc.). The intervention period will 
be 12 weeks in duration, with more frequent participant contact during weeks 1- 
6 (2 supervised exercise sessions), and reduced contact during weeks 7-12 
(one supervised exercise session). In accordance with recent recommendations 
for PwMS [13], and as used in our pilot study, the intervention will be staged- 
adapted and participants will be encouraged to exercise within their own 
capabilities, which will be influenced by individual symptomatology. An exercise 
physiologist and specialist physiotherapist will oversee the delivery of the 
intervention.
During weeks 1-6, participants will attend two supervised sessions per week at
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the Centre for Sport and Exercise Science (CSES) and will be required to 
undertake one additional session in their home environment. Supervised 
sessions will involve small groups of up to three participants led by an exercise 
therapist/researcher. Each session will last approximately 1 h and participants 
will be offered a range of aerobic exercises (e.g. stepping, cycle-ergo, walking, 
rowing, and arm-cranking). Participants will be asked to complete short bouts 
(e.g. 5x3-min, with 2-min rest intervals) of low to moderate intensity aerobic 
exercise (50-69% of maximum heart rate). As the intervention progresses and 
when appropriate, participants will be encouraged to participate in longer 
periods of aerobic exercise (e.g. 5x4-min) or to take shorter rests between 
bouts. Sessions will also incorporate exercises that focus upon developing 
muscle strength. Participants will undertake 1-3 sets of strength training 
exercises for large skeletal muscle groups using light weights, Therabands and 
body resistance, which will be progressed according to individual capabilities. 
Balance board and static stretching exercises for large skeletal muscle groups 
will also be incorporated into the sessions. Heart rate, ratings of perceived 
exertion and minutes of specific exercises completed in each session will be 
recorded by the researcher to allow for an assessment of the exercise dose 
achieved each week.
During weeks 7-12 participants will attend CSES once per week and complete 
two home sessions per week on their own. We hypothesise that the gradual 
increase in home-based sessions within the intervention group will help to 
facilitate independent exercise participation after the intervention phase is 
completed. As for the supervised sessions, the home sessions will be geared 
towards the mobility and symptoms of each participant. During the single 
weekly supervised session at CSES, they will undertake aerobic exercise (as in
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weeks 1-6) and discuss and receive advice on the content of their home-based 
exercise sessions, which will aim to mirror that of the supervised sessions, in 
terms of intensity and duration of aerobic exercise and additional tailored 
exercises for strength, flexibility and balance. Participants will be encouraged to 
seek out opportunities to exercise either in the home or in the local community 
(e.g. healthy living centres, health walks, fitness centres, swimming pools, etc.), 
based on their individual needs and preferences, and will receive instructions on 
how to complete a physical activity log for quantification of structured exercise 
sessions achieved outside of the supervised sessions.
4.4.6 Theoretical model for facilitating physical activity behaviour change
The supervised exercise sessions will also incorporate cognitive-behavioural 
techniques (e.g. goal setting, finding social support, understanding the 
costs/benefits of exercise etc.) to promote long-term participation in physical 
activity. Using the Transtheoretical Model [14] as a guiding framework, this 
aspect of the intervention will be aimed at equipping PwMS with the skills, 
knowledge and confidence to engage in a more physically active lifestyle (Table
4.1).
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Table 4.1. Strategies used in exercise counselling.
Suggested time­
frame 
(individual)
Processes and 
mediators of change
Exercise counselling framework:
Examples of skills and techniques to be used
Weeks 1-2 of Consciousness Raising Review first session:
the (benefits), • How did it feel? Was it difficult/easy?
intervention Dramatic relief (risks) • Did you enjoy it?
Tools: decisional • What to expect in the coming weeks
balance • Finding time for exercise - fitting it in the gaps.
• Your exercise preferences. Consider previous exercise 
experiences
Exercise knowledge
• Benefits of exercise/consequences of inactivity
• How often, how hard and for how long?
• Where and when?
• Contra-indications to exercise—when and when not to 
exercise
• Importance of hydration
• Importance of warming up and cooling down
Weeks 3-4  of Self re-evaluation Which physical exercises do 1 prefer?
the Decisional balance • Previous exercise experiences, why this worked/failed.
intervention Consciousness raising • What other exercises might you like to try? 
Are you enjoying the sessions?
• What do you like/dislike?
• What would you change?
• Is it what you had expected?
• What benefits have 1 noticed?
Exercise knowledge
• Training principles—de-training, overload and 
adaptation
Weeks 5 -6  of Self re-evaluation Introduce goal setting
the Goal setting/self­ • What is it and how might it help?
intervention regulation • Set one SMART goal
Social support Exercise review
• How do you feel after 5-6 weeks?
• What do you enjoy most?
Findings support for exercise
• Thinking of others who might encourage participation in 
exercise
• Consider ways in which to exercise with other people
• What opportunities are there, how available are they?
Weeks 6-12 of Goal setting/self­ Review goals
the regulation • Did you achieve them?
intervention Stimulus control (identify • If yes well done! If not, why not? What can we do to
situations and help change this?
relapse prevention) Cues for action
Reinforcement • Think of tasks that might prompt participation in
management (reward exercise
success) Thinking about moving on from the programme
Self-liberation (making • Avoiding relapse from exercise
commitments, goal • Future exercise options
setting) Looking/planning ahead—SWOT analysis
• What will help me to exercise in the future?
• What will stop me?
What have 1 achieved so far
• Review exercise, what has been learned?
• Thinking positively and taking positive action 
Moving on
• Action plan for home
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4.4.7 Outcome measures
4.4.7.1 Timing of assessments and setting
Unless otherwise stated, outcomes will be blindly assessed at three time-points: 
baseline, after the 12-week intervention and 6-months later. Personal 
characteristics (e.g. postcode, marital status, ethnicity, etc.) and condition 
specific data (e.g. time since diagnosis, medication, onset of symptoms, use of 
health care resources etc.) will be collected. Large print versions of the 
questionnaires will be available. Clinicians at the collaborating hospitals will 
perform the neurological tests and an experienced researcher will assess other 
outcomes at the SHU site. Self assessment questionnaires (for participants to 
take home) will be used where indicated to reduce the assessment burden for 
PwMS. These will take approximately 1.5 h to be completed. Patients in the 
usual care control group will be assessed at the same time points.
4.4.7.2 Primary outcomes
Physical activity levels will be monitored over a 7-day period, using a 
combination of self-report physical activity questionnaire/recall diary and 
accelerometry (Actigraph GT1M, Actigraph, LLC, FI, USA). The advantages of 
using both measures are that the objective measures can provide a more 
accurate measure of physical activity, whilst the subjective measure gives 
context. The Leisure Score Index (LSI) of the Godin Leisure Time Exercise 
Questionnaire [15,16] will be used to measure self-reported physical activity 
behaviour. Quantification of structured exercise sessions at the CSES and in 
the home environment will be verified using a physical activity log comprising a 
checklist for type, duration, and intensity of exercise achieved. The Actigraph is 
reported to be amongst the most extensively validated accelerometers and has
145
been proven to correlate reasonably with doubly labelled water derived energy 
expenditure techniques [18]. Functional exercise capacity (proxy measure of 
compliance to the intervention) will also be assessed using the 6-minute walking 
test (6MWT), according to a standardised protocol [19]. This test is sensitive to 
change following exercise interventions in PwMS [17,20].
4.4.7.3 Secondary outcomes
4.4.7.3.1 Neurological impairment and clinical functional ability.
The EDSS [21] will be assessed according to standard clinical procedures by 
the neurology consultant using two standardised methods. The EDSS has been 
shown to be reliable and valid and is frequently used for evaluating neurological 
impairment in research involving adults with MS. The Multiple Sclerosis 
Functional Composite (MSFC) [22] is a measure of clinical functional ability. It 
includes a timed 25-foot walk and measures of arm/hand function (9-hole peg 
test) and cognitive function (paced auditory serial addition).
4A.7.3.2. Quality of life, fatigue and qualitative analysis of patient experiences. 
The Multiple Sclerosis Quality of Life-54 questionnaire (MSQOL-54) [23] is a 
generic HRQOL instrument based on the Medical Outcome Short Form-36 (SF- 
36) Health Survey, but with 18 additional items relevant to PwMS. Both 
dimensional and composite scores will be used in the analyses. This will be 
self-assessed by the participants. Perceived effects of fatigue will be assessed 
using the Modified Fatigue Impact Scale (MFIS), which has been validated for 
PwMS [24,25]. This will be self-assessed by the participants. At the end of the 
intervention, a random sample of 30 PwMS from the intervention group will be 
invited to participate in a one-to-one, semi-structured interview and focus group
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sessions to elicit detailed and confidential accounts of their experiences. The 
interview schedule will be similar to that used by Dodd et al. [26] and will 
concentrate on patients' experiences, barriers and attitudes towards exercise, 
perceived benefits and adverse effects of the intervention. This qualitative 
aspect will help to overcome the limitations of rating scales in assessing 
treatment benefits in PwMS.
4.4.7.3.3 Cost effectiveness of the pragmatic exercise intervention.
An economic evaluation will be undertaken alongside the trial Service (NHS) 
perspective will be used in the primary economic analysis. This and other 
methods will be in accordance with UK National Institute for Health and Clinical 
Excellence (NICE) Technology Appraisal Guidelines [28]. Data collection will 
also account for costs incurred by the participants themselves for 
supplementary analysis, to allow for a broader perspective to be taken. The cost 
of the programme for each participant at each arm of the trial will need to be 
estimated. This is achieved by collecting costs for staff time, facilities hire, 
equipment and staff travel. Resource use data will be recorded for all 
participants, accounting for their health service use over the 3-months of follow- 
up. Use of primary care will be obtained from self-completed resource use items 
included in the health follow-up questionnaires. Use of hospital services, i.e. 
inpatient admission (including length of stay and speciality), outpatient 
attendances and A&E visits, will be obtained from hospital records. To enable a 
broader-base costing, PwMS will also be asked about their use of social 
services. The Medical Outcome Short Form-36 (SF-36) Health Survey 
generates summary measures for physical and mental health which can be 
used for the assessment of effectiveness [29]. The SF-36 summary measures
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can be derived from the MSQOL-54 [23]. The one-page EuroQoL EQ-5D [30] 
will be included to provide an additional preference-based measure.
4.4.7.3.4 Data analysis.
Differences in primary and secondary outcomes between groups will be 
compared using intention to treat analysis. Outcomes will be compared over the 
follow-up period using mixed model analysis, adjusting outcomes for baseline 
scores. Effect size statistics will be determined to indicate the clinical impact of 
the intervention. Multiple regression will be used to explore dose-response 
effects on outcome. Associations between ‘exercise dose’ (product of total 
exercise duration x average intensity of each session) and change in health 
outcomes will be assessed using regression modelling, adjusting for gender and 
EDSS score. Imputation methods will be used to assess data losses through 
level drop-out and loss to follow-up. All results will be reported as means and 
95% confidence intervals. Our medical statistician (AR) blinded to group 
allocation will undertake the analysis.
The main cost effectiveness analysis will be an intention to treat comparison of 
the costs of providing a pragmatic exercise therapy intervention as opposed to 
the standard treatment for PwMS, compared to gains in the SF-36 scores at the 
individual patient level. The final result will be presented as a ratio of the 
differences in costs and quality-adjusted life years (QALYs) between the two 
arms of the trial, with a 95% confidence interval estimated by bootstrapping. 
Results will be plotted on the cost effectiveness plane and then transformed into 
cost effectiveness acceptability curves with their associated frontier [27]. There 
will be considerable uncertainty in many of the cost estimates and the 
underlying estimate of benefit. Furthermore, an important consideration in the
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long term cost effectiveness of this intervention is likely to be the longevity of 
the benefits and cost consequences, therefore highlighting the importance of 
undertaking sensitivity analysis.
The qualitative analysis (both interviews and focus groups) will be guided by a 
‘framework approach’ to data collection and analysis. A thematic analysis will be 
used to explore the narrative accounts of individuals within (and across) the 
focus groups and interviews. Interview and focus group audio recordings will be 
transcribed verbatim. Three researchers will verify the identification and 
refinement of themes from the research. The analytical process will be 
facilitated by the use of QSR Nvivo software.
4.5 Discussion
MS affects around 100,000 people in the UK [31] and the clinical symptoms of 
the disease impose a significant burden to patients, the healthcare system and 
wider economy. This study intends to generate new knowledge on the 
effectiveness of a pragmatic approach to implementing exercise therapy in 
relation to physical activity behaviour change up to 9 months of follow-up and a 
range of other key health outcomes in PwMS of varying disability levels (EDSS 
range: 1.0-6.5). Dose-response relationships between exercise therapy and 
health outcomes will also be explored. In addition, the study will yield novel data 
on exercise preferences and rate of exercise progression in the facility and 
home-based settings, cost-effectiveness in relation to service usage and an 
abundance of rich qualitative data on participant experiences and subjective 
health benefits.
Systematic reviews and a meta-analysis show that exercise therapy is a safe, 
non-pharmacological treatment strategy for PwMS and can bring many health
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benefits, including improvements in muscle power, physical and psychosocial 
functioning and quality of life [32-34]. Exercise therapy may also have an 
important role to play in the management of fatigue [35], which affects >75% of 
PwMS either persistently or sporadically [36] and with up to 55% of PwMS 
describing it as their most severe symptom [37]. Fatigue negatively affects 
quality of life [38,39], mental alertness [40] and cognitive processing [41] and 
has a major impact on the high levels of unemployment in PwMS [42,43]. A 
systematic review of clinical fatigue treatments for PwMS concluded that the 
effectiveness of pharmacological and psychosocial interventions was likely to 
be modest at best but was most often reported to be ineffective [44]. Hence, 
alternative approaches to fatigue management are clearly needed and 
treatment modalities that can be incorporated into self-management strategies 
could have particular appeal to patients, their carers and healthcare providers. 
Further research is needed to understand the relative effectiveness of different 
exercise regimens for evoking improvements in clinical symptoms in PwMS of 
different disability levels. There is also a need to assess the impact of 
interventions designed to equip PwMS with the skills and confidence needed to 
become independent exercisers. Evidence suggests that PwMS is less 
physically active than the general population [45]. Physical inactivity resulting 
from a predominantly sedentary lifestyle has the potential to exacerbate 
functional impairments and increase the risk of developing other health 
concerns such as cardiovascular disease, obesity, type-2 diabetes and some 
cancers [13]. Pragmatic physical activity interventions, involving cognitive 
behavioural techniques to promote confidence for self-directed exercise, have 
been effectively implemented in other populations, including those with chronic 
diseases [46-49] and are likely to be more cost-effective than long-term
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supervised programmes of exercise therapy.
We have designed an exercise therapy intervention which is predominantly 
home-based in the latter stages, but with a tapered programme of supervised 
sessions to guide and support PwMS. The rationale is to provide PwMS with the 
skills, knowledge and confidence to engage in a more physically active lifestyle, 
hence promoting better self-management of the condition. A stronger evidence- 
base for the long-term impact of such approaches on exercise participation and 
important health outcomes will help to build greater confidence in exercise 
therapy amongst health professionals and motivate a greater number of PwMS 
to engage in exercise for improved self-management of their condition. 
Consequently, this could mean fewer GP visits, lower overall burden on 
healthcare systems and further tangible economic returns resulting from 
improved occupational productivity. If effective, the intervention could also 
become part of the treatment pathway for PwMS within the National Health 
Service and other healthcare organisations.
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5.1 Preface to Chapter 5
Chapter four outlines the Methods used for the main study trial, whilst chapter 
five provides detailed information on the recruitment strategies, rates and 
estimated costs for the main study trial. Results from which suggested that 
recruitment via MS clinics yielded the greatest number of participants, whilst 
recruitment from consultant mail-outs was the most cost effective strategy, 
suggesting that to reach recruitment targets a variety of methods need to be 
employed.
Chapters six and seven report the results from the main trial, including clinical, 
functional, quality of life and cost effectiveness outcomes. Permission for its 
reprint in this thesis has been gained from the publishers (Appendix 9.14).
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5.2 Abstract
Background: The success of a clinical trial is often dependant on whether 
recruitment targets can be met in the required timescale. Despite an increase in 
research into the benefits of exercise in people with Multiple Sclerosis (PwMS), 
no trial has reported detailed data on effective recruitment strategies for large- 
scale Randomised Control Trials (RCTs). The main purpose of this report is to 
provide a detailed outline of recruitment strategies, rates and estimated costs 
for the Exercise intervention for Multiple Sclerosis (EXIMS) trial to identify best 
practice for future trials involving MS patient recruitment.
Methods: EXIMS recruited 120 PwMS, to a 12-week exercise intervention, with 
participants randomly allocated to either exercise or usual care control groups. 
Participants were sedentary, aged 18-65 years and had an Expanded Disability 
Status Scale (EDSS) score of 1.0-6.5. Recruitment strategies included 
attendance at MS outpatient clinics, consultant mail-out and trial awareness 
raising activities.
Results: 120 participants were recruited over 34-months. To achieve this, 369 
potentially eligible and interested participants were identified. A total of 60% of 
participants were recruited via MS clinics, 29.2% from consultant mail-outs and 
10.8% through trial awareness. The randomisation yield was 33.2%, 31.0% and 
68.4% for MS Clinic, consultant mail-outs and trial awareness strategies 
respectively. The main reason for ineligibility was being too active (69.2%), 
whilst for eligible participants the most common reason for non-participation 
was the need to travel to the study site (15.8%). Recruitment via consultant 
mail-out was the most cost-effective strategy, with MS clinics being the most 
time consuming and costly.
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Conclusions: To reach recruitment targets in a timely fashion a variety of 
methods were employed, although consultant mail-outs were the most cost- 
effective recruitment strategy, use of this method alone would have not reached 
the required number of participants in the required time period, leading to costly 
extensions to the project or failure to reach the number required for statistical 
power. Thus a multifaceted approach to recruitment is recommended for future 
trials.
5.3 Background
One of the most difficult challenges in clinical trials is whether appropriate 
participants can be identified and consented quickly (Lindbald, Zingeser and 
Sismanyazici, 2011). Many trials either fail to reach recruitment targets or have 
to be extended (McDonald et al., 2006). This then either leads to an under­
powered study, or an extension to the duration of the study often at additional 
cost, impacting on the time required to inform clinical practice and utilising funds 
that could have been used for other research (Treweek et al., 2011; McDonald 
et al., 2011). The implementation of an efficient and effective recruitment 
strategy for patients on clinical trials is critical if expensive delays and failures to 
meet predetermined targets are to be avoided (Probstfield and Frye, 2011).
The introduction of CONSORT guidelines (Moher et al., 2001) has improved the 
quality of recruitment information reported for randomised control trials. 
However, detailed data on recruitment, including methods used, rates achieved 
and cost are still underreported. More detailed data would help to identify 
strategies to improve recruitment, benefiting both researchers and research 
(Treweek et al., 2011) and ultimately patients.
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In recent years there has been an increase in the number of studies that have 
investigated the possible health benefits of exercise for people with multiple 
sclerosis (PwMS) (Asano et al., 2009; Latimer-Cheung et al., 2013 and Sa 
2014). Although detailed recruitment data for exercise interventions in other 
clinical populations, such as breast cancer patients and wheelchair users, are 
available (Ott et al., 2006; Daley et al., 2007; Nary et al., 2011), to date no study 
has reported recruitment data for a large-scale randomised control exercise trial 
for PwMS. In recent years, the number of clinical trials in MS has increased, 
leading to an increased need to recruit research participants from a limited 
patient pool, and with modern trials often needing large sample sizes to ensure 
adequate statistical power (Montalban, 2011).
The Exercise Intervention for Multiple Sclerosis (ExIMS) trial was a large-scale 
randomised control trial involving 120 people with mild to moderate MS. It was 
designed to investigate the short and longer-term health impacts of a 12-week 
pragmatic exercise programme (Carter et al., 2014; Tosh et al., 2014). The 
main purpose of this report is to provide a detailed outline of the recruitment 
methods, rates and estimated cost to help inform future research of this type. In 
addition, we aim to determine which recruitment method provided the highest 
yield of participants and the lowest cost per participant.
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5.4 Methods
5.4.1 Trial Design
A brief description of the trial design is reported here as detailed protocol and 
outcomes papers for this study have been published elsewhere (Saxton, et al., 
2013; Carter et al., 2014; Tosh et al., 2014). Power calculations indicated that 
we would need 100 PwMS to complete the trial. This alongside the retention 
rates observed in our feasibility study of 87% immediately following the 
intervention and 80% at 3-months (Carter et al., 2013), lead to a recruitment 
target of 120 PwMS (60 in each group). The project was funded for three years, 
and an initial recruitment target of five participants per month, over 24 months 
was set, with recruitment beginning in February 2009. A sample of 120 PwMS, 
with mild to moderate disability (EDSS < 6.5) was recruited. Participants were 
randomized to a 12-week pragmatic exercise intervention (2 x supervised and 1 
x home-based session per week for 6-weeks followed by 1 x supervised and 2 x 
home-based sessions per week for 6-weeks, plus usual care) or usual care 
alone. The primary outcome was self-reported exercise behaviour at 3-months 
using the Godin Leisure Time Exercise Questionnaire (GLTEQ) (Godin et al., 
1985). In addition accelerometry was used to provide an objective measure of 
daily activity and step count (Actigraph GT2M accelerometer, Actigraph, LLC, 
FL, USA). Secondary outcome measures included fatigue, health related quality 
of life, functional ability and neurological impairment. Outcomes were assessed 
at baseline, immediately post intervention (3 months) and 6 months post 
intervention (9 months). This study was approved by the South Yorkshire 
Research Ethics Committee (08/H1310/69) according to the principles of the 
declaration of Helsinki and all participants provided informed consent prior to 
enrolment.
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5.4.2 Eligibility Criteria
Regardless of the recruitment method used, all participants were screened by a 
consultant neurologist prior to entering the trial. Participants were included if 
they; had a clinical diagnosis of MS using the McDonald diagnostic criteria for 
MS (Polman et al 2011); had an Expanded Disability Status Score (EDSS) 
(Kurtze, 1983) between 1.0 and 6.5; aged 18-65 years; were stable on disease 
modifying treatment for > three months prior to recruitment; were clinically 
stable (had not experienced a relapse in at least four weeks); were physically 
able to participate in exercise three times per week and were able to provide 
written informed consent. Exclusion criteria were; failure to meet any of the 
inclusion criteria; experiencing illness that would be a contra indicator to 
exercise; living further than 20 miles from the trial centre; unwilling to be 
randomised to either group; already engaged in moderate structured exercise > 
three times per week for > 30 min per session consistently for the last six 
months. Participants who were initially screened out due to either having 
changed their drug treatment in the last three months or having had a relapse in 
the previous four weeks were re-assessed following the required lapse of time 
and recruited if the eligibility criteria were then met.
5.4.3 Recruitment Methods
Participants were recruited continuously until the required sample size was 
obtained. All recruitment methods and procedures were approved by the South 
Yorkshire Research Ethics Committee. Regardless of recruitment method the 
following procedures were adhered to (table 5.1).
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Table 5.1. Recruitment process for ExIMS trial.
Recruitment Process
• Potentially eligible participants identified (consultant neurologist, mail-out, 
other)
• Trial manager made aware of participants interest
• Trial manager speaks (phone or in person) with participant to outline study, 
answer questions and screen participants for all eligibility criteria
• If interested and eligible participant booked in for trial familiarisation session 
(phone or in person)
• Potential participant attends trial familiarisation at trial site and is given 7 
days to consider participation
• Participant booked in for initial appointment to provide informed consent 
and participate in baseline assessment
5.4.3.1 Consultant Referral at MS Outpatient Clinic
Consultant referral at MS outpatient clinics was the primary recruitment 
strategy, as consultant recommendations are thought to play a crucial role in 
participants’ decisions to enrol in a clinical trial (Lindbald et al., 2012; Probstfield 
and Frye, 2011). In addition, recruitment by this method would reduce the 
possibility of patients being contacted who did not meet the eligibility criteria.
MS outpatient clinics took place at the Royal Hallamshire Hospital, Sheffield on
a weekly basis. The project's lead consultant (BS) and two other neurology
consultants assisted with identifying potentially eligible and interested
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participants. Each consultant saw approximately 13 patients per clinic (10 
follow-ups and three new patients) over a 3.5-hour period. A trial researcher 
attended all clinics, enabling any participants identified to speak with them 
about the trial, ask any questions and confirm eligibility. If interested, 
participants were booked in for a familiarisation session at the trial site.
5.4.3.2 Consultant Mail-out
To maintain a consistent flow of patients onto the study, participant mail-outs 
were timed to take place during periods of low recruitment. Letters were sent in 
batches of no more than 125 to manage the flow of patients onto the study and 
ensure that all participants who responded could be contacted in a timely 
manner. All mail-outs were sent from the project's lead consultant (BS) and 
contained the logos of the Hospital, the University and the funding body (MS 
Society). The details of the participants to be included in the mail-outs were 
obtained from the local MS Risk Sharing Scheme database and clinic waiting 
lists. Notes of potential participants were screened for all available eligibility 
criteria (clinical diagnosis of MS, distance from trial centre, EDSS score and 
age). In addition, those that had been previously contacted about the project 
through other means and stated that they did not wish to take part were 
screened out at this stage. Letters contained a reply slip, stamped addressed 
envelope and the participant information sheet, along with a contact number for 
further information. The trial manager contacted all interested participants on 
receipt of the reply slip to answer any questions and confirm eligibility. No 
attempt was made to contact patients who did not respond to the invitation letter 
from their consultant.
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5.4.3.3 Trial Awareness Strategies
Other trial awareness strategies included leaflets and posters at clinics, therapy 
centres and regional MS Societies, presentations and attendance at regional 
MS Society events and to local MS physiotherapy teams, referral from other 
professionals such as MS nurses and word of mouth. Despite being reported as 
a potentially successful recruitment method (Daley et al., 2007), we chose not 
to use local media (radio, television and newspapers) as it was felt that this may 
attract too many individuals who did not meet the study eligibility criteria. It was 
agreed that this strategy would be used only as a last resort.
5.4.3.4 Incentives
Participants were reimbursed travel costs (40 p per mile up to a maximum of 
£10 per visit) for all visits to the trial centre, with free parking made available. 
Those more severely disabled were also offered the option of a taxi service if 
other methods of transport would restrict their ability to participate. Flexible 
appointment times and start dates were made available to help participants fit 
the trial commitments around work, children and fatigue patterns. To 
encourage participation the usual care group were offered up to 4 exercise 
sessions following the study. This option was taken up by 20% of the usual care 
participants who completed the study.
5.4.3.5 Data analysis
Participant recruitment rates were calculated as the average number of 
participants recruited per month over the duration of the recruitment period. 
Response rates were reported as percentage interested and percentage
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recruited. Recruitment yields were calculated as total recruited divided by the 
number of interested participants. Recruitment time was estimated based on 
time taken to ascertain interest and eligibility in the study and does not include 
any other time taken to carry out familiarisation visits and consent as this was 
the same for all recruitment methods. The time cost of each method is 
calculated per participant recruited, based on the average salary cost per hour 
of the trial researcher.
5.5 Results
A total of 349 potentially eligible participants were identified via the recruitment 
methods (217 MS Clinic, 113 consultant mail-out and 19 trial awareness) (See 
Figure 5.1). For CONSORT checklist and flow diagram please see Additional 
file 1.
5.5.1 Recruitment Rates
The original recruitment period was planned to take place over a period of 24 
months. This was extended to a period of 34 months (February 2009 to 
November 2011), due to lower than expected recruitment rate of 3.5 ± 0.32 
(mean ± 95% Cl) participants per month (See Fig. 5.2). Recruitment was carried 
out by attending MS Clinics and using trial awareness strategies throughout this 
period. Mail outs were conducted in the second year of the trial at time-points 
where lower levels of recruitment from the clinic were observed in the trials first 
year (July, August and February and October).
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Figure 5.1. Flow diagram of participant recruitment to the ExIMS trial.
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5.5.2 Response Rates
Out of approximately 3,393 people with MS who attended the MS outpatient 
clinic during the recruitment period, 217 were identified as potentially interested 
and eligible, 6.4% (n=217/3393). Of these, 10.6% were ineligible (n=23/217) 
and 56.2% (122/217) declined to participate.
Mail outs were sent to 311 potentially eligible participants. From this, 133 
(42.8%) PwMS expressed an interest in the trial, 11.2% of which were ineligible 
(n=15/133) and 47.3% of whom (63/133) declined to participate.
Our trial awareness strategies provided 19 interested individuals from an 
unknown pool of potential participants, from which 5% (n=1/19) were ineligible 
and 21.1% (n=4/19) declined to participate.
5.5.3 Randomisation Yields/Accrual Rates
The randomisation yield was 33.2% (72/217) from the MS Clinic, 31.0% 
(35/113) for consultant mail-outs and 68.4% (13/19) for those contacted via trial 
awareness strategies. This lead to 60% (72/120) of participants being recruited 
via MS clinics, 29.2% (35/120) via mail-outs and 10.8% (13/120) via trial 
awareness strategies.
5.5.4 Reasons for Ineligibility
A total of 39 (23 MS Clinic, 15, mail-out and 1 trial awareness) participants who 
had expressed an interest were ineligible. In order of prevalence the main 
reasons for ineligibility were; too active 69.2% (27/39), recent change in disease 
modifying therapy 10.3% (4/39), recent MS relapse 7.7% (3/39), participating in
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another trial 5.1% (2/39), no definitive diagnosis of MS 5.1% (2/39) and too old 
2.6% (1/39).
5.5.5 Reasons for Declining Participation
The reasons that eligible participants declined to participate in order of 
prevalence were; gave no reason 66.3% (126/190), issues with transport/travel 
to the trial site 15.8% (30/190), other commitments 12.1% (23/190), negative 
perceptions of exercise 5.3% (10/190) and loss of benefit worries 0.5% (1/190).
Table 5.2. Estimated time to identify and recruit participants and the associated 
costs.
Recruitment
Method
Time Spent
Recruiting
(hours)
Time per 
potential 
Participant 
(hours)**
Time per 
Recruited 
participant 
(hours)***
Cost Per 
Recruit 
(based on 
estimated 
cost of a 
researcher - 
£25/hour)
MS outpatient 304.5 (87 1.4 (304.5/217) 4.2 (304.5/72) £105 (£25x4.2)
clinic clinics)
Consultant 20 (5 mail- 0.2 (20/113) 0.6 (20/35) £15 (£25x0.6)
mail-out outs)
Trial 26* 1.5 (29/19) 2.2 (29/13) £55 (£25x2.2)
awareness
strategies
All Strategies 350.5 1.4 2.9 £72.50
(350.5/349) (350.5/120) (£25x2.9)
giving talks at various MS events. **Time per potential participant (hours) is calculated as time spent recruiting 
(hours)/number of potentially eligible participants. "“ Time per recruited participant (hours) is calculated as time spent 
recruiting/number of participants recruited.
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5.5.6 Recruitment Time/Cost
MS clinics required the longest recruitment time of 4.2 hours per participant, 
whilst the consultant mail-out had the shortest recruitment time of 0.6 hours per 
participant (See table 5.2).
5.6 Discussion
5.6.1 Recruitment Rates
Recruitment to this study was slower than anticipated at 3.5 ± 0.32 (mean ±
95% Cl) participants per month, leading to the trial failing to recruit on time and 
an extended recruitment period of 34 months (from an initial target of 24 
months) needed to reach the target number of participants. Recruitment rates 
have not previously been reported for large-scale exercise trials in PwMS, but a 
non-exercise intervention using computerised cognitive behavioural therapy for 
PwMS reported slightly lower rates of 2.6 per month (Cooper et al., 2011), 
whilst a multi-centre RCT for a group based fatigue management programme 
reported recruitment of 13.0 participants per month (across three sites), 
equating to 4.3 per trial site (Thomas et al., 2013). However both these trials 
had a lower patient time commitment than ExIMS. Exercise trials with other 
clinical groups have reported similar recruitment rates, for example, wheel chair 
users, 2.9 per month (Nary et al., 2011), breast cancer survivors, 3.8 per month 
(Daley et al., 2007) and elderly stroke survivors, 4.0 per month (Taylor-Piliae et 
al., 2014). This suggests that our observed recruitment rate of 3.5 participants 
per month is a realistic target for future randomised controlled exercise trials for 
PwMS that require regular attendance.
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5.6.2 Response Rates
The response rate from a potentially large pool of participants at MS clinics was 
low at 6.4%. Reasons for this may either be related to patients being ineligible 
(changing to new medication, suffering a relapse, new patient, other 
neurological condition), consultants too busy to recruit during clinic and/or 
patients not being interested in the study. As might be expected response rates 
to personalised consultant study invitation letters were higher (42.8%), as this 
strategy was much more targeted towards eligible individuals. However, this still 
leaves nearly 60% of potential participants who did not respond to the invitation. 
As suggested by Daley et al., (2007) it is possible that non-responders, were 
either deterred by the 'demanding nature of exercise trials' or were already 
engaged in regular physical activity. The latter seems less likely due to the 
lower physical activity rates reported in PwMS (Motl and Pilutti, 2012).
5.6.3 Randomisation Yields/Accrual Rates
The trial recruited 60% of the 120 participants from the MS outpatient clinic, with
29.2% recruited via consultant mail-out and 10.8% via trial awareness
strategies. However, the randomisation yield (number recruited/number
interested) was similar for both the MS Clinic and consultant mail-outs (33.2 and
31.0% respectively), suggesting that both methods are useful in attaining
recruitment targets. Values reported in the exercise literature are varied, with
an exercise trial for wheelchair users reporting a randomisation yield of 41.8%
(Nary et al., 2011) and an exercise trial with breast cancer survivors reporting
yields of 13.3% from consultant letters and 29.7% from community strategies. In
addition, a cognitive behavioural trial for PwMS had relatively low yields of 4.5%
for the MS Clinic and 4.0% from mail-outs (Cooper et al., 2011). Hence, our
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data suggest that PwMS are as interested as other clinical populations in 
participating in a supervised exercise trial and may be more interested in an 
exercise trial than other behavioural interventions with similar time constraints.
5.6.4 Reasons for Ineligibility
There were a number of reasons why people interested in the trial were 
ineligible to take part. The most common reason for ineligibility was already 
being too active to participate (69.2%), as they were already engaged in 
moderate structured exercise > three times per week for > 30 min per session 
consistently for the last six months. This is consistent with reasons for non- 
eligibility reported in a similar exercise intervention with breast cancer survivors 
where 55% of those interested were ineligible due to being already too active 
(Daley et al., 2007). The number of potential participants screened out through 
being already too active was much less (8.5%) in a group of wheelchair users 
(Nary et al., 2011), suggesting that physical disability may impact heavily on 
current exercise levels. Our data suggests that despite the physical disabilities 
of MS, there are many people with mild to moderate levels of disability from the 
condition that are managing to participate in moderate intensity exercise over a 
prolonged time period. However, data from the wheelchair exercise study (Nary 
et al., 2011) would suggest that PwMS having higher levels of disability may be 
less physically active.
5.6.5 Reasons for Choosing not to Participate
The reasons that eligible participants have given for choosing not to take part in
exercise intervention studies has rarely been reported, but can give a valuable
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insight into areas of trial design that maybe improved to enhance recruitment. 
Many PwMS (66.3%) did not specify why they had declined to take part. 
However, out of those that did, the need to travel to the trial site, negative 
perceptions of exercise and loss of benefit worries are all factors that could 
potentially be overcome in future trials through design modifications and patient 
education.
5.6.6 Recruitment Time/Cost
Recruitment is a time consuming process with some community based trials 
reporting up to 10-hours per participant to recruit (Rdesinski et al. 2008). This 
study averaged 2.9 hours per participant. Study mail-outs were reported to be 
the most efficient recruitment method at only 0.6 hours per participant. 
However, this only recruited 29.2% of the studies overall cohort, suggesting the 
importance of the more time consuming method of recruitment through MS 
outpatient clinics. Although this method required 4.2 hours per participant, it 
yielded 60% of the study's total cohort. In the present study costs are based on 
a researcher doing all the recruitment regardless of method, however, it is noted 
that if recruitment at clinic had incurred additional consultant time, costs would 
be much higher for this method.
5.6.7 Limitations
There was the potential for cross-contamination across recruitment pathways,
as participants may have been reached by more than one method (for example
PwMS may have seen trial awareness information, before attending an
appointment at the MS clinic, which may have made them more likely to recruit
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from this method). This could be improved in future studies by asking 
participants if they have been made aware of the study by any other means. In 
addition, it was not a requirement of the study for individuals to provide reasons 
for declining to take part in the study/ it would be useful to include methods for 
collecting this data so that strategies can be developed to increase recruitment 
yield and hence decrease recruitment costs.
5.7 Conclusion
Achievement of pre-determined recruitment targets is a critical factor influencing 
the success of RCTs. Well-designed feasibility work and a combination of 
recruitment methods can help to ensure that a trial is appropriately designed to 
reach targets. Although consultant mail-outs were shown to be the most cost- 
effective recruitment strategy, this method alone may well be insufficient to 
meet recruitment targets in time-limited RCTs. This study reports for the first 
time the pros and cons of different recruitment methods in randomised 
controlled exercise trials involving PwMS and would recommend a combination 
of methods to meet recruitment targets. The results provide novel insights into 
challenges of trial recruitment in this context and can be used to inform the 
design of future trials in this population; recruitment for other types of trial such 
as drugs trials may be different.
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5.9 Additional File
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6.1 Preface to Chapter 6
Chapter five provides detailed information regarding recruitment to a large scale 
randomised control exercise trial, whilst chapter six provides the results from 
the primary and secondary outcome data, immediately and after six months of 
follow-up. Results suggest that significant improvements in self-reported 
physical activity levels, fatigue and health related quality of life, with sustained 
improvements in some of the domains of quality of life.
In order for this research to influence practice cost effectiveness data is 
required. Results from this analysis are outlined in chapter seven. Permission 
for its reprint in this thesis has been gained from the publishers (Appendix 9.14).
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6.2 Abstract
Background: Exercise programmes that can demonstrate evidence of long- 
lasting clinical effectiveness are needed for people with multiple sclerosis 
(PwMS).
Objective: The objective of this study was to assess the effects of a practically 
implemented exercise programme on self-directed exercise behaviour and 
important health outcomes in PwMS to nine months of follow-up.
Methods: We conducted a parallel-arm, randomised controlled trial: 120 PwMS 
(Expanded Disability Status Scale (EDSS) 1.0-6.5) randomised to a three- 
month exercise intervention plus usual care, or usual care only. Two supervised 
plus one home-exercise session (weeks 1-6) were followed by one supervised 
and two home-exercise sessions (weeks 7-12). Cognitive-behavioural 
techniques promoted long-term exercise behaviour change. Outcomes were 
blindly assessed at baseline and at three and nine months after randomisation. 
The primary outcome was self-reported exercise behaviour (Godin Leisure Time 
Exercise Questionnaire (GLTEQ)). Secondary outcomes included fatigue and 
health-related quality of life (HRQoL).
Results: The intervention increased self-reported exercise (9.6 points; 95% Cl:
2.0 to 17.3 points; p = 0.01) and improved fatigue (p < 0.0001) and many 
HRQoL domains (p ^  0.03) at three months. The improvements in emotional 
well-being (p = 0.01), social function (p = 0.004) and overall quality of life (p = 
0.001) were sustained for nine months.
Conclusion: This pragmatic approach to implementing exercise increases self- 
reported exercise behaviour, improves fatigue and leads to a sustained 
enhancement of HRQoL domains in PwMS.
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6.3 Introduction
Supervised facility-based exercise programmes can offer comprehensive 
support and guidance for people with multiple sclerosis (PwMS) but over the 
long-term are likely to prove difficult because of time barriers, transport issues 
and ealth constraints (e.g. fatigue).1 A major challenge is to develop pragmatic 
and cost-effective exercise programmes that can safely engage PwMS in 
exercise and provide robust evidence of a long-lasting impact on important 
health outcomes. Interventions that promote and provide support for sustainable 
home-based exercise, including use of community facilities, may help to 
overcome some of these problems but, to date, only very few studies have 
assessed the health impacts of exercise in community-based settings.2-4 The 
inclusion of cognitive-behavioural strategies might also be effective for 
increasing confidence for self-directed exercise, as reported in other clinical 
populations.5-7
Here, we report the effects of a pragmatic Exercise Intervention for people with 
MS (EXIMS) on self-directed exercise behaviour and important health 
outcomes, including fatigue and health-related quality of life (HRQoL). We 
hypothesised that participants randomised to the intervention group (EXIMS) 
would show an increase in physical activity levels and improvements in a range 
of health outcomes up to nine months of follow-up in comparison with 
participants randomised to usual care alone.
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6.4 Materials and Methods
6.4.1 Controlled Trial
This was a two-arm, parallel, randomised controlled trial. PwMS were 
randomised (1:1) to receive the EXIMS intervention plus usual care or usual 
care only. Full details of the protocol have been published previously.8 This 
study was approved by the South Yorkshire Research Ethics Committee and 
conducted according to the principles of the Declaration of Helsinki. Written 
informed consent was obtained from participants before entering the study.
6.4.2 Recruitment of participants and baseline assessment
A total of 120 PwMS were recruited via the Sheffield MS Clinic and 
flyers/community adverts displayed at the local South Yorkshire MS Society 
branches. All patients were assessed by a consultant neurologist with an 
interest in MS prior to entering the trial. The inclusion criteria for the trial were 
clinical diagnosis of MS, as defined by the modified McDonald criteria,9 with an 
Expanded Disability Status Scale (EDSS) score of 1.0-6.5, and able to walk a 
10-metre distance; aged 18-65 years; clinically stable for at least four weeks 
prior to entering the study; physically able to participate in exercise three times 
per week; able to provide written informed consent. Participants on disease- 
modifying therapy (interferon beta, glatiramer acetate and natalizumab) had 
been stable on this treatment for at least three months. Exclusion criteria were 
comorbid conditions impairing the ability to be physically active three times per 
week; unwilling to be randomised; living more than 20 miles from the trial 
centre; already engaged in structured exercise or brisk walking ^  3 times per
week for ^  30 minutes per session for at least six months.
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6.4.3 Randomisation and concealed allocation
Minimisation was used to balance the potentially confounding variables of 
gender and EDSS score (low: 1.0-3.5; higher: 4.0-6.5). Treatment allocation 
was concealed from the study researchers by using a distant randomisation 
service at the University of York, UK. The allocation was not disclosed to 
members of the research team until participants had completed their baseline 
assessments. Due to the nature of the intervention, neither the participants nor 
researchers involved in the day-to-day running of the trial could be blinded to 
treatment allocation.
6.4.4 Pragmatic exercise intervention
An exercise physiologist supervised the delivery of the intervention but with 
physiotherapist input during the early stages of the programme. During weeks 
1-6, participants attended two supervised sessions per week at a university 
exercise research facility and engaged in one additional self-directed exercise 
session in their home environment. Supervised exercise sessions involved up to 
three participants and lasted for approximately one hour. Studies show that 
aerobic exercise, resistance exercise and combined programmes bring health 
benefits to PwMS.10,11 Hence, the programme was designed to be pragmatic 
and accessible, taking into account exercise preferences and giving choices. 
Aerobic exercise was the core exercise modality as it is accessible (i.e. includes 
community-based walking exercise) and does not require equipment. 
Participants were asked to complete short bouts (e.g. 5 x 3  minutes, with two- 
minute rest intervals) of low to moderate intensity aerobic exercise (e.g. 
stepping ergometer, cycle-ergometer, treadmill walking, rowing ergometer, arm-
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cranking) at 50%-69% of predicted maximum heart rate (220-age) or 12-14 on 
the Borg Ratings of Perceived Exertion Scale.12 Intensity was monitored 
continuously during exercise training sessions. As the intervention progressed, 
participants were encouraged to participate in longer periods of aerobic 
exercise (e.g. 5 x 4  minutes) or to take shorter rests between bouts.
Where appropriate, participants also performed exercises for strength and 
control. The prescribed strength training was based on individual functional 
needs, as assessed by the trial physiotherapist (NS). Strength training was 
undertaken by 48 of 60 participants in the intervention group and typically 
involved two to six different resistance exercises (e.g. wall press-ups, arm-curls, 
leg abduction, wall squats and/or regular squats, knee extensions, calf raises, 
sit-to-stand) each session. Body resistance, light weights and Therabands were 
used to provide resistance and one to three sets of five to 20 repetitions were 
performed, depending on level of disability and strength, as well as stage of the 
programme (exercises were progressed according to individual capabilities and 
strength gains). Balance board, balance exercises and exercise ball work were 
included where control and coordination were a problem and static stretching 
exercises for large skeletal muscle groups were also included in the sessions if 
appropriate.
During weeks 7-12 participants attended the centre once per week and
completed two additional self-directed exercise sessions in their home or local
community. The home-exercise sessions were intended to mirror the
supervised sessions in terms of intensity and duration of aerobic exercise, and
also included tailored exercises for strength, flexibility and balance. Participants
were encouraged to seek out opportunities to exercise in the local community
(e.g. healthy living centres, health walks, fitness centres, swimming pools, etc.),
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based on their individual preferences. Details of supervised and home-exercise 
sessions were recorded in an exercise log.
The supervised exercise sessions incorporated cognitive-behavioural 
techniques (e.g. goal setting, finding social support, understanding the 
costs/benefits of exercise, etc.) to promote long-term participation in physical 
activity. Using the Transtheoretical Model13 as a guiding framework, this aspect 
of the intervention was aimed at equipping PwMS with the skills, knowledge and 
confidence to engage in a more physically active lifestyle. The cognitive- 
behavioural elements were integrated into the exercise sessions using 
strategies appropriate to the conversation, stage of change and 
concerns/questions raised by participants. Further details of the theoretical 
model for facilitating physical activity behaviour change have been published 
previously.8 Participants in the usual care group were offered three exercise 
sessions at the university exercise research facility and individual exercise 
advice after the study.
6.4.5 Outcome measures
Outcomes were assessed at baseline, and at three months (post-intervention) 
and nine months after randomisation. The primary outcome was self-reported 
exercise behaviour at three months using the Godin Leisure Time Exercise 
Questionnaire (GLTEQ).14 The GLTEQ asks participants to recall the frequency 
of strenuous, moderate and mild intensity exercise for periods >15 minutes over 
the past seven days and is a valid measure of habitual exercise in PwMS.15 
Daily movement and step counts were objectively assessed using an 
accelerometer (Actigraph GT2M accelerometer, Actigraph, LLC, FL, USA), worn
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on the waist during waking hours, except when bathing/showering or swimming. 
Accelerometers were programmed for an epoch length of one minute and the 
average daily movement count (vertical axis) and daily step count over a seven- 
day period were recorded.
Secondary outcomes included fatigue, HRQoL, functional ability and 
neurological impairment. Fatigue , was assessed using the Modified Fatigue 
Impact Scale (MFIS).16 HRQoL was measured using the MSQoL-54.17 The 
Multiple Sclerosis Functional Composite (MSFC)18 was used as a measure of 
clinical functional ability. It includes a timed 25-foot walk and measures of 
arm/hand function (9-hole peg test) and cognitive function (Paced Auditory 
Serial Addition Test: PASAT). Functional exercise capacity was assessed using 
the six-minute walk test (6MWT).19 The EDSS20 (neurological impairment and 
disability) was assessed by a single trained consultant neurologist according to 
standard clinical procedures21 in the hospital setting. Other outcomes were 
blindly assessed by an experienced researcher not directly involved with the 
day-to-day running of the trial.
6.4.6 Sample size
The sample size estimation was based on self-reported physical activity data 
(GLTEQ) from our pilot study.22 It was estimated that a sample of 50 patients for 
each group would be sufficient to detect a moderate effect size difference (80% 
power and a 5% significance level) in GLTEQ (standard deviation, SD = 2.29). 
Hence, we aimed to recruit 60 participants for each group to allow for a 15% 
loss to follow-up at the primary time point (based on our pilot study data).22
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6.4.7 Statistical analysis
Repeated-measures mixed modelling was used to compare outcomes between 
the randomised groups at the three- and nine-month follow-ups, adjusting for 
baseline score, EDSS and gender. The distribution of the majority of outcomes 
were skewed, therefore the analyses were bootstrapped (1000 replications) to 
provide more reliable estimates. All analyses were by intention to treat, whereby 
participants were analysed in the arm to which they were randomised 
irrespective of whether they complied with the intervention. Multiple imputation 
of missing values was performed using the imputation by chained equations 
(ICE) command in STATA 12. Variables included in the imputation were age, 
gender, baseline EDSS, and baseline, three- and nine-month follow-up scores 
for all outcomes. Five imputations were carried out and mixed-model analysis 
was performed on each imputed dataset. The adjusted means and confidence 
intervals (CIs) from each analysis were then consolidated using Rubin’s rules. 
Sensitivity analysis was performed to determine the effect of outliers in the 
GLTEQ scores by their removal from the analysis. Bivariate associations 
between key variables were analysed using the Pearson Product Moment 
correlation coefficient. No corrections for multiple testing were made in the 
analysis. Analyses were undertaken by the trial statistician, blinded to treatment 
allocation, using STATA 12 and results are generally reported as means and 
CIs.
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6.5 Results
6.5.1 Participant flow and recruitment
The trial took place from March 2009 to August 2012. Of 349 potential 
participants who were assessed for eligibility, 120 (34%) were randomised 
(Figure 6.1). The two groups had similar demographic, anthropometric and MS 
disease characteristics at baseline (Table 6.1). In the two years preceding the 
study, 55 relapses were experienced by 30 participants in the usual care group 
in comparison to 54 relapses experienced by 33 participants in the exercise 
group.
Table 6.1. Baseline characteristics of participants allocated to usual care only or 
usual care plus EXIMS. Values are numbers (percentages) or mean ± SD.
Characteristics Usual care group(n = 60) EXIMS group(n = 60)
Age (years) 46.0 ± 8.4 45.7 ±9.1
Female 43 (71.7%) 43 (71.7%)
White 57 (95%) 54 (90%)
Employed full time 16(27%) 9(15%)
Employed part time 14 (23%) 17(28%)
Time since MS diagnosis (years) 9.2 ± 7.9 8.4 ± 7.4
EDSS score subgroup 3.8 ±1.5 3.8 ± 1.5
0-3.5 28 (47%) 29 (48%)
4.5-6.5 32 (53%) 31 (52%)
Mean score 3.8 ± 1.5 3.8 ± 1.5
MS subtype
Relapsing-remitting 47 (78%) 51 (85%)
Secondary progressive I I  (18%) 7(12%)
Primary progressive 2 (3%) 2 (3%)
Anthropometric variables and blood
pressure
Height (m) 1.68 ±0.07 1.68 ±0.08
Body mass (kg) 76.4 ± 15.5 79.4 ± 17.8
BMI (kg/mJ) 27.1 ±5.8 28.0 ± 5.4
Waist circumference (cm) 92.8 ± 13.6 95.1 ± 14.4
Waist:Hip ratio 0.86 ± 0.08 0.87 ± 0.09
Systolic blood pressure (mm Hg) 129 ± 16 126 ± 14
Diastolic blood pressure (mm Hg) 82 ± 10 83 ± 10
MS: multiple sclerosis; EDSS: Expanded Disability Status Scale; BMI: body mass index.
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6.5.2 Loss to follow-up and MS relapses
A total of 13 participants (six from the intervention group and seven from the 
usual care group) were lost to follow-up at three months. An additional eight 
participants were lost to follow-up at nine months (five from the intervention 
group and three from the usual care group; Figure 6.1). Participants that 
dropped out of the study were slightly younger than the study completers (43.3 
vs 46.3 years) and had higher baseline EDSS and total fatigue scores (4.5 vs
3.6 and 48.0 vs 42.6, respectively). During the nine-month study period, 16 MS 
relapses were experienced by 14 of the usual care participants in comparison to 
10 MS relapses experienced by nine participants in the exercise group. 
Participants were encouraged to rejoin the trial following recovery, and 
complete or partial follow-up data were obtained for 21 of the 23 relapsing 
participants.
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Allocated to Usual Care 
(n=60)
120 Recruited to the study 
and randomised
Allocated to EXIMS 
(n=60)
6 withdrew
•  MS relapse (n=l)
•  III health
•  Poor adherence(n=l)
•  Unable to contact (n=2)
349 potential participants 
approached at MS clinic or 
responded to recruitment 
letter
7 withdrew
•  MS relapse (n=l)
•  III health (n=2)
•  Work commitments (n=l)
•  Unable to contact (n=3)
229 Excluded
•  Eligibility criteria not met (n=39)
•  Other commitments (n=23)
•  Too far to travel (n=30)
•  Not interested in exercise (n=10)
•  Worries about losing welfare 
benefits (n=l)
•  No reasons given (126)
Follow-up 1 (n=53) Follow-up 1 (n=54)
3 withdrew
•  No reason given (n=l)
•  Unable to contact (n=2)
5 withdrew
•  MS relapse (n=l)
•  Unable to contact (n=4)
Follow-up 2 (n=49)Follow-up 2 (n=50)
Figure 6.1. Flow of participants through the trial. EXIMS: pragmatic Exercise 
Intervention for people with MS.
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6.5.3 Adherence to the EXIMS intervention
Adherence to the supervised and home-exercise sessions was very good, with 
participants attending an average of 16.2 of the 18 supervised sessions (90%; 
range 7-18 sessions) and participating in an average of 14.6 of the 18 
prescribed home-exercise sessions (81%, range 2-18 sessions). Home 
exercise during the intervention period comprised walking, use of home 
exercise equipment, public facilities (including swimming) and gardening for the 
majority of participants. The volumes of supervised and home-based aerobic 
exercise are presented in Figure 6.2. No serious adverse events or serious 
symptom exacerbations were recorded.
6.5.4 Primary and secondary outcomes
Baseline scores for the primary and secondary outcomes were comparable for 
the two groups (Table 6.2). An increase in GLTEQ was observed in the exercise 
group versus usual care at the primary time point of three months (p = 0.01) 
and a non-significant increase was still apparent after nine months (p = 0.08; 
Figure 6.3). The improvement in self-reported exercise behaviour was 
accompanied by increases in objectively measured daily step counts at three 
months (p = 0.009) in the exercise group versus usual care, but at nine months 
daily step counts were similar to baseline levels (Figure 6.3). All dimensions of 
fatigue were significantly improved in the exercise group in comparison with 
usual care at three months (p <0.0001), with the change in total fatigue scores 
being positively correlated with baseline levels (Table 6.3). Interestingly, volume 
of supervised aerobic exercise achieved was negatively correlated with the 
change in total fatigue scores at the three-month follow-up (Table 6.3).
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Table 6.2. Baseline primary and secondary outcome data for participants 
allocated to usual care only and usual care plus EXIMS. Values are presented 
as mean ± SD.
Characteristics Usual care group EXIMS group
Mean (SD) N  Mean (SD) N
Physical activity 
Godin LTEQ score 
Accelerometer daily step counts 
Fatigue 
Physical 
Cognitive 
Psychosocial 
Total MF1S 
MSQoL-54 
Physical health 
Role limit physical 
Role limit emotional 
Pain
Emotional well-being 
Energy
Health perceptions 
Social function 
Cognitive function 
Health distress 
Sexual function 
Change in health 
Sex satisfaction 
Overall quality of life 
Physical health component 
Mental health component 
MSFC 
25-ft walk test (s)
9-hole peg test DH average 
9-hole peg test NDH average 
PASAT
Six-minute walk test (m)
17.5 ( 14.8) 59
4695 (2711) 59
2 1.6 (7.5) 60
17.2 (8.1) 60
4.0 (2.1) 60
42.8(15.7) 60
52.2 (30.1) 60
32.9 (38.6) 60
60.6 (43.2) 60
65.7 (24.1) 60
65.1 (18.3) 60
39.0(16.5) 60
42.3(18.4) 60
65.3 (24.8) 60
67.5 (21.0) 60
57.8 (26.4) 60
70.0 (32.7) 55
45.4(19.3) 60
52.3 (28.6) 55
62.4 (20.3) 60
51.2(18.8) 60
62.8 (21.7) 60
8.9(10.6) 59
25.0 (6.1) 59
29.6(13.4) 60
43.3 (14.2) 60
395 (140) 57
20.3 (21.9) 58
4488(2251) 60
22.7 (7.9) 60
18.3 (9.2) 60
4.1 (2.0) 60
45.0(17.0) 60
45.7 (28.7) 60
31.8 (40.7) 59
58.8 (43.9) 59
63.0 (29.6) 60
64.2(18.8 60
39.9(20.1) 60
42.0 (23.3) 60
66.0 (23.3) 60
61.3 (25.0) 60
52.5 (28.4) 60
64.4(31.8) 55
44.6 (24.0) 60
53.1 (29.5) 57
58.3 (21.8) 60
48.8 (21.5) 60
59.5 (22.5) 60
8.2 (6.6) 60
26.0 (8.9) 59
27.7 (7.6) 59
40.6(13.8) 60
373 (134) 59
EXIMS: pragmatic EXerclse Intervention for people with MS; LTEQ: Leisure Time Exercise Questionnaire; MFIS: Modified Fatigue Impact Scale; 
MSQoL-54: MS quality of life-54; MSFC: Multiple Sclerosis Functional Composite; PASAT: Paced Auditory Serial Addition Test; DH: dominant hand; 
NDH: non-dominant hand.
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Figure 6.3. Adjusted mean differences in self-reported exercise (GLTEQ) and 
accelerometry step counts between the intervention and usual care control 
groups at 3 months and 9 months (adjusted for baseline, gender and EDSS). 
Values are means with error bars representing 95% confidence intervals. **p^
0.01 between the groups. GLTEQ: Godin Leisure Time Exercise Questionnaire.
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The improvements in fatigue were not maintained at nine months (Table 6.4). 
Positive changes in many quality of life domains in favour of the exercise group 
were also observed at three months, with improvements in emotional well-being 
(p = 0.01), social function (p = 0.004) and overall quality of life (p = 0.001) being 
maintained for nine months (Table 6.4). The exercise intervention had no effect 
on functional ability or neurological impairment (Table 6.4). At baseline, EDSS 
scores were positively correlated with total fatigue scores and negatively 
correlated with the volume of aerobic exercise achieved (Table 6.3). Body 
weight also remained unchanged in both groups but there was evidence of a 
reduction in waist circumference at both follow-up time points (non-significant at 
three months) and reduction in diastolic blood pressure at nine months in the 
exercise group versus usual care (Table 6.5). Multiple imputation analysis gave 
similar results to the primary available case analyses, and exclusion of outliers 
in GLTEQ scores had no impact.
Table 6.3. Bivariate association between EDSS, total fatigue, GLTEQ and total 
volumes of supervised and home-based aerobic exercise for the intervention 
group.
Total fatigue (B/L) A GLTEQ A Total fatigue Supervised aerobic 
exercise (min)
Home-based aerobic 
exercise (min)
EDSS (B/L) 0.36b -0 .I2 0.24 -0.62b -0.29’
Total fatigue (B/L) 0.03 0.37b -0 .4 1b —0.12
A GLTEQ -0.08 0.00 0.03
A Total fatigue -0.32’ -0.05
EDSS: Expanded Disability Status Scale; GLTEQ: Godin Leisure Time Exercise Questionnaire. Values in the table show Pearson Product Moment 
correlation coefficients. B/L indicates baseline measures; A indicates difference between baseline and three-month follow-up; Total volumes of super­
vised and home-based aerobic exercise are shown in minutes; *p < 0.0S; bp < 0.01.
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Table 6.4. Secondary outcomes at three months and nine months in 
participants allocated to usual care and usual care plus EXIMS.
Follow-up time 
point (months)
Usual care group 
mean (sd)
EXIMS group 
mean (sd)
Difference in adjusted 
means (95% Cl)
Bootstrapped p value
Fatigue
Physical 3 21.2(8.9) 17.9(8.3) -4.3 (-6.2 to -2.5) <0.0001
9 20.7 (8.5) 20.1 (7.8) -1.2 (-3.0 to 0.7) 0.22
Cognitive 3 17.7(8.2) 14.9(9.6) -3.6 (-5.5 to -1.8) <0.0001
9 16.7(9.6) 16.0(8.8) -1.4 (-3.3 to 0.5) 0.15
Psychosocial 3 4.2 (2.1) 2.9 (2.2) -1.2 (-1.7 to -0.7) <0.0001
9 4.0 (2.4) 3.5 (1.9) -0.3 (-0.8 to 0.3) 0.36
Total MFIS 3 43.2(17.3) 35.8(18.2) -9.2 (-12.8 to -5.7) <0.0001
9 41.3 (18.8) 39.6(16.6) -2.9 (-6.6 to 0.8) 0.12
MSQoL-54 
Physical health 3 51.4 (31.2) 52.8 (27.4) 6.9 (2.8 to 11.0) 0.001
9 54.3 (33.1) 51.9(28.8) 2.9 (-1.5 to 7.3) 0.20
Role limit physical 3 40.2 (42.2) 47.1 (40.4) 7.6 (-1.9 to 17.2) 0.12
9 39.4 (43.6) 39.6(41.2) -0.8 (-10.2 to 8.7) 0.88
Role limit emotional 3 64.1 (42.1) 70.6(41.4) 7.7 (-4.9 to 20.2) 0.23
9 61.0(46.3) 67.4 (39.8) 4.8 (-8.2 to 17.9) 0.47
Pain 3 67.2 (26.6) 70.2 (25.9) 5.4 (0.5 to 10.2) 0.03
9 64.0 (25.6) 64.5 (28.3) 1.0 (-4.2 to 6.2) 0.70
Emotional well being 3 54.3 (14.2) 60.2(12.9) 7.3 (3.5 to l l. l ) <0.001
9 66.2(21.9) 71.4 (17.5) 5.9 (1.2 to 10.5) 0.01
Energy 3 38.1 (18.9) 53.2(18.2) 13.6 (8.8 to 18.3) <0.0001
9 41.3(18.3) 46.1 (19.4) 2.5 (-2.2 to 7.2) 0.29
Health perceptions 3 40.3 (20.0) 50.2 (24.0) 9.4 (4.7 to 14.1) <0.001
9 44.0(19.5) 43.9(19.7) -1.4 (-6.7 to 3.9) 0.61
Social function 3 67.5 (25.0) 76.9 (21.3) 8.9 (4.2 to 13.5) <0.001
9 65.8(25.1) 74.1 (21.7) 7.1 (2.2 to 12.0) 0.004
Cognitive function 3 67.6(21.1) 67.0 (27.4) 4.4 (-0.2 to 9.0) 0.06
9 69.9 (22.9) 66.4 (27.8) l.l (-4.0 to 6.2) 0.68
Health distress 3 61.8 (26.9) 68.7 (24.9) 11.5 (6.6 to 16.4) <0.001
9 63.2 (25.8) 61.6(26.4) 1.3 (-4.5 to 7.0) 0.67
Sexual function 3 70.4 (29.4) 74.1 (30.3) 7.5 (1.3 to 13.7) 0.02
9 69.4 (29.6) 71.8 (25.9) 4.2 (-2.9 to 11.2) 0.25
Change in health 3 44.5 (22.2) 62.0 (24.5) 17.6 (10.9 to 24.4) <0.0001
9 47.3 (20.3) 50.0(21.9) 3.0 (-3.8 to 9.9) 0.39
Sex satisfaction 3 51.6(33.5) 64.1 (27.7) 9.8 (2.3 to 17.3) 0.01
9 56.9 (31.0) 58.0 (25.2) 0.19 (-7.7 to 8.1) 0.96
Overall quality of life 3 60.6(19.2) 68.1 (20.3) 9.9 (6.3 to 13.5) <0.0001
9 60.4(21.1) 65.9(20.1) 6.7 (2.6 to 10.7) 0.001
Physical health component 3 52.5(21.4) 59.7 (20.6) 9.0 (5.6 to 12.4) <0.0001
9 53.3 (21.1) 54.1 (21.7) 2.0 (-2.0 to 6.0) 0.32
Mental health component 3 60.8 (20.0) 65.5 (20.2) 7.3 (2.6 to 12.0) 0.002
9 63.8(24.1) 65.9 (21.0) 3.5 (-2.1 to 9.2) 0.22
MSFC 
25-ft walk test (s) 3 9.9(16.4) 6.7 (4.1) -1.4 (-3.0 to 0.2) 0.09
9 8.8(10.8) 7.2 (4.7) 0.4 (-1.0 to 1.9) 0.58
9-Hole pin test DH average 3 25.2 (7.4) 26.4(13.1) -0-6 (-1.7 to 0.5) 0.26
9 25.8(10.5) 26.9 (14.7) -1.5 (-3.0 to 0.1) 0.06
9-Hole pin test NDH average 3 28.4(14.8) 26.8 (7.8) -0.6 (-1.8 to 0.6) 0.30
9 29.4(14.9) 27.0 (7.7) -0.7 (-1.7 to 0.4) 0.21
PASAT 3 46.0(13.7) 41.9(15.0) -1.8 (-4.4 to 0.8) 0.17
9 46.9(13.9) 47.4 (9-9) 2.3 (-0.4 to 5.0) 0.10
Six-minute walk test (m) 3 398 (152) 406(128) 13 (-6 to 31) 0.18
9 382(169) 394(137) 18 (-9 to 46) 0.20
MFIS: Modified Fatigue Impact Scale: MSQoL-54: MS quality of life-54; MSFC: Multiple Sclerosis Functional Composite: PASAT: Paced Auditory Serial Addition Test: D H : 
dominant hand: N D H : non-dominant hand; 95% Cl: 95% confidence Intervals: values are presented as mean (±SD), w ith difference scores adjusted for baseline, gender 
and Expanded Disability Status Scale (EDSS).
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Table 6.5. Anthropometric, blood pressure and EDSS scores at three- and nine- 
month follow-ups in participants allocated to usual care only and usual care plus 
EXIMS.
Follow-up time point Usual care group 
(months) mean (SD)
EXIMS group 
mean (SD)
Difference in adjusted 
means (95% Cl)
Bootstrapped 
p value
Body mass (kg) 3 77.0(15.6) 79.1 (18.0) 0.4 (-0.8 to 1.5) 0.52
9 77.3 (15.6) 78.8(18.7) 0.1 (-1.2 to 1.5) 0.88
BMI (kg/m2) 3 27.2 (5.9) 28.0 (5.2) 0.2 (-0.3 to 0.7) 0.51
9 27.2(6.1) 28.0 (5.5) 0.3 (-0.4 to 1.0) 0.40
Waist
circumference (cm)
3 90.9(14.0) 90.5 (14.3) -1.4 (-2.8 to 0.1) 0.07
9 91.3 (14.2) 90.5 (14.7) -2.0 (-3.7 to -0.2) 0.03
WaisoHip ratio 3 0.85 (0.09) 0.85 (0.09) -0.002 (-0.02 to 0.01) 0.71
9 0.85 (0.09) 0.84 (0.09) -0.01 (-0.02 to 0.002) 0.10
Systolic blood 
pressure (mm Hg)
3 129.6(18.4) 125.6(13.0) - l . l  (-4 .0 to 1.7) 0.44
9 127.2(16.4) 124.8(13.6) 0.1 (-3.1 to 3.3) 0.94
Diastolic blood 
pressure (mm Hg)
3 83.0(10.7) 81.9 (8.6) - l . l  (-3.2 to 0.9) 0.28
9 83.8(10.1) 81.5 (8.6) -2.3 (-4.6 to -0.1) 0.04
EDSS 3 3.9 (1.6) 3.5 (1.3) -0.1 (-0.4 to 0.2) 0.41
9 3.9 (1.7) 3.7 (1.5) —0.1 (—0.4 to 0,2) 0.36
EXIMS: pragmatic EXercise Intervention for people with MS; BMI: body mass Index; EDSS: Expanded Disability Status Scale. Values are presented as 
mean (±SD), with difference scores adjusted for baseline, gender and EDSS.
6.6 Discussion
This was the first robustly designed randomised controlled trial to investigate 
the effects of a practically implemented progressive exercise programme on 
self-directed exercise behaviour and important health outcomes in PwMS up to 
nine months of follow-up. Significant increases in self-reported exercise 
behaviour (GLTEQ) and step counts were observed in the intervention group 
versus controls at three months. A smaller difference in GLTEQ score (6.9 
points, 95% Cl: -0.9 to 14.7) in favour of the intervention group was also 
apparent after nine months, though this was not statistically significant and 
there was no evidence of a sustained increase in step counts at this time point.
Whilst the GLTEQ is reported to be a valid measure of habitual exercise
behaviour in PwMS,15 the possibility that self-reporting bias explains the
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discrepancy between GLTEQ scores and accelerometry step counts at nine 
months cannot be overlooked. However, difficulties interpreting accelerometer 
step-count data in PwMS have been highlighted,23 and activities such as 
stationary cycling, seated upper-body exercise, gardening and swimming can 
go undetected when using accelerometry. Although body weight remained 
unchanged, evidence of a reduction in waist circumference at both follow-up 
time points (non-significant at three months) and the reduction in diastolic blood 
pressure at nine months provides support for the maintenance of physical 
activity in the exercise group. These findings also show that the exercise 
intervention had an important impact on risk factors for cardiovascular disease. 
Hence, the apparent discrepancy between GLTEQ score and accelerometry 
step counts may reflect a shift to predominantly undetectable non-ambulatory 
activities over the study follow-up period, but this needs to be verified by future 
research. Despite this, our results suggest that the magnitude of change in self­
directed exercise behaviour at nine months was reduced and was less clinically 
relevant.
The exercise group experienced improvements in multidimensional fatigue and 
in most HRQoL dimensions at three months. These improvements are 
consistent with previous systematic reviews,24,25 although some conflicting 
evidence also exists.26,27 Fatigue negatively affects HRQoL28 and has a major 
impact on the high levels of unemployment in PwMS,29 with ^75%  of the MS 
population experiencing symptoms persistently or sporadically.30 For these 
reasons, pragmatic interventions that can alleviate fatigue are likely to have an 
important impact on HRQoL and ability to remain in employment. Baseline 
fatigue scores in the exercise group were positively associated with EDSS
scores at baseline and the reduction in symptoms observed at the three-month
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follow-up. This suggests that PwMS experiencing the highest levels of fatigue 
also experienced the greatest improvements with exercise training. However, 
higher volumes of supervised aerobic exercise were associated with less 
pronounced reductions in fatigue, suggesting that there could be an optimum 
level of aerobic exercise for symptom relief in PwMS. The changes in fatigue 
and GLTEQ scores were unrelated.
Improvements in emotional well-being, social function and overall HRQoL were 
maintained to nine months in the exercise group (versus controls), whereas the 
difference between groups in other HRQoL domains and fatigue was diminished 
at the final follow-up. The lack of a sustained improvement in other HRQoL 
domains and fatigue might be explained by a reduction in self-directed exercise 
over the follow-up period. Although previous studies suggest that short-term 
exercise interventions can have lasting effects on fatigue and HRQoL up to 
three months,2,31,32 continued engagement in exercise is likely to be needed for 
the longer-term enhancement of many HRQoL dimensions and MS fatigue. A 
higher level of contact with participants after the intervention period could have 
been used to provide additional support and motivation for self-directed 
exercise. Although this has resource implications, our results suggest that 
strategies for maintaining contact with participants after an initial period of 
supervision (e.g. posted literature, mobile phone text messaging, social media, 
etc.) warrant further investigation.
There were no changes in measures of functional ability (6MWT) or 
neurological impairment (EDSS and MSFC) and these results are consistent 
with some4,26,31,33,34 but not all previous exercise intervention studies.3,26,27 
Evidence suggests that regular exercise may be more effective in retarding
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disease progression in PwMS,35 rather than reversing the neuropathological 
changes that underpin neurological and functional impairments.36
A key limitation of the study is that it included ambulatory participants with only 
mild to moderate disease (EDSS ^  6.5) and at the present time, the 
effectiveness of exercise interventions for people with more severe disability is 
unknown. Many eligible PwMS declined to take part in the study without giving a 
reason (N = 126; 66%) and a more comprehensive understanding of the 
barriers and facilitators to exercise in PwMS could be used to inform the design 
of future programmes. In the remaining 34%, unwillingness to travel, other 
commitments, not being interested in exercise and worries about losing welfare 
benefits were cited as the reasons for not taking part. At least 30 potentially 
eligible PwMS considered the distance too far to travel (Figure 1), hence, 
providing the supervised component in a broader range of community settings 
may help to engage more PwMS in exercise programmes.
In conclusion, the observed improvements in self-directed exercise behaviour, 
HRQoL and fatigue suggest that EXIMS could be an effective way to practically 
implement progressive exercise rehabilitation within health care settings. 
EXIMS provides a tailored programme of preferred supervised and home-based 
exercises that are appropriate for individuals with different physical abilities and 
the level of uptake (39%) and high level of adherence (>80%) provides 
evidence that it is accessible to many PwMS. This study recruited participants 
with a range of neurological impairment (EDSS: 1.0-6.5), suggesting the results 
can be generalised to a broad spectrum of ambulatory PwMS. Strategies for 
promoting continued contact between participants and exercise practitioners 
beyond the initial period of supervision, however, may be needed to maintain
meaningful improvements in important health outcomes.
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7.0 GENERAL DISCUSSION
7.1 Review of Findings
This thesis includes five published papers based around the design and 
implementation of a pragmatic exercise trial for PwMS. The first study paper 
(chapter three) investigated the feasibility of such an approach. The following 
chapters (chapter four to seven) contain the study protocol, recruitment details, 
key findings and cost-effectiveness data from the main trial (ExIMS).
7.1.1 Feasibility Trial
The feasibility trial presented in this thesis (chapter three) explored the 
feasibility of a pragmatic exercise intervention (supervised and home-based), 
that was both tailored to the individual and designed to promote confidence and 
motivation for long-term exercise behaviour change. Our results suggest that 
this type of trial design is feasible and effective for PwMS, with excellent 
retention (10 weeks, 93%; 3 months, 86%) and high compliance (>75% of all 
sessions) alongside a good progression in training load (duration and intensity). 
Moreover, our initial data suggests that important behavioural and QoL benefits 
might be experienced by PwMS and retained for up to three months follow-up. 
However, the impact of this type of intervention long-term should be viewed with 
caution as this may not reflect adherence to exercise beyond three month. 
Despite the reported benefits of exercise (Latimer-Cheung et al., 2013; Sa, 
2013) PwMS participate in less physical activity (Ellis and Motl, 2013) than the 
general population and appear to find long-term adherence to exercise 
interventions difficult (Hale et al., 2012). Therefore our results suggest that a 
pragmatically designed and theoretically underpinned exercise intervention may
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have the potential to increase the likelihood of long-term exercise behaviour 
change.
When retention was compared with previous supervised interventions of similar 
exercise load (73 to 85% at follow-up 1) (Petajan et al., 1996; Klieff and 
Ashburn, 2005; Van den Berg et al., 2006; Cakt et al., 2010) and other home- 
based trials (95 to 100% at follow-up 1) (DeBolt and McCubbin, 2004; 
Finkelstein et al., 2008) for PwMS, results were favourable. Moreover, retention 
in the feasibility trial was comparable to data reported after three months of 
follow-up (83% at 3 months follow-up) (McCullagh et al., 2008). Compliance 
was also excellent (80% of participants completing at least 70% of both 
supervised and home sessions), with the supervised component reporting 
similar figures to previous research (65 to 97%) (Petajan et al, 1996; Mostert 
and Kesselring, 2002; McCullagh et al., 2008). In addition, when compared to 
compliance in home-sessions during a similar combined exercise programme 
(100% of participants completing <50%) (McCullagh et al., 2008), this study 
design proved beneficial. Thus, suggesting that the addition of cognitive 
behavioural strategies to the study design may have had a positive impact on 
home-exercise behaviour.
The progression of exercise load was patient led and involved increasing
intensity and/or duration whilst maintaining an RPE of between 11 and 13
(Fairly light to somewhat hard). The progression reported in this study is similar
to other participant led progression rates (Rasova et al., 2006) and was well
tolerated (no adverse events). Exercise type was also participant led, with all
participants including treadmill, rowing and cycling ergometry in their supervised
programme, despite rowing only previously being recommended for well-
functioning patients (Dalagas et al., 2008). In addition, the most popular home
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exercise was walking, in accordance with previous research (Rasova et al.,
2006).
Cautious consideration of the outcome data reported indicated that PwMS can 
experience important clinical, physical and QoL benefits that may still be 
present after three months follow-up, as previously suggested by McCullagh et 
al., (2008). A large-scale trial, with a longer follow-up was warranted before 
conclusions regarding exercise benefits and maintenance could be determined.
7.1.2 Main Trial
7.1.2.1 Study Protocol
With this in mind chapter four outlines the protocol for an adequately powered 
two-group randomised control trial. The trial design aimed to generate new 
knowledge by investigating the effects of a pragmatic exercise trial containing 
cognitive behavioural strategies in a large population of PwMS for up to six- 
months of follow-up, reporting impact on physical activity behaviour, key health 
outcomes, and cost-effectiveness. In addition, the design included participants 
with slightly higher levels of disability from MS (up to EDSS 6.5 - Constant 
bilateral support required to walk 20 metres without resting) to determine impact 
on different disability levels, as suggested by Latimer-Cheung et al., (2013).
The study design was similar to that used in the feasibility study, containing 
cognitive behavioural strategies to promote long-term exercise behaviour 
change, exercise programmes that were individually tailored and a combination 
of home and supervised exercise sessions. However, the programme was 
extended from 10 to 12 weeks and changed to include a tapering of contact and
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an increase in home exercise sessions during the second six weeks to build the 
skills and confidence for long-term self-management.
The majority of exercise and physical activity research studies in MS prior to 
this thesis have been inadequately powered and of poor research design. With 
regard to intervention design most have included either home or supervised 
exercise interventions, with only a few using a combined (supervised and home- 
based) approach (Surakka et al., 2004). Moreover to our knowledge no 
previous research has looked at the impact of a combined tapered approach to 
exercise for PwMS, although this has been used in other clinical groups, such 
as prostate and breast cancer patients (Bourke et al., 2011a, 2011b, 2014; 
Rogers et al., 2014). In addition, only more recent research trials have included 
a cognitive behavioural approach in combination with an exercise intervention in 
PwMS (Beckerman et al., 2013; Coote et al., 2014), thus making this study 
design unique, with design elements included to promote long-term exercise 
behaviour change.
7.1.2.2 Trial Recruitment
Chapter five provides a detailed account of the recruitment methods, rates and 
estimated costs for the main study trial. The main purpose of this chapter was to 
provide recruitment data to inform future research of this type and to determine 
which recruitment methods were the most successful in terms of numbers and 
cost per participant. This type of in-depth data for exercise interventions in MS 
is currently unavailable and will assist the design of future trials, enabling them 
to achieve recruitment targets in a timely fashion. This is essential if we are to 
ensure that research is adequately powered and does not require costly
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extensions to enable completion (Treeweek et al., 2011; Polman et al., 2011). 
The recruitment data show that a variety of recruitment methods need to be 
employed if participants are to be recruited efficiently to exercise trials. Targeted 
consultant mail-outs were reported to be the most cost effective approach. 
However, insufficient numbers could be reached via this method and additional 
more time consuming methods, such as recruiting at MS outpatient clinics, was 
required for sufficient numbers of participants to be reached.
The recruitment rate of 3.5 participants per month achieved in this trial is 
comparable to other non-pharmacological intervention trials in MS. Previous 
interventions using PwMS have reported either marginally lower (Cooper et al., 
2011) or higher (Thomas et al., 2013) rates per month, with exercise 
intervention trials in other clinical populations again reporting similar rates of 
between 2.9 and 4.0 participants per month (Daley et al., 2007; Nary et al.,
2011; Taylor-Piliae et al., 2014). This indicates that this is a realistic target to 
use.
Response rates were highest from targeted consultant invite letters (42.8%) and 
lowest from attendance at MS outpatient clinics (6.4%), despite the large 
number of PwMS attending clinics, many did not meet the eligibility criteria. 
These methods should not however be discounted as the trial recruited 60% of 
its participants from this route, with only 29.2% coming from consultant letters 
and 10.8% from other trial awareness strategies. Randomisation yield (number 
recruited/number interested) for recruitment from the MS outpatient clinics and 
consultant letters was similar (33.2% and 31.0% respectively), suggesting both 
methods are useful in attaining targets.
The most common reason given for ineligibility to participate in the trial was
already being too active (69.2%), this is consistent with results reported for
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similar exercise trials in cancer survivors, where 55% were to active (Daley et 
al., 2007). This is surprising given the low levels of physical activity reported in 
the UK, with PWMS reported to be even more inactive than the general 
population (Klaren et al., 2013). However, those who wish to take part in an 
exercise study are likely to have an interest in and be more motivated to 
exercise. This suggests that we may not be reaching those who have limited 
interest in exercise and may need to look at more appealing interventions and 
other ways to incentivise this group to volunteer to take part in trials of this type. 
Options could include offering taster sessions prior to consent.
Many eligible participants (66.3%) chose not to give a reason for declining to 
participate. However, of those who did, travel to the site was the most 
commonly cited reason. Ensuring adequate travel arrangements or arranging 
community venues for exercise sessions could alleviate these concerns and 
should be considered in the design of future exercise trials in MS.
To adequately budget for recruitment to future trials it is important to not only 
understand where participants were recruited from, but how long it took to 
recruit each participant, with some community-based interventions reporting to 
take up to 10 hours per participant to recruit (Rdesinski et al., 2008). This trial 
reported that consultant mail-out was the most efficient method of recruitment at 
0.6 hours per participant, with MS outpatient clinics requiring seven times this 
amount at 4.2 hours per participant. This provides an indicator of the time 
allocation required for recruitment in future trials. The results from this study 
provide a unique insight into trial recruitment for exercise interventions in MS 
and may be used to inform the design of future trials of this type.
Future trials would benefit from using a comprehensive recruitment strategy that
includes methods to recruit individuals less keen on exercise, to ensure that a
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representative sample of patients is recruited in an efficient and timely fashion.
If the project is of a similar design and requires more than three patients a 
month to be recruited, a multi-centre trial is recommended. This would have the 
added benefits of testing generalisability across a variety of different settings.
7.1.2.3 Main Trial Results
Following on from the design of the ExIMS trial reported in chapter four and the 
recruitment strategies reported in chapter five, chapter six reports the primary 
and secondary outcome data from the main trial. Additional cost-effectiveness 
data is reported in appendix 8.15. The paper reported in chapter six aims to 
demonstrate if a robust pragmatically designed intervention, containing 
cognitive behavioural strategies to promote long-term participation, would show 
an increase in physical activity levels and improved health outcomes at up to 
nine months of follow-up, when compared with usual care. In addition the paper 
looks at dose response relationships and whether level of disability from MS 
has an impact on outcomes.
This research fills an essential gap in knowledge, as despite a large volume of 
literature in the area of exercise and MS, many questions have remained 
unanswered (Reitberg et al., 2005; Asano et al., 2009). The majority of current 
trials have been of poor quality and have not involved a pragmatic approach 
with cognitive behavioural strategies to promote long-term adherence to 
exercise (Asano et al., 2009). Moreover, none have begun to answer the 
questions regarding the dose response relationship and the impact of disability 
status on outcomes. The ExIMS trial reported significant improvements in 
exercise behaviour (GLTEQ and accelerometer step counts), fatigue and health
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related QoL at three months follow-up, with significant improvements in 
emotional wellbeing, social function and overall QoL being sustained at up to 
nine months follow-up. These improvements were reflected in the effect sizes 
calculated, where small to moderate effects were reported (Appendix 8.14).
In line with previous systematic reviews on exercise interventions for PwMS 
(Latimer-Cheung et al., 2013) ExIMS reported a significant increase in physical 
activity (GLTEQ and step count) at three months follow-up. However, only the 
self-report data (GLTEQ) showed a notable sustained increase at nine months. 
There are two possible reasons for this, firstly self-report bias could have 
impacted on the data reported in the questionnaire and secondly, accelerometry 
for PwMS can be difficult to interpret (Weikert et al., 2010) and does not 
account for activities such as swimming, cycling and rowing ergometry, which 
were reported to be popular in the feasibility trial for this study (Carter et al., 
2013). However, physiological data collected for diastolic blood pressure and 
waist circumference did indicate that there may still have been some increase in 
physical activity levels at nine months follow-up, with both showing significant 
improvement. Thus, suggesting that the programme may have an important 
long-term impact on cardiovascular health for PwMS. This is essential as PwMS 
are reported to have 2.4 times greater risk of death due to cardiovascular 
disease than the general population (Lalmohamed et al., 2012).
In addition to the significantly increased physical activity reported for the
intervention group, when compared with usual care control at three months
follow-up, multidimensional fatigue and most dimensions of health related QoL
were also significantly improved. This is comparable with data reported in
previous systematic reviews on exercise interventions for PwMS (Motl and
Gosney, 2008; Andreason et al., 2011). When physical activity was no longer
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reported to be significantly enhanced at nine months, follow-up improvements 
were no longer noted in fatigue and some of the health related QoL domains, 
despite improvements in emotional wellbeing, social function and overall quality 
of life remaining significant when compared with usual care control.
Previous research suggests that improvements in fatigue and QoL can be 
maintained up to three months follow-up even when improvements in exercise 
capacity have returned back to normal (McCullagh et al., 2008). No measures 
were taken in the current study at three months post intervention and it is 
possible that by six months post intervention that these changes had 
diminished. Thus, suggesting that continued engagement in exercise is required 
to maintain improvements in fatigue. This is supported by current literature that 
suggests that although the cause of MS fatigue is unknown it may be linked to 
immune dysfunction, with pilot work suggesting that aerobic exercise activates 
genes responsible for the immune response not observed in healthy controls. 
However, this disappears when exposure to exercise is removed (Mulero et al., 
2015).
The study also reported that individuals experiencing the highest levels of
fatigue at baseline, experienced the greatest improvements from the exercise
intervention. This is comparable with the hypothesis drawn in the systematic
review by Andreasen et al., (2011), who suggested that exercise interventions
that demonstrated an impact on fatigue were those that had clinically fatigued
patients at baseline. Chapter six also indicates that PwMS achieving high
volumes of exercise during the intervention reported less pronounced
improvements in fatigue, implying that an optimum level of training may exist.
This finding warrants further research as data reported in a systematic review
by Andreasen et al., (2011), suggests that at present 'it is not possible to draw
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solid conclusions on optimal exercise duration, frequency and intensity'. It is 
likely that maintenance of exercise and hence fatigue and health related QoL 
domains during the follow-up may have been enhanced if the protocol had 
included additional contact with participants in the six month period following the 
intervention. However, this additional resource would increase the cost of the 
intervention and may impact on the cost-effectiveness results reported in 
chapter seven.
The ExIMS trial did not show any significant changes in functional ability 
(6MWT) or neurological impairment (MSFC, EDSS) when compared with usual 
care control. However, the study was not powered to demonstrate a change in 
these outcomes. In addition, studies lasting less than a year have only been 
reported to show subtle differences in EDSS (Brown and Kraft, 2005).
7.1.2.4 Economic Evaluation
Chapter six builds on current evidence that suggests that exercise can be 
beneficial for PwMS. However, if exercise is to be integrated into services 
provided for PwMS an economic evaluation is required to determine if the 
pragmatic approach used in the ExIMS trial provided a cost effective treatment 
strategy. The published article reporting the results of the economic evaluation 
for the ExIMS trial is contained in appendix 8.15. Data collected on hospital 
admissions suggested that there were four admissions during the trial, despite 
the scoping review in this thesis suggesting exercise to be safe. Due to the 
relapsing remitting nature of most of the participants in this trial, this is not 
considered abnormal or related to the intervention, with admissions in the usual 
care and exercise groups being similar. Data collected from ExIMS suggests
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that the exercise intervention group was both more expensive and more 
effective than usual care alone, with no significant differences in cost or benefit 
between groups at six months follow-up. However, the intervention reported a 
high probability of being cost effective, with the calculated incremental cost 
effectiveness ratios (ICER) falling comfortably within the excepted thresholds of 
£20,000 per quality adjusted life years (QALY) used by NICE (Appleby et al.,
2007). These results were maintained regardless of whether ExIMS was to be 
provided in the NHS or privately. Furthermore, the intervention was likely to 
become more cost effective over time, with the costs occurring in the first three 
months. This suggests that the ExIMS intervention is likely to be cost effective 
and provide cost benefits to the NHS. In addition, sub-group analysis suggested 
that if the intervention were to be targeted towards those who were less active 
and more severely affected by MS then the cost effectiveness of the ExIMS trial 
may be even greater.
7.2 Limitations of the Present Research
The results reported in this thesis suggest that the pragmatically designed
ExIMS trial increases self-reported exercise behaviour, improves fatigue and
provides a sustained improvements in many of the health related QoL domains,
leading to a high probability of the intervention being cost effective. However,
these findings should be interpreted based on the strengths and limitations of
the research. The inclusion of a feasibility trial and a robust research design
offers considerable improvement on previous aerobic exercise trials in PwMS,
where participant numbers were much lower (between 11 and 54) (see Table
3a) and methodology often of poor quality (Doring et al., 2012). To our
knowledge the ExIMS trial is the first MS and exercise RCT, with concealed
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allocation, blind assessment and sample size based on statistical power 
calculations derived from a feasibility study. However, despite this, the research 
studies presented here do have some methodological weaknesses that should 
be taken into consideration when interpreting the findings presented in this 
thesis. The limitations fall into four main categories; research design, treatment 
fidelity, data interpretation and choice of outcome measures.
With regard to research design it should be noted that due to the nature of the 
intervention (exercise therapy) double blinding of participants and researcher 
was not possible, with only assessments able to be blinded. This is reported to 
possibly lead to exaggerated estimates of treatment impact (Schulz et al.,
1995). In addition, the use of a usual care control group, instead of an attention 
control, could impact on the internal validity of the study as it may not be clear if 
some of the improvements in outcome measures were due to the additional 
attention rather than the specific nature of the intervention. However, it is felt 
that the chosen study design of usual care control would be the most desirable 
in order to answer the question of whether the new treatment could improve 
outcomes over and above usual practice. The option of a three group design, 
with intervention plus usual care, attention plus usual care and usual care only 
(Freedland, 2013), may have resolved this issue. However this would have 
been beyond the scope of the funding for the ExIMS trial and would have 
involved more participants having to take part who were not receiving the 
potentially beneficial intervention treatment arm.
It is noted that the study could have contained more stringent assessment of
treatment fidelity, where treatment fidelity is defined as 'the degree to which an
experimental manipulation has been implemented as intended' (Taylor et al.,
2015). With regard to the physiological protocol it is felt that this was adequately
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controlled, as the study intervention was delivered by experienced researchers 
who followed a detailed protocol, with appropriate data collected on intervention 
dose (compliance and adherence). Nevertheless the study would have 
benefited from a built in treatment fidelity assessment to ensure the integrity of 
the behavioural element of the intervention. However, this was beyond the 
scope of the funding provided for the feasibility work and the main ExIMS 
research trial reported in this thesis.
With regard to the intervention design it is felt that the post intervention follow- 
up duration of three month (feasibility trial reported in chapter three) and six 
months (ExIMS trial reported in chapters four to seven), although longer than 
that reported in previous exercise trials in MS (Latimer-Cheung, 2013) may 
have still benefited from being extended further, in order to determine the true 
long-term impact of the programme. With some of the clinical outcome 
measures such as EDSS and MSFC reported to require at least one year 
before meaningful differences can be observed (Brown and Kraft, 2005). 
Moreover, it is felt that an extension to 12 months of follow-up would have 
improved the results from the cost effectiveness analysis (chapter seven), as 
intervention costs were front loaded. In addition, further contact during the 
follow-up phase may have been beneficial in providing additional support and 
motivation for long-term improvements in exercise behaviour, thus enhancing 
the maintenance of improved exercise behaviours during the follow-up phase. 
However, it is noted that this would have resource implications, which would 
have to be measured up against the potential benefits to be gained.
The generalizability of the results may have been limited as eligible and
interested participants who volunteered to participate in both the feasibility study
(chapter three) and the ExIMS trial (chapters four to seven) may not be
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representative of the broader MS population. This is likely to be due to the 
inclusion criteria limiting the study to participants that were ambulatory with an 
EDSS of up to 6.5, thus meaning that the results cannot be utilised with higher 
disability levels. In addition, there was only a limited number of individuals 
recruited at the higher end of the disability spectrum (5.0 - 6.5), limiting the 
ability of the study to determine the impact across different disability levels. 
Employing a recruitment strategy that ensured a balance of participants from 
each disability sub-group would have assisted with this, but may have led to an 
inadequate number of participants being recruited to the trial or a lengthy delay 
in completion. In addition, data from our recruitment paper (chapter five) 
suggested that those interested in being recruited to the trial had an interest in 
exercise participation with 69.2% being ineligible due to already being too 
active. This indicates that the impact of this intervention for PwMS not already 
contemplating exercise participation may differ to the results reported in this 
trial. Therefore, different recruitment strategies would be required to recruit this 
subset of the MS population.
There are two major considerations when interpreting the meaningfulness of the 
data reported in this thesis. Firstly, the study team were unable to conduct 
reliability and repeatability testing on the study population. This would have 
been the ideal scenario as it would have enabled better interpretation of the 
results in relation to the exact setting and population that they were based upon. 
However, data conducted independently on the reliability and repeatability of 
outcome measures used with PwMS does exist in the literature, a summary of 
which is outlined in the consensus meeting recommendations by Paul et al., 
(2014). In addition, this work was not covered by the ethics approval for this
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study and any further assessments would have increased participant burden, 
something the ethics committee had already raised concerns over.
Secondly, it must also be noted that the data from the ExIMS trial (chapter six) 
is generally reported in terms of means, p values and confidence intervals. How 
best to analyse and report data from RCT's is often debated by statisticians. 
However, there is a growing body of literature reporting the need for the data to 
be reported as p values, confidence intervals and effect sizes to enable the 
meaningfulness of the data to be correctly interpreted (Maher et al., 2013). 
Therefore, it is suggested that the data reported in this paper could be 
strengthened, if effects sizes were reported, in addition to the confidence 
intervals and p values reported in chapter six. These have been calculated and 
presented in appendix 8.14.
The final set of limitations reported for this thesis pertains to the outcome 
measures used. Firstly, as noted in the review of findings, self-report data 
formed part of the economic evaluation and exercise behaviour assessment. 
Although this is common procedure for economic results reported alongside 
clinical trials, it must be noted that this can lead to inaccurate results and 
incomplete data sets. However, the finite funding available for the ExIMS trial 
meant that this was the only option available to the study team. In addition, 
despite the GLTEQ used being reported as a valid measure of exercise 
behaviour in PwMS (Motl et al., 2006), there is a possibility of self-report bias 
inflating the results. Secondly, the general variability of outcome measures used 
to report findings from clinical trials with PwMS must be mentioned, as this 
makes the comparison of the results from ExIMS with other similar trials for 
PwMS difficult.
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7.3 Implications for Practice
There is a lack of quality evidence regarding exercise training and physical 
activity for PwMS (Reitberg et al., 2005; Asano et al., 2009). Therefore, many 
questions such as; what is the long-term impacts of exercise; is there an 
optimum dose and does this differ for different disability levels, remain 
unanswered (Doring et al., 2012; Sa, 2013). Current evidence is sufficient to 
suggest that mild to moderate intensity exercise is safe and effective at 
increasing fitness and may improve symptoms of fatigue and quality of life in 
patients with mild to moderate disability from MS (Latimer-Cheung et al., 2013; 
Sa, 2013). The ExIMS trial reported in chapter's four to seven was the first 
robustly designed pragmatic exercise trial for people with mild to moderate MS, 
designed to begin to answer some of these questions. The results from this 
thesis can be inferred for ambulatory individuals with mild to moderate disability 
from MS, with the effectiveness of the intervention for those with more severe 
disability from MS remaining unclear.
The ExIMS trial demonstrated that a pragmatic approach is effective at 
enhancing self-directed exercise behaviour and retaining some important health 
outcomes at up to six months of follow-up and is likely to be cost effective if 
implemented by the National Health Service (NHS).
In addition, it suggests that there is an optimum level of exercise for
improvements in fatigue and that exercise is likely to be more beneficial for
people experiencing higher levels of fatigue. Moreover, it indicates that some
long-term benefits in health related QoL are retained at up to six months follow-
up. However, it is suggested that for long-term improvements in fatigue
participants need to maintain the elevated levels of fitness achieved following
the three month intervention. Therefore it is recommended that coqnitive
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behavioural strategies form an essential component in the design of future 
exercise interventions, with further contact during follow-up required to maintain 
participant's confidence and motivation to exercise following the intervention. It 
should also be noted that the ExIMS trial is the only study to our knowledge to 
use an individually tailored programme guided by the individual, with input and 
advice from both specialist exercise scientists and physiotherapists. This 
approach is recommended in the future for the design of exercise programmes 
that provide PwMS with the ability to become more physically active and 
participate in more regular exercise.
This thesis provides valuable evidence to guide the design of future exercise 
interventions and provides robust and detailed data to enable more 
comprehensive guidelines for exercise and physical activity to be drawn up. On 
the basis of this new evidence it is recommended that exercise becomes part of 
the treatment pathway for PwMS within the NHS.
The broadcasting of the new knowledge made available from this thesis has 
been carried out within the scientific community through publication of the 
results (Saxton et al., 2013; Carter et al., 2013; Carter et al., 2014; Tosh et al., 
2014; Carter et al., 2015) and presentation at research conferences (Society for 
Research and Rehabilitation, 2009; European Committee for Treatment and 
Research in MS, 2010; Physiotherapy UK, 2014; British Association of Sport 
and Exercise Science, 2014). In addition, results and take-home messages 
have been presented at practitioner (MS Frontiers, 2009, neuroinflamation 
forum, 2011; newly diagnosed course, 2009; neurological enablement service, 
2010) and patient (MS Society living with MS days, 2009, 2010, 2012) led 
events to ensure the message is delivered to a wider audience. Moreover the
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published results from this trial have been cited in the updated 'NICE Guidelines 
for Management of Multiple Sclerosis in Primary and Secondary Care' (2014).
7.4 Directions of Future Research
To date review articles in the area of exercise and MS have consistently stated 
that there is a need for more high quality RCT's, with sample sizes based on 
statistical power calculations (Sa, 2013; Doring et al., 2012) and interventions 
tailored to individuals symptoms and lifestyle (Asano et al., 2009). In addition, 
there is also a need for studies to take into account different disability levels and 
longer-term impact (Doring et al., 2012). For exercise interventions to have the 
greatest impact there is a need for future studies to use a mixed methods 
approach, examining the motivational responses that determine exercise 
behaviour and enabling the barriers to exercise participation in this population 
group to be fully explored (Kasser, 2009), with studies also designed to include 
cognitive behavioural strategies to promote long-term exercise behaviour 
change (Coote et al., 2014; Giedl et al., 2014).
The publications presented in chapter three to seven of this thesis, begin to 
answer these questions. However, there are still many questions that need to 
be answered as most studies have involved people with mild to moderate 
disability from MS, exercising at a moderate intensity (Asano et al., 2009). 
Therefore, there is a requirement for further high quality RCT's designed to 
explore the following research topics:
• Exercise for people with more severe disability from MS (EDSS greater 
than 6.5).
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• The feasibility of higher intensity exercise for people with mild disability 
from MS.
• Early educational intervention to prevent rapid decline in exercise 
participation on diagnosis.
• The optimum type and dose of exercise for fatigue management for 
people with clinical levels of fatigue from MS.
7.4.1 Exercise for people with more severe disability from MS
Despite the rapid increase of research into exercise for people with mild to 
moderate MS over the last 10 to 15 years, research into exercise for those with 
more severe disability has been sparse. The results from this thesis (chapters 
three to seven) have looked at the acceptability of a pragmatic tailored 
approach to exercise for PwMS (EDSS 1.0-6.5) and whether the dose able to 
be achieved is different for those with more severe disability. Results suggest 
that although some participants at the upper limits of our inclusion criteria were 
able (EDSS 6.0-6.5) to achieve excellent compliance levels, with 1 achieving 
100%. Most however found attending the supervised sessions difficult, with high 
drop-out levels experienced in this population group, thus supporting research 
suggesting the need for a tailored approach to physical activity interventions, 
directed by disability status (Cavanaugh et al., 2011). The challenge now is to 
explore the type of physical activity interventions that would be acceptable and 
achievable for people with more severe MS and what benefits could potentially 
be gained from participation in interventions aimed at decreasing sedentary 
behaviour and increasing physical activity in this population group. Such 
research has the potential to have a significant impact on the lives of PwMS and
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their families. Hence, there is a need to investigate what type of intervention 
would be feasible for people with moderate to severe MS and what potentially 
benefits this could have on physical activity behaviour and health outcomes.
7.4.2 Feasibility of high intensity exercise for people with mild disability 
from MS.
Current guidelines recommend that people with MS exercise at a moderate 
intensity (Reitberg et al., 2005; Latimer-Cheung et al., 2013), as most current 
exercise research is conducted at this intensity (Rognomo et al, 2004). Thus, 
meaning that even if individuals have very mild or benign MS they are still 
advised to avoid high intensity exercise as there is no current research available 
to suggest whether it is safe or not. This may lead to the type of scenario where 
an individual whom is currently very active may be recommended to 
significantly alter their current exercise habits on diagnosis, when they may not 
have to. High intensity interval training (HIIT) has grown in popularity over 
recent years, as it has been shown to be an effective alternative to traditional 
endurance training (Bird and Hawley, 2012), despite having a substantially 
lower time commitment (Gibala et al., 2012). In addition, this type of exercise 
has also been used successfully with other clinical populations such as 
diabetics (Adams, 2013) and obesity (Lunt et al., 2014). It is therefore 
recommended that future research investigates the feasibility of higher 
intensities of exercise for people with mild disability from MS to determine if it is 
safe and beneficial for this population group.
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7.4.3 Early educational intervention to prevent rapid decline in exercise 
participation on diagnosis of MS
PwMS participate in less physical activity than the general population (Motl et 
al., 2005; Plow and Motl., 2012), by nearly one standard deviation, with almost 
60% of individuals with MS participating insufficient physical activity to provide 
minimal health benefits (Motl et al., 2015). Unpublished qualitative data 
collected during the ExIMS trial suggests that at diagnosis PwMS currently 
receive little if any advice and support on what type of exercise is beneficial and 
that this continues long-term, with health professionals and gym instructors 
unable to provide adequate advice. In addition, if PwMS wish to access 
additional information on exercise and physical activity, their preferred source is 
the Internet (Sweet et al., 2013). This is a resource also utilised by health care 
professionals wishing to promote physical activity (Cullen, 2002). Unfortunately, 
current information found on websites such as the MS Society and MS Trust is 
generic, lacks detail and contains limited use of behaviour change techniques 
(Shirazipour et al., 2015).
Qualitative research suggests that fear of making the condition worse (Kayes et 
al., 2011) and fatigue (Smith et al., 2011) may contribute to the observed 
decline in physical activity and structured exercise following a diagnosis of MS.
Therefore, cost effective strategies that provide support to individuals to help 
them maintain and or take up new forms of exercise and physical activity both 
at diagnosis and as disability levels and symptoms change are crucial. This 
would enable PwMS to maintain a healthy relationship with exercise that 
enables them to better self-manage their condition and gain maximum benefits 
from being more physically active.
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Survey research with 318 PwMS based in the United Kingdom, reported that 
PwMS are looking for 3 key things from the health care service; information on 
management, relevant tailored advice and access to appropriately skilled 
professionals (Somerset, 2011). Therefore, an education based programme 
combining individual therapy and group education sessions on exercise and 
lifestyle issues, ran by appropriately trained professionals would go some way 
to meeting the needs of PwMS (Plow et al., 2009). Lifestyle education 
programmes have been used successfully to increase physical activity 
participation with other clinical populations i.e. diabetes (DESMOND) (Skinner 
etal, 2006) and claudication (CEDRIC) (Tew et al., 2015). Positive benefits of 
educational sessions have also been reported for PwMS, with Feys et al., 
(2013), reporting that a one day practical and theory based education 
programme for physical activity may have a long-term impact on physical 
activity and perceived impact of MS. This positive impact is supported by Ng et 
al., (2013), who reported short and long-term increases in self-efficacy and 
health related quality of life from a four day interdisciplinary wellness education 
programme. However, both of these studies did not include a usual care control 
group and contained only self-report outcome measure which may have 
positively biased the results. In addition, these studies lacked a theoretical 
underpinning designed to increase self-efficacy and promote long-term 
adherence to positive behaviour change.
It is, therefore, recommended that future research investigates the impact of a 
robustly designed trial containing both individual tailored advice and group 
sessions, with the theoretical underpinning to increase knowledge and 
confidence to exercise and promote long-term exercise adherence for PwMS.
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This has the potential to provide a cost effective solution to declines in exercise 
participation observed in PwMS.
7.4.4 The optimum type and dose of exercise for fatigue management for 
people with clinical levels of fatigue from MS.
Data synthesis from systematic reviews (Latimer-Cheung et al., 2013; 
Andreasen et al., 2013) and meta-analysis (Pilluti et al., 2013; Asano and 
Finlayson, 2014) suggests that exercise may provide a useful approach to 
managing fatigue for PwMS. However, quality research is sparse and does not 
enable inference across different types of MS and disability levels (Asano and 
Finlayson, 2014), or what type and dose provide optimum results (Latimer- 
Cheung et al., 2013; Asano and Finlayson, 2014). Results from this thesis 
(Chapter six) suggest that individuals experiencing the highest levels of fatigue 
have the potential to experience the greatest improvements, as supported by 
Andreason et al (2011). In addition, our data also suggests that there may be an 
optimum dose of exercise, with individuals achieving the highest dose of 
exercise during the ExIMS trial not achieving the greatest improvements in 
fatigue.
Therefore, it is recommended that future research explores the optimum type 
and dose of exercise required to gain benefits in PwMS presenting with clinical 
levels of fatigue.
7.5 Conclusion
The studies presented in chapter's three to seven of this thesis report on the 
feasibility, design, recruitment, health outcomes and cost effectiveness of a
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pragmatically designed exercise intervention. The intervention uses a unique 
approach that is individually tailored, employs cognitive behavioural techniques 
to promote long-term adherence and is designed to contain tapered 
supervision, being predominantly home-based in the latter stages. Data suggest 
that to recruit to this type of study a mixture of approaches are required for 
targets to be met, with an average recruitment rate of 3.5 participants a month 
being a realistic goal. Our main outcomes suggest that this pragmatic approach 
was not only feasible, but results from ExIMS indicate that this type of 
intervention can provide significant increases in self-directed exercise 
behaviour, fatigue and health related QoL, with significant improvements for 
some domains of QoL being sustained at up to nine months follow-up. In 
addition, this intervention is highly likely to be cost effective if implemented by 
the NHS.
Prior to this research systematic reviews and meta-analysis into the benefits of 
exercise for people with MS have consistently highlighted a need for more 
robustly designed research trials, containing long-term follow-up and 
participants with higher levels of disability from MS. This thesis has taken a 
notable step towards filling in the gaps in the literature, by providing data from a 
robustly designed pragmatic exercise trial, which has recruited people with a 
range of neurological impairment (EDSS 1.0-6.5) and has included a longer- 
term follow-up (six months).
Our results provide a strong evidence base to suggest that a pragmatic
approach to exercise can have important long-term health benefits that improve
self-management and should encourage health professionals to motivate
individuals with MS to exercise. It is hoped that exercise will now be considered
as part of the treatment pathway for PwMS within the NHS, with results
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presented in this thesis already cited in the 'NICE Guidelines for Management of 
Multiple Sclerosis in Primary and Secondary Care' (2014). However, if 
outcomes are to be optimised and increased levels of activity maintained, there 
is a need for strategies to provide continued contact between participants and 
the delivery team following the intervention.
Furthermore, there are still many questions that remain unanswered, as the 
majority of exercise research has involved people with mild to moderate levels 
of disability from MS, exercising at a moderate intensity. There is a need for 
more high quality RCT's exploring the benefits of exercise for people with more 
severe disability from MS, and the feasibility of higher intensity exercise for 
people with mild disability from MS. In addition, further details are required on 
the optimum dose of exercise for improvements of important health outcomes 
such as fatigue.
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National Research Ethics Service
South Yorkshire Research Eihfcs Committee
1;! Ptscr VfckKfa Ccrrktor 
Nnrtfcem Gkrysrai Hnsgrtnl 
HsrnifsRosia 
SJ*«!Si8ld
SS7AU
T«f«phon* 011422SS153 
Facslmle: 0114 258 24ft9 Ernzd: ^ aabrown^ slknhs.uk
2S October 2DQ8
Dr John M Saxton
Reads' in Clinical B m tim  p i^iidogy
Sheffield Haltom Uni verity
Centre for Sped and Bceids# Science
Sheffield
S102SP
Dear Dr Saxton
Full title of study: the effects of a pragmatic exercise therapy intervention
on physical activity ami important health outcomes 
influencing msinfananea in people with multiple 
sclerosis.
REC reference number:
I acknowledge receipt of your letter dated 23 October 2C03 ccrrtplying with the 
conditions speciled in the RECs favourable optton letter dated 3G September 2003 
end enclosing Bis fallowing; document
* Pdrfcipaiit Information Sheet, Version, 2, dated 23 October 2DOS.
Ydurs sincerely
Joan Biwn
Seurth Yorkshire REC Coordinator
Tl»k twelfth Clhka PswftiiH** *1 4n irg im tf  tniwnlm* 10 Ycrktfcif* Hj^bt? Strategic HfesttHJUitrcdqr
7t)t Witteal fiasssncti £tVcs Ser/ke (ttfESJ tvpnam tr tte  NSE5 D.Vwtfcnrh? wfthto 
I k *  l h t h r . 0  W k n t  SJifcf-/A jjf.'xy ii*vf firtiWdh EihkS O&nmMtCW A’S £np*jnd
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Appendix 8.2 - Patient information sheet
Sheffield Teaching Hospitals WlaM
NHS Foundation Trust
re  J Sheffield  
 ^  1 H a lla m  University
The effects of a pragmatic exercise intervention in 
people with multiple sclerosis.
Introduction
Exercise is increasingly being accepted as a component of symptom management in 
people with Multiple Sclerosis. High quality research evidence exists to support the 
benefits of exercise on physical function, muscle power, exercise tolerance, quality of 
life and mobility-related activities in people with MS.
In this study you will be randomly allocated to either an exercise or usual care group. 
The randomisation is generated by a computer sequence, we have to do this in order 
to make sure the results are scientific.
At the beginning and following the study we will measure your physical function, asking 
you to complete a series of physical tests. We will also assess your feelings of quality 
of life, physical activity levels and fatigue by asking you to complete some 
questionnaires and take a blood sample for immunological analysis. The data from this 
study will contribute to the evidence-base for exercise therapy in MS and inform health 
policy through clinical guideline recommendations.
This patient information sheet for the study answers the most frequently asked 
questions and is your copy to keep.
Q: What is the main purpose of the study?
A: The aim of the study is to investigate whether a practically designed exercise 
programme is effective in providing improvements in physical activity and health 
outcomes which are likely to have a positive impact on your physical function and 
quality of life. We will also explore what amounts of exercise are most effective and 
whether exercise is more or less beneficial for people with different disability levels.
Q: Why has my Doctor told me about this study?
A: You have been selected as being a suitable patient from your medical history, and 
because you are receiving treatment for multiple sclerosis.
Q: What will I have to do?
Patient Information Sheet
Version 2: 23rd October 2008
Frequently asked questions
A: All patients who are interested in entering the study will be initially invited to attend 
an appointment with the study researcher at The Centre for Sport and Exercise
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Science at Sheffield Hallam University. You will have the opportunity to go through this 
information sheet again and ask any questions you might have about the study. You 
will also be shown around the exercise training facility and assessment room and taken 
through the procedures. You will be given a consent form to take home and complete. 
This is so that you can have time to decide whether or not you would like to take part in 
the study.
Assessment
If you decide to take part you will be asked to attend the University for an initial 
assessment session before you are randomised to either the exercise intervention or 
the usual care group. You should bring your completed consent form with you to the 
first session. You will be assessed on a total of 3 occasions; at the start of the 
programme, immediately following the 12 week intervention and 6-months following the 
intervention. In addition, at the end of the supervised exercise sessions some 
individuals will be randomly chosen to participate in a 1 -to-1 interview and focus group 
sessions at the University to discuss you experiences of the research study.
At the University
During the assessment session we will take a small blood sample and complete series 
of functional and physical tests. These include measurement of resting heart rate and 
blood pressure, height, weight and waist:hip girths, completion of the MS Functional 
composite test (25 ft walk, 9 hole peg test and paced auditory serial addition test) and a 
six minute walk test. These visits should last no more than 45 minutes.
At Home
You will also be asked to complete a self assessment questionnaire. This can be 
completed at home and will include measures of physical activity behaviour, quality of 
life, fatigue and cost effectiveness. This should take no longer than 1 hour to complete. 
You will also be asked to wear an accelerometer (a small device worn like a 
pedometer) for a 7 day period and keep a physical activity recall diary during this 
period. In addition, salivary cortisol will be measured on three consecutive days at 4 
time points. A special watch will be provided to help you remember.
At the Hospital
You will also be required to have an appointment with a consultant at the Royal 
Hallamshire Hospital to assess your disability score (EDSS). This appointment should 
take no more than 30 minutes.
Q: What will I have to do if I am allocated to the exercise intervention group?
A: After the baseline assessment sessions, you will be asked to participate in 3 
exercise sessions a week over a 12 week period. For the first 6-weeks this will consist 
of 2 supervised exercise sessions and 1 exercise session at home. In the second 6- 
weeks you will be asked to complete 1 supervised exercise session a week and 2 
exercise sessions at home. Supervised sessions will take place at The Centre for 
Sport and Exercise Science at Sheffield Hallam University, Collegiate Crescent 
Campus (off Ecclesall Road) and are lead by experienced exercise professionals, with 
programmes overseen by the project physiotherapist.
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Supervised exercise will take place in small groups (up to 3-4 people) and will begin 
with a gentle warm up. Each exercise session will consist of completing short bouts of 
exercise (1-5 mins), with rest intervals, at a low-moderate intensity. Where appropriate, 
strength, balance and flexibility work may also be performed. Heart rate, ratings of 
perceived exertion and minutes of specific exercises achieved will be recorded by the 
researcher to allow for an assessment of the exercise dose achieved each week. 
Please allow 45-60 minutes for your exercise session. All exercise sessions are 
tailored to your level of ability, according to your symptoms, fitness and personal goals.
Q: What will I have to do if I am allocated to the usual care group?
A: Patients allocated to the usual care group will be asked to continue with their usual 
daily routine. You will only be required to attend the complete the assessments 
(outlined previously), which will be at the beginning, end of the 12-week study period 
and after a further 6-months for a follow up.
Q: How long will the study last?
A: The exercise intervention will last 12 weeks. We will monitor your progress 
throughout, to make sure that the exercise programme progresses at an appropriate 
rate. You will then be assessed 6 months after the end of the intervention to see if it 
has had a more long term impact.
Q: Will there be any effects on my follow-up treatment?
A: No, your participation in this study will not affect your follow-up treatment in any way.
Q: What are the possible benefits of taking part in this study?
A: Previous research suggests that the exercise intervention has the potential to 
improve your physical and mental wellbeing. Possible benefits specifically include; 
increased endurance, increased mobility (walking/balance), improved mood, increased 
quality of life and possible improvements to fatigue.
Q: Are there any side-effects of taking part?
A: If you haven't exercised for a while, it might initially make you feel you are breathing 
harder than usual or slightly sweaty. Exercise may also initially make you feel tired, but 
as you do it more regularly this should feel increasingly better.
Q: What are the possible disadvantages and risks of taking part?
A: The potential for risks of anything untoward happening during the exercise will be 
minimal.
Q: If I decide to participate, will my GP be notified?
A: With your consent, we will write and inform your family doctor that you are taking 
part in this study.
Q: Do I have to take part?
A: It is up to you to decide whether or not to take part. If you decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form.
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Q: What if I do not wish to take part?
A: Your participation is entirely voluntary. If you decide not to take part, this will not 
affect the standard of care you receive from the hospital or any health professional.
Q: What if I change my mind during the study?
A: You are free to withdraw from the study at any time without it affecting your future 
treatment.
Q: What will happen to the information from the study?
A: The overall conclusions of the study will be available to you; however, it will not be 
possible to produce an individualised report of your performance.
Q: Will my taking part in this study be kept confidential?
A: Yes, the confidentiality of our study participants and their data is of utmost 
importance. All data from this study will be annonymised. This means that you will be 
allocated a number during the study and this will be used to store data. In addition, we 
will need to obtain your permission to allow the research team access to your medical 
records, and to information collected during the study. This is one of the clauses, which 
you will sign in agreement on the official consent form.
Our procedures for handling, processing and storage of and destruction of data are 
compliant with the Data Protection Act 1998.
Q: Who Is organising and funding the research?
A: The research is organised by The Centre for Sport and Exercise Science, Sheffield 
Hallam University in collaboration with the Sheffield Teaching Hospitals NHS 
Foundation Trust. Funding for the research has been provided by the Multiple Sclerosis 
Society.
Q: Who has reviewed this study?
A: The South Yorkshire Research Ethics Committee has reviewed this study.
Q: What if I have further questions?
A: f you have any further questions with regards to this study you may phone:- 
Name: Dr. John Saxton (Project Co-ordinator) Tel: 0114 225 4414 
Name: Anouska McConnell (Study researchers) tel. 0114 225 5633 
Name: Mr. Basil Sharrack (Consultant Neurologist) Tel: 0114 271 3608
Q: What if I wish to complain about the way this study has been conducted?
A: f you have any cause to complain about any aspect of the way in which you have 
been approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms are available to you and are not compromised in any 
way because you have taken part in a research study. The normal hospital complaints 
procedure applies, and you should contact the following person:
Name: Professor Chris Welch (Medical Director) Tel: 0114 271 1900
You can also complain to any individual of the research team
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Name: Dr. John Saxton (Project Co-ordinator) Tel: 0114 225 4414
Name: Anouska McConnell (Study researchers) tel. 0114 225 5633
Name: Mr. Basil Sharrack (Consultant Neurologist) Tel: 0114 271 3608
Sheffield Hallam University has the following policies in place for the legal liability of the 
University; (a) Professional indemnity (£10 million); and (b) Public liability (£20 million)
Q: What if I am Harmed?
A: n the event that something does go wrong and you are harmed during the research 
study, there are no special compensation arrangements. If you are harmed and this is 
due to someone's negligence then you might have grounds for legal action for 
compensation, but you could have to pay your legal costs.
Thank you for taking the time to consider participating in this study
Dr.John Saxton (Project co-ordinator)
General Information about Research
Independent advice can be sort from the Patients' Advisory Liaison Service (PALS), 
Royal Hallamshire Hospital, B Floor, Glossop Road, Sheffield, South Yorkshire, S10 
2JF, (0114 271 2450).
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Appendix 8.3 - Informed consent form 
Sheffield Teaching Hospitals fU iM  M l SheffieldH a lla m  UniversityNH5 Foundation Trust Mu&pteSderosisSodety
PATIENT CONSENT FORM
Sheffield Hallam University and 
The Sheffield Teaching Hospitals Trust
The effects of a pragmatic exercise intervention in people with multiple 
sclerosis.
Patient Identification Number for this study:
Study Investigators: Dr John Saxton, Dr Basil Sharrack, Miss Anouska McConnell.
Name of researcher:
1. I confirm that i have read and understood the information sheet dated 
23rd October 2008 Version 2 for the above study. I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily.
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected.
3. I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals 
of the research team, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my 
records.
4. I agree to my G.P. being informed of my participation in the study.
5. I agree to take part in the above study.
tick box
Name of Patient Date Signature
Name of individual taking 
consent (if not researcher)
Date Signature
Researcher Date Signature
3 copies to be kept; 1 for site file; 1 for patient; original to be kept in medical notes
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Appendix 8.4 - Letter to general practitioner
Sheffield Teaching Hospitals E S S  Sheffield
nhs  Foundation Trust I  1 < ^  K F * H a lla m  University
Muliipfe Sclerosis Society
-- date here --
Dear Dr <NAME>
Re: Patient Name (D.O.B: Date)
I am writing to inform you that Patient Name has consented to participate in an 
exercise intervention based at The Centre for Sport and Exercise Science, Sheffield 
Hallam University.
The new project is offering individuals with mild to moderate Multiple Sclerosis (MS) the 
opportunity to exercise in a safe and supportive environment. This study is generously 
supported by the Multiple Sclerosis Society and is in collaboration with consultant 
neurologists at the Royal Hallamshire Hospital. The study aim is to investigate whether 
a pragmatically designed exercise intervention is effective in evoking improvements in 
physical activity behaviour and health outcomes which are likely to have a positive 
impact on maintenance and quality of life in people with MS. In addition, we will be 
exploring the dose-response relationship between exercise and the primary/secondary 
outcomes in those with mild and more severed disease and evaluating the cost 
effectiveness of the intervention.
If you have any concerns or questions regarding your patient participating in this study 
please do not hesitate to contact me, my direct line telephone number is 0114 225 
5633.
Yours sincerely,
Anouska McConnell, MSc, BSc, BASES Accredited (physiology support)
Senior Sport and Exercise Science Officer, The Centre for Sport and Exercise 
Science, Sheffield Hallam University
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Appendix 8.5 - Protocol
PROPOSED INVESTIGATION
1. BACKGROUND AND PURPOSE OF PROPOSED INVESTIGATION
1.1 General background
Living with MS can be a difficult experience, both physically and psychologically. 1-3 
Some of the most common symptoms for people with MS (PWMS) include excessive 
fatigue,4 limb weakness,5 motor abnormalities and sexual dysfunction.6 Research has 
also indicated that there is an increased prevalence of falls in this population.7-8 In 
addition, poor mental health9 and symptoms of fatigue affecting quality of Iife4,10 
represent a substantial problem for PWMS. Hence, there is a need for clinicians and 
researchers to address issues that could have an impact on the long-term health- 
related quality of life of PWMS, particularly given that MS affects many young and 
middle-aged individuals, 11 who have a life expectancy close to normal. 12 There is 
evidence that PWMS are involved in fewer recreational activities than the general 
population.13 Physical inactivity however, contributes to a sedentary lifestyle that 
increases the risk of developing other health concerns (e.g. heart disease, obesity, 
isolation, depression and infections).
1.2 Pilot study
This research team recently completed a pilot study which investigated the effects of a 
supervised exercise therapy intervention, relative to usual care, upon physical 
functioning and other health-related outcomes in PWMS. A total of 30 (4 male and 26 
female) PWMS (EDSS < 5.5) were recruited. The intervention involved patients 
attending one-to-one supervised exercise sessions at a dedicated exercise therapy 
room at Sheffield Hallam University twice per week over 10 weeks. Participants were 
also asked to complete one home session each week during the intervention phase of 
the trial. Analysis of covariance showed that the exercise group participated in more 
moderate intensity exercise (P<0.003) and had better perceptions of general health 
status (P<0.03). There were also strong trends for less pain (P<0.054) and greater 
aerobic capacity (time to a perceived exertion of 17 on the Borg RPE Scale) (P<0.053) 
in the exercisers versus usual care controls. Adherence to the exercise therapy 
intervention was excellent, with 80% of patients able to attend 70% (14/20 sessions) or 
more of the supervised exercise sessions. PWMS also self-reported completing an 
average of 7/10 the prescribed home exercise sessions. PWMS in the intervention 
group were asked to complete a series of open-ended questions about their 
experiences. The responses showed that PWMS enjoyed the intervention, including 
the structure and content of the sessions. The sessions also provided patients with 
feelings of energy, vitality and a sense of achievement. On completing the 10-week 
intervention, over 90% of patients indicated that they felt confident they would continue 
to exercise in their communities.
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1.3 Purpose of the proposed investigation
The results from our pilot study are in agreement with a growing evidence-base 
supporting the beneficial effects of exercise therapy for PWMS. 14-19 Our experience 
shows that supervised exercise interventions are acceptable to PWMS and that they 
can reap important health benefits from participation. The challenge now is to assess 
the efficacy of pragmatic and cost-effective ways to implement exercise therapy. 
Although one-to-one supervised facility-based exercise programmes can offer more 
support and guidance to MS patients (as clearly demonstrated in our pilot study), over 
the long-term they may prove difficult for many PWMS due to time barriers, transport 
issues and health constraints (e.g. fatigue). In addition, they are very labour intensive, 
require specialist equipment, and are unlikely to be cost-effective. Hence, the purpose 
of the proposed investigation is to investigate whether a pragmatically-designed 
exercise intervention is effective for evoking improvements in physical activity 
behaviour and health outcomes in PWMS. We will also explore dose-response 
relationships between physical activity and the primary/secondary outcomes in those 
with mild and more severe disease and evaluate the cost effectiveness of the 
intervention.
1.4 Study research questions
1.4.1 Primary research questions
1. Will PWMS who are randomised to pragmatic exercise therapy have improved 
functional and health outcomes in comparison to usual care only controls at 3-months 
and 6-months of follow-up?
2. Will PWMS who are randomised to pragmatic exercise therapy have increased 
structured exercise and free living physical activity levels in comparison to usual care 
only controls at 3-months and 6-months of follow-up?
3. Is inclusion of a pragmatic exercise therapy intervention in the patient care 
pathway a more cost-effective treatment strategy than current medical care alone in 
PWMS?
1.4.2 Secondary research questions
1. What dose of exercise is achievable by PWMS during facility-based supervised 
and home-exercise portions of the intervention?
2. Is dose of physical activity associated with improvement in outcomes in people 
with mild to moderate MS and those more severely affected?
3. Are improvements in physical function and fatigue as a result of the exercise 
intervention associated with positive changes in serum cytokine and salivary cortisol 
levels?
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2. PLAN OF INVESTIGATION
2.1 Study design
The proposed study is a randomised controlled trial with participants being stratified 
according to gender and EDSS score (low: up to 3.5, high: up to 6.5). Research Ethics 
Committee approval will be sought and all patients will provide informed written 
consent prior to involvement in the trial.
2.2 Patient recruitment
A total of 120 people with MS (PWMS) will be recruited by Consultant Neurologists at 
the collaborating hospitals and via flyers/community adverts displayed at the local 
South Yorkshire MS Society branches. All patients will be seen by a neurologist prior to 
entering the trial, regardless of their route of recruitment. In total, around 50 potential 
participants per week are seen at the collaborating hospital centres. In addition, we will 
have access to several hundred PWMS who are affiliated with local South Yorkshire 
MS Society branches. We will seek to feature the trial in the msmatters newsletter 
during recruitment and aim to recruit the required sample of 120 PWMS over 24- 
months; this equates to a recruitment rate of 5 PWMS per month. Patient travel 
expenses will be reimbursed.
2.2.1 Inclusion criteria
Clinical diagnosis of MS with an EDSS score of between 1.0-6.5, and able to 
walk 10 m distance
Aged 18-65 years
Participants must have been clinically stable for at least 4 weeks prior to 
entering the study
Participants on disease modifying therapy (Interferon and Grateramer Acetate) 
must have been stable on this treatment for at least 3 months prior to entering the 
study
Physically able to participate in some form of exercise three times per week 
Able to provide written informed consent
2.2.2 Exclusion criteria
Failure to meet any of the above inclusion criteria
Experiencing illness that impairs their ability to be physically active three times 
per week
Not willing to be randomised to either the exercise intervention or usual care 
control group
Living more than 20 miles from the trial centre
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Already engaged in purposeful structured exercise or brisk walking exercise n 3 
times per week for □ 30 min per session and have been so on a consistent basis 
during the previous 6-months
2.2.3 Sample size calculations and expected loss to follow-up
The sample size estimation is based on physical activity behaviour change data from 
our pilot study20,21 and an estimated post-intervention difference in 6-minute walk test 
(6MWT) between the groups.22 A sample of 50 patients randomised to each group will 
be sufficient to detect a moderate effect size difference (80% power and a 5% 
significance level) of 1.3 units on the Godin physical activity scale (sd = 2.29 [our pilot 
study data]) and an increase of 56 m (sd = 99.4 m) in 6MWT22 (an increase in 6MWT 
of 56 m was accompanied by improved neurological function after a 12 week aerobic 
exercise programme in PWMS).22 This figure rises to 60 in each group to allow for a 
15% loss to follow up.
2.3 Pragmatic exercise therapy intervention
2.3.1 General overview and rationale
At baseline, participants in the intervention group will receive a pack of printed 
information that details important information about exercise and MS (e.g. safely 
increasing exercise over time, minimising injuries, dealing with fatigue, taking heart rate 
and buying shoes, etc). The intervention period will be 12 weeks in duration, with a 
more frequent contact phase during the first 6-week block, and reduced contact during 
the second 6-week block. Programmes of at least 10 weeks are more likely to provide 
sufficient time for patients to adapt to exercise. In accordance with recent 
recommendations for PWMS,23 and as used in our pilot study, the intervention will be 
staged-adapted and participants will be encouraged to exercise within their own 
capabilities, which will be influenced by individual symptomatology. Several leaders in 
the field of exercise adherence suggest that allowing patients to exercise at their 
preferred intensity enhances compliance.24 A physiotherapist will oversee the delivery 
of the intervention. The Centre is easily accessible by public transport and there is 
dedicated parking.
2.3.2 Pragmatic exercise therapy intervention
During weeks 1-6, participants will attend two supervised sessions per week at the 
Centre for Sport and Exercise Science (CSES) and will be required to undertake one 
additional session in their home environment. Supervised sessions will involve small 
groups of up to three participants led by an exercise therapist/researcher. Each session 
will last approximately 1 -hour and participants will be offered a range of exercises (e.g. 
stepping, cycle-ergo, walking, arm-cranking). Sessions will also incorporate exercises 
that focus upon developing muscle strength, function, balance and flexibility. 
Participants will be asked to complete short bouts (e.g. 5 x 3-min, with 2-min rest 
intervals) of low to moderate intensity exercise (50-69% of maximum heart rate). As the 
intervention progresses and when appropriate, participants will be encouraged to 
participate in longer periods exercise (e.g. 5 x 4-min) or to take shorter rests between 
bouts. Heart rate, ratings of perceived exertion and minutes of specific exercises 
completed in each session will be recorded by the researcher to allow for an
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assessment of the exercise dose achieved each week. Supervised exercise will also 
include cognitive-behavioural techniques (e.g. goal setting, finding social support, 
understanding the costs/benefits of exercise etc.) to promote long-term participation in 
physical activity. Using the Transtheoretical Model25 as a guiding framework, this 
aspect of the intervention will be aimed at equipping PWMS with the skills, knowledge 
and confidence to engage in a more physically active lifestyle.
During weeks 7-12 participants will attend CSES once per week and complete two 
home sessions per week on their own. We hypothesize that the gradual increase in 
home-based sessions within the intervention group will help to facilitate independent 
exercise participation after the intervention phase is completed. As for the supervised 
sessions, the home sessions will be geared towards the mobility and symptoms of 
each participant. During the single weekly supervised session at CSES, they will 
undertake aerobic exercise (as in weeks 1-6) and receive instructions on how to 
complete muscle/strength and body-conditioning exercises in the home environment. 
They will also be encouraged to access exercise facilities/opportunities in their 
community (e.g. healthy living centres, health walks, fitness centres, swimming pools, 
etc) and receive instructions on how to complete a physical activity log for 
quantification of structured exercise sessions achieved outside of the supervised 
sessions.
2.4 Outcome measures
2.4.1 Timing of assessments & setting
Unless otherwise stated, outcomes will be blindly assessed at three time-points: 
baseline, after the 12-week intervention and 6-months later. Personal characteristics 
(e.g. postcode, marital status ethnicity, etc.) and condition specific data (e.g. time since 
diagnosis, medication, onset of symptoms, use of health care resources etc) will be 
collected. Large print versions of the questionnaires will be available. Clinicians at the 
collaborating hospitals will perform the neurological tests and an experienced 
researcher will assess other outcomes at the SHU site. Self-assessment 
questionnaires (for participants to take home) will be used where indicated to reduce 
the assessment burden for PWMS. These will take approximately 1.5 hr to complete. 
Patients in the usual care control group will be assessed at the same time points.
2.4.2 Primary outcome measures
Physical activity levels will be monitored over a 7-day period, using a combination of 
self-report physical activity questionnaire/recall diary and accelerometry (Actigraph 
GT1M, Actigraph, LLC, FI, USA). The advantages of using both measures are that the 
objective measures can provide a more accurate measure of physical activity, whilst 
the subjective measure gives context. The Leisure Score Index (LSI) of the Godin 
Leisure Time Exercise Questionnaire20,21 will be used to measure self-reported 
physical activity behaviour. Quantification of structured exercise sessions at the Centre 
(intervention group) and in the home environment (experimental and control groups) 
will be verified using a physical activity log comprising a checklist for type, duration, 
and intensity of exercise achieved. The Actigraph is reported to be amongst the most 
extensively validated accelerometers and has been proven to correlate reasonably with
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doubly labeled water derived energy expenditure techniques.26 Functional exercise 
capacity (proxy measure of compliance to the intervention) will also be assessed using 
the 6-minute walking test (6MWT), according to a standardised protocol.27 This test is 
sensitive to change following exercise interventions in PWMS.22,28
2.4.3 Secondary outcome measures
2.4.3.1 Neurological impairment and clinical functional ability
Expanded Disability Status Scale Score (EDSS)29 will be assessed according 
to standard clinical procedures by the neurology consultant. The EDSS has been 
shown to be reliable and valid and is frequently used for evaluating neurological 
impairment in research involving adults with MS.
Multiple Sclerosis Functional Composite (MSFC)30 is a measure of clinical 
functional ability. It includes a timed 25-foot walk and measures of arm/hand function 
(9-hole peg test) and cognitive function (paced auditory serial addition).
2.4.3.2 Quality of life, fatigue and qualitative analysis of patient experiences
The Multiple Sclerosis Quality of Life-54 questionnaire (MSQOL-54)31 is a 
generic HRQOL instrument based on the Medical Outcome Short Form-36 (SF-36) 
Health Survey, but with 18 additional items relevant to PWMS. Both dimensional and 
composite scores will be used in analyses. This will be self-assessed by the 
participants.
Perceived effects of fatigue will be assessed using the Modified Fatigue Impact 
Scale (MFIS), which has been validated for PWMS.32,33 This will be self-assessed by 
the participants.
At the end of the intervention, a random sample of 30 PWMS from the 
intervention group will be invited to participate in a one-to-one, semi-structured 
interview and focus group sessions to elicit detailed and confidential accounts of their 
experiences. The interview schedule will be similar to that used by Dodd et al. (2006)34 
and will concentrate patients’ experiences, barriers and attitudes towards exercise, 
perceived benefits and adverse effects of the intervention. Both interviews and focus 
groups will be guided by a "framework approach" to data collection and analysis. A 
thematic analysis will be used to explore the narrative accounts of individuals within 
(and across) the focus groups and interviews. Interview and focus group audio 
recordings will be transcribed verbatim. Three researchers will verify the identification 
and refinement of themes from the research. The analytical process will be facilitated 
by the use of QSR Nvivo software. This qualitative aspect of the study is considered 
very important and could help to overcome some of the limitations of rating scales in 
assessing treatment benefits in PWMS.
2.4.3.3 Immunological analysis
Disruption to the neuroendocrine axis and alterations in immune activation have been 
implicated in MS.35,36 As exercise is known to be an important modulator of immune 
and endocrine parameters and may have an impact on circulating cytokines in 
PWMS37, levels of serum IL-6, TNF-n, IL-4, IL-10 and CRP and salivary cortisol will 
be measured by ELISA. This exploratory component of the study may shed light on the
267
complex mechanisms underlying symptoms of fatigue in MS and the role of exercise in 
alleviating such symptoms.
2.4.3.4 Cost effectiveness of the pragmatic exercise intervention
An economic evaluation will be undertaken alongside the trial using recommended 
practice.38 The NHS perspective will be used in the primary economic analysis. This 
and other methods will be in accordance with NICE Technology Appraisal 
Guidelines.39 Data collection will also account for costs incurred by the participants 
themselves for supplementary analysis, to allow for a broader perspective to be taken.
Cost data: The cost of the programme for each participant at each arm of the trial will 
need to be estimated. This is achieved by collecting costs for staff time, facilities hire, 
equipment and staff travel. Resource use data will be recorded for all participants, 
accounting for their health service use over the 3-months of follow-up. Use of primary 
care will be obtained form self-completed resource use items included in the health 
follow-up questionnaires. Use of hospital services, i.e. inpatient admission (including 
length of stay and speciality), outpatient attendances and A&E visits, will be obtained 
from hospital records. To enable a broader-base costing, PWMS will also be asked 
about their use of social services. Effectiveness data: The Medical Outcome Short 
Form-36 (SF-36) Health Survey generates summary measures for physical and mental 
health which can be used for the assessment of effectiveness.40 The SF-36 summary 
measures can be derived from the MSQOL-54.31 The one-page EuroQoL EQ-5D41 
will be included to provide an additional preference-based measure.
2.5 Data analysis
Differences in primary and secondary outcomes between groups will be compared 
using intention to treat analysis. Outcomes will be compared over the follow-up period 
using mixed model analysis, adjusting outcomes for baseline scores. Effect size 
statistics will be determined to indicate the clinical impact of the intervention. Multiple 
regression will be used to explore dose-response effects on outcome by examining the 
relationship between recorded physical activity and outcomes. A sub-group analysis of 
the effect of disease severity on dose-response will be performed by the inclusion of 
the interaction of severity of disease and physical activity in the regression analysis. 
Imputation methods will be used to assess data losses through level drop-out and loss 
to follow-up. All results will be reported as means and 95% confidence intervals. Our 
medical statistician (AR) blinded to group allocation will undertake the analysis.
Cost effectiveness analysis will be undertaken by a Health Economist (YO: co­
applicant). The main analysis will be an intention to treat comparison of the costs of 
providing a pragmatic exercise therapy intervention as opposed to the standard 
treatment for PWMS, compared to gains in the SF-36 scores at the individual patient 
level. The final result will be presented as a ratio of the differences in costs and QALYs 
between the two arms of the trial, with a 95% confidence interval estimated by 
bootstrapping. Results will be plotted on the cost effectiveness plane and then 
transformed into cost effectiveness acceptability curves with their associated frontier.38 
There will be considerable uncertainty in many of the cost estimates and the underlying 
estimate of benefit. Furthermore, an important consideration in the long term cost
268
effectiveness of this intervention is likely to be the longevity of the benefits and cost 
consequences, therefore highlighting the importance of undertaking sensitivity analysis.
2.6 Timescale and milestones
Milestone number Target date Milestone title
1 01.08.08 Apply for Ethics and Research Governance approval
2 01.11.08 Project start date: begin to recruit PWMS
3 31.10.10 Complete recruitment of 120 PWMS and baseline assessments
4 15.02.10 Complete the 12 wk intervention in all PWMS
5 31.08.11 Complete all 6-month follow-up assessments
6 15.09.11 Complete collation of all 12 wk and 6-month follow-up data
7 30.09.11 Complete statistical analysis of the data
8 31.10.11 Complete final report/prepare manuscripts for publication
3.0 INVESTIGATOR EXPERTISE
This research team already has an established track-record of working together on 
exercise trials with PWMS and other patient populations. The experience of the 
research team covers a wide range of disciplines that are highly relevant to the 
requirements of this project. We have an excellent track record of running randomised 
controlled exercise trials that have been funded by the BHF, Cancer Research-UK, The 
Health Foundation, American Institute for Cancer Research, the Department of Health 
(MidRec), the Medical Research Council and Heart Research UK.
3.1 Applicants, roles and responsibilities
Dr John Saxton (Principal Investigator: Clinical Exercise Physiology) is Reader in 
Clinical Exercise Physiology at Sheffield Hallam University. He is a member of the 
Physiological Society and a BASES accredited research physiologist. Role: Trial 
management and co-ordination, responsible for day-to-day supervision of research 
assistants, oversee assessment and evaluation of physiological outcomes.
Dr Amanda Daley (Lead Co-applicant: Health Psychology) is a British Psychological 
Society (BPS) chartered psychologist and a BASES accredited Sport and Exercise 
Psychologist. Amanda is Lecturer in Health Psychology at the University of Birmingham 
Medical School. Role: Trial management and co-ordination, oversee quality control of 
the interventions, health psychology input.
Dr Basil Sharrack (Co-applicant: Neurology) is Consultant Neurologist at the Royal 
Hallamshire Hospital with considerable expertise in conducting research trials and
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studies with PWMS. He has published widely in the field of MS research. Role: Patient 
recruitment, assessments and clinical input.
Ms Jane Petty (Co-applicant: Physiotherapy) is National Lead for the Physiotherapy 
Programme for the MS Society in England and Wales and previously employed as a 
physiotherapist at the Royal Hallamshire hospital, Sheffield. Role: Clinical input, 
oversee exercise interventions, patient recruitment.
Ms Yemi Oluboyede (Co-applicant: Health Economics) is a Health Economist at the 
University of Sheffield. Yemi is been involved in the design analysis and reporting of 
several RCTs, which have compared new and existing health technologies. Role: 
Overlook the cost effectiveness analysis.
Ms Andrea Roalfe (Co-applicant: Medical Statistics) is Senior Lecturer in Medical 
Statistics at the University of Birmingham and Research Facilitator for the Primary Care 
Clinical Research and Trials Unit. Role: Sample size calculations, overlook the analysis 
of all trial data.
3.2 Research staff
Ms Anouska McConnell (named research assistant). Anouska is a BASES Accredited 
Sport and Exercise Physiologist who gained extensive experience of delivering 
exercise interventions to PWMS in our recent pilot study. Role: Hands-on delivery of 
exercise interventions in PWMS.
Ms Sue Green (named research assistant). Sue is an experienced exercise scientist, 
who has worked on a number of research projects with different patient populations at 
Sheffield Hallam University. Role: Assisting the delivery of exercise intervention and 
related tasks.
3.3 Collaborator and advisors
Professor Nicola Woodroofe (Collaborator), Sheffield Hallam University will advise on 
MS research issues, help to coordinate trial management meetings and supervise the 
immunological analysis in her laboratory. Dr S J L Howell (Collaborator) and Dr S Price 
(Collaborator), Consultant Neurologists at the Royal Hallamshire Hospital, Sheffield) 
will assist with clinical decisions and neurological assessments. Dr Jeremy Hobart 
(advisor), Consultant Neurologist at the Peninsula Medical School, will form part of the 
trial steering group and will advise on interpretation of the results. Dr Helen Crank 
(advisor), Sheffield Hallam University, has considerable expertise in qualitative 
analysis techniques and will overlook that aspect of the research.
5.0 JUSTIFICATION FOR FINANCIAL SUPPORT (TOTAL FUNDING REQUESTED: 
£197,536)
Personnel: Funding is requested to support the salary costs for a 0.6 FTE Research 
Assistant (AM) (£91873). She would be responsible for recruiting the PWMS and
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delivery of intervention. A second 0.2 FTE research assistant (SG) is required to assist 
AM in organising and delivering supervised exercise (£15,531). To ensure scientific 
rigour, a third 0.1 FTE Research Assistant is requested for the blind assessment of 
outcomes and data collation (£8,437) and £12,196 is requested to meet the salary 
costs of hands-on physiotherapy support for one session per week (0.1 FTE). This 
would ensure that the delivery of supervised exercise and advice to PWMS is in 
accordance with good physiotherapy practice. Part-time administrative support (£6028) 
is requested for 0.5 days per week (0.1 FTE) to help with the booking of patients, and 
other project-specific administrative tasks, including the transcribing of interview and 
focus group qualitative accounts. Consumables/miscellaneous costs: A sum of £5474 
is requested for the objective statistical analysis of the research data and £12,537 is 
requested for the evaluation of cost effectiveness. Funding to cover participant travel 
expenses is also being requested. At an average of £10.00 per visit for 18 supervised 
exercise sessions and two assessment visits at baseline, post-intervention and 6 - 
months in the intervention group (N=60) and for two assessment visits at baseline, 
post-intervention and 6 -months in the usual care controls (N=60), this amounts to 
£19,136 over the lifetime of the project. We are also requesting funding of £1275 to 
meet expenses incurred by the research team attending project management meetings 
and £2157 to meet the costs of presenting the research data at scientific/clinical 
conferences. To ensure scientific rigour, patients will be randomised using a distant 
randomisation service (£2095). As the trial will need to be registered with the ISRCTN 
scheme, a sum of £206 is requested to cover this expense. Consumables funding of 
£13368 is requested to support the costs of the circulating cytokine analysis. Finally, in 
order to optimise dissemination of the results, and especially among PWMS, we are 
requesting £2064 towards the development of resources for the MS Society website 
and regional ‘Awareness Days’, etc. Equipment: We are requesting a sum of £5160 to 
support the costs of purchasing 20 Actigraph accelerometers. This is an unobtrusive 
device, worn on the thigh, which would enable us to collect more objective data on free 
living physical activity levels over a 7-day time period in all participants.
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Appendix 8.6 - Recruitment Flyer
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i What are we doing? |----------- —
■ We are offering people with mild to moderate Multiple Sclerosis 
(MS) the opportunity to take part in an exercise study 
examining the effects of a practically designed exercise 
programme on people with MS.
- Why are we doing it?
■ Current evidence regarding the beneficial effects of supervised 
exercise on physical function, mobility and quality of life for 
people with MS is strong. This study aims to look at the impact 
of a more practically designed exercise programme on 
improvements in physical activity and health. In addition, we 
are going to explore what amount of exercise is most beneficial 
and whether the benefits vary between those with different 
disability levels.
Can you help us? i.................
■ We are hoping to recruit 120 people, living within 20 miles of 
the University. We are looking for people with a clinical 
diagnosis of MS who are physically able to participate in some 
form of exercise 3times a week.
* Where does the project take place?
■ At the Centre for Sport and Exercise Science, Sheffield Hallam 
University. People vtfio take part will be asked to either follow 
standard advice from their health care team or follow a 1 2  week 
exercise programme.
Where can I find out more? --------------
■ For firther information on the eligibility criteria or an informal 
chat about the study, please contact Anouska McConnell on 
0114 225 5633 or e-mail a.mcconnell@shu.ac.uk.
i \  r  
LV,J
Sheffield reaching Hospitals ijL
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Appendix 8.7 - Assessment protocol
ExIMS: Assessment Procedures
If required the participant attends an initial hospital visit for their EDSS assessment and 
signs their consent (X3).The participant then attends the University for their 
assessment, if a hospital visit has not been required then the consent is signed here. At 
the first University visit the participant is provide with the questionnaires, saliva kit and 
accelerometer for the home data collection and booked in to return in 1 -week. At this 
second University visit the blood sample will be taken and home assessment materials 
collected. Repeat tests are conducted at the same time of day where possible.
Hospital Visit - Neurology consultant
■ Expanded Disability Status Score (EDSS)
University Visit (1)
Equipment: Blood pressure monitor, heart rate monitor, MSFC kit, scales, stadiometer, 
small tape measure (Waist:Hip), large tape measure (6 MWT), lap counter, 2 cones, 
stop watch, chair.
Pre-test questionnaires:
■ Complete Medical, Demographic and health related events information 
Blood Pressure/Resting Heart Rate
■ Contra indicators to 6 MWT = resting HR >120, BP>190/100 
Anthropometry
■ Body Mass - Measured to the nearest 0.05kg
■ Waist-hip ratio - Measured to the nearest 0.5 cm using an inelastic measurement 
tape
The Multiple Sclerosis Functional Composite
■ 25 Foot walk to assess leg function/ambulation:
o The subject is instructed 'I'd like you to walk 25 ft as quickly as possible,
but safely. Do not slow down until you have passed the finish line. 
Ready, go.'
o Timing begins when the lead foot crosses the start line and ends when the
lead foot crosses the finish line, 
o Time is recorded to the nearest 0.1 s.
o Two trials are carried out, one in each direction,
o Record if a walking aid is used
■ 9 hole peg test to assess Arm/hand function
o Place the 9-hole peg test on the table directly in front of the patient,
o Arrange the pg test so that the side with the pegs is directly in front of the
hand to be tested and the empty peg board is in front of the other hand, 
o The test will be ran twice with the dominant hand and then twice with the non­
dominant hand.
o The subject is instructed 'On this test, I want you to pick up the pegs one
at a time, using one hand only, and put them into the holes as quickly as
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you can in order until all the holes are filled. Then, without pausing, 
remove the pegs one at a time and return them to the container as 
quickly as you can. We'll have to do this 2 times with each hand. We'll 
start with your dominant hand. You can hold the peg board steady with 
your non dominant hand. If a peg falls on the table, please retrieve it and 
continue the task. If a peg falls on the floor, keep working on the task 
and I will retrieve it for you. See how fast you can put all the pegs in and 
take them out again. Are you ready? begin.'
■ Paced auditory serial addition test to assess cognitive function
o Read the following instructions to the patient 'On this tape you are
going to hear a series of single digit numbers that will be 
presented at the rate of one every 3 seconds. Listen for the first 
two numbers, add them up, and tell me your answer. When you 
hear the next number, add it to the one you heard on the tape right 
before it. Continue to add the next number to each proceeding one. 
Remember you are not being asked to give me a running total 
rather the sum of the last two numbers that were spoken on the 
tape'.
o For example 'if the first two numbers are 5 and 7, you would say 12.
If the next number is 3 you would say______ ' (pause and wait for
answer). 'Then if the next number is 2 you would say_______ '
o 'This is a challenging task. If you lose your place, just jump back in 
- listen for 2 numbers in a row and add them up and keep going. 
There are some practice items on the tape. Let's try these first.' 
o Play the sample items, if the patient gets 2 or more answers correct 
proceed to test. If not redo practice items a maximum of 3 times 
o Before starting the test remind the patient 'if you get lost, just jump 
back in because I can't stop the test once it has begun.' 
o After 5 consecutive no responses remind the patient by saying 'jump 
backin'.
o On the answer sheet circle correct answers, write in patients response 
for incorrect answers. For no response place a dash, if patient emends 
cross out initial response and write SC (self-corrected).
6 MWT
■ The course should be marked out with a starting line at one end and a cone at the 
other to mark the turning point.
■ Participants should wear comfortable clothes and shoes and use their usual 
walking aid and should not have exercised vigorously within 2 -hours of the visit.
■ The test does not require a warm-up and the participants should sit and rest in a 
chair near the start position for at least 1 0 -minutes before the test.
■ Take start heart rate and overall fatigue and RPE using the Borg scale (10-point 
scale).
■ Participant instructions;
"The object of this test is to walk as far as possible for 6-minutes. You will 
walk back and forth in this hallway. Six-minutes is a long time to walk, so you 
will be exerting yourself. You will probably get out of breath or become 
exhausted. You are permitted to slow down, stop, and rest as necessary. You 
may lean against the wall while resting, but resume walking as soon as you are 
able.
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You will be walking back and forth around the cones. You should pivot 
briskly around the cones and continue back the other way without hesitation. 
Now I'm going to show you. Please watch the way I turn without hesitation."
Demonstrate by walking one lap yourself. Walk and pivot around the cone briskly.
"Are you ready to do that? I am going to use this counter to keep track of the 
number of laps you complete. I will click it each time you turn around at this 
starting line. Remember that the object is to walk AS FAR AS POSSIBLE for 6- 
minutes, but don't run or jog. Start now or whenever you are ready."
Home Assessment
■ Stand near the start line throughout the test. As the patient starts to walk start the 
timer. Do not talk during the walk, except for standard phrases where an even tone 
of voice should be used. Each time the participant returns to the start line click the 
lap counter letting the participant see that you have done this.
■ If the participant stops walking during the test and needs a rest, say this: "You can 
lean against the wall if you would like: then continue walking whenever you feel 
able." Do not stop the timer. If the participants stops and refuses to continue (or 
you decide they should not) fetch a chair and record time, distance and reason for 
stopping."
■ Instructions;
o 1-minute: "You are doing well. You have 5-minutes to go." 
o 2-minute: "Keep up the good work. You have 4-minutes to go." 
o 3-minutes: "You are doing well. Halfway done."
o 4-minutes: "Keep up the good work you have 2-minutes left."
o 5-minutes: "You are doing well. You only have 1-minute left to go."
o 5:45 minutes: "In a moment I am going to tell you to stop. When I do,
just stop right where you are and I will come to you." 
o 6 -minutes: "Stop" Walk over to the patient taking a chair with you if
required. Mark the floor and record distance, laps etc.
Home Assessment
Information provided at first university assessment and returned 7 days later at second 
visit.
Health Questionnaire booklet
■ Multiple Sclerosis Quality of Life-54 questionnaire
■ Modified Fatigue Impact Scale (MFIS)
■ Godin Leisure-Time Exercise Questionnaire & IPAQ (Short)
■ EuroQol EQ-5D
Accelerometer
■ Wear accelerometer on dominant hip for 7 days, except when sleeping, washing or 
swimming.
■ Complete brief activity diary during this time period
Saliva Samples
■ Collect 3-days of saliva samples as outlined on instruction sheet
University Visit (2)
Bloods
■ Collect venous blood sample - 3 serum tubes (yellow) and 3 EDTA plasma tubes 
(purple) and label with date time and patient ID.
■ Spin plasma straight away, at ~ 2500-3000 rpm for 20-mins. Allow Serum to clot 
for about 2 0 -mins before doing the same (use the centrifuge that can be cooled to 
4 degrees and always keep the blood cool after taking it and while processing it,
i.e. put it in the fridge/put it on ice or place one of those cold packs on it. Make sure 
centrifuge is well balanced or there could be a bit of a mess when you open it up!).
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Appendix 8.8 - Data collection sheet (Assessment)
ExIMS: Assessment Data Collection Sheet
STH Study Number: 15153_________________  Date:
Patient ID Number: Time point:
QUESTIONNAIRES 
M SQL-54/ MFIS/EuroQoL/Godin 
EDSS (consultant) 
Health Related Events 
Demographics
Accelerometer Number
□
□
□
□
MSFC
25ft Walk □
9 Hole Peg Test | |
Cognitive Function | |
IMMUNOLOGY
Blood Sample Q
Saliva Sample Q
Blood Pressure
HEALTH SCREENING
1 2
Systolic (mmHg)
Diastolic (mmHg)
Resting HR
Medical Questionnaire Q  
Consent Form | |
ANTHROPOMETRY 
Body Measurements Girths
Measurement
Body Mass
(kg)
Stature (cm)
BMI (kg/m*)
Girth Location Circumference (cm)
1 2 3 Average
Waist (cm)
Hip (cm)
Waist/Hip
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AEROBIC CAPACITY (6 MWT)
Humidity (%): 
Circuit Length:
Number of laps: 
Total Dist. (m): 
Walking aid: 
Stop/Pause Reason: 
What stopped you walking further? 
Predicted Max HR(bpm): _________________  % Max HR reached: _
Signature of Person Completing Form: ___________________________
Name of Person Completing Form: ___________________________
Temperature (°C):
Time
(min)
Heart
Rate
(bpm)
RPE
Fatigue breathless­
ness
Start
0 - 1
1 - 2
2-3
3-4
4-5
5-6
Finish
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Appendix 8.9 - Home assessment booklet
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H o m e  A s s e s s m e n t :  C h e c k l is t
STH Study Number: 15153_______________  Date:
Participant ID:   Time point:
Date
✓Start of Day End of Day
• Complete Health Questionnaire
• Wear Accelerometer and complete 
7-Day Exercise Diary
• Collect Saliva Samples (3-days) and 
complete Record Sheet
Next Appointment:_____________________
You will need to arrive at this visit having fasted for 12-hr so that we can take a 
blood sample from you. You should also bring with you this completed booklet, 
your saliva samples and accelerometer. This visit should take ~ 15-30 minutes.
CONTACT DETAILS
Anouska McConnell
Centre for Sport and Exercise Science 
Faculty of Health and Wellbeing 
Sheffield Hallam University 
Collegiate Crescent Campus 
Sheffield, S10 2BP
Tel: 0114 225 5633 E-Mail: a.mcconnell@shu.ac.uk
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A c c e le r o m e te r :  7  D a y  E x e rc is e  D ia ry
STH Study Number: 15153__________________ Date:
Participant ID:   Time point:
INSTRUCTIONS
This diary is to be completed for the 7-days that you where your accelerometer.
Your accelerometer should be worn around your waist, with the device placed on your 
dominant hip. The device can be worn above or below clothing but must be held snugly 
against the body. Remember the device should be removed when sleeping at night and 
must not get wet, so please remove before showering, bathing or swimming.
Please record the total amount of time you have spent doing physical activity (of 
moderate intensity or higher) on every day of the week.
Please note, by moderate intensity we mean a level of activity that noticeably 
increases your heart rate and breathing rate. You may sweat, but you are still able to 
hold a conversation, but you can't sing (e.g. fast walking, swimming, dancing, cycling 
and heavy gardening).
Week commencing:
Please give your answers to the nearest 10mins (tick one box for each day).
0
mins
1-10
mins
11-20
mins
21-30
mins
30 + 
mins
Main Activities
Monday □ □ □ □ □
Tuesday □ □ □ □ □
Wednesday □ □ □ □ □
Thursday □ □ □ □ □
Friday □ □ □ □ □
Saturday □ □ □ □ □
Sunday □ □ □ □ □
Additional Comments:
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S a liv a  S a m p le :  R e c o rd  S h e e t
STH Study Number: 15153___________  Date:
Participant ID:   Time point:
How to take a sample using the tubes:
1. Identify the tube labelled with the correct time
2. Remove the stopper and cotton swab
3. Place the swab in your mouth and chew on it for one minute
4. Place the swab back into the tube and firmly replace the stopper
5. Refrigerate the sample as soon as possible
When to take samples:
We would like you to take samples four times a day for three days, at 8 am, 12noon, 
5pm and 9pm. Please take each sample as close as possible to these times and make 
a note of the exact time in the table below. Up to 30mins before or after the target time 
is fine, so if you remember slightly before the target time, take the sample while you are 
thinking about it!
Sample Time Record:
Alarm time Actual time the sample was taken
DAY 1: 8  am
1 2  noon 
5 pm 
9pm
DAY 2: 8  am
1 2  noon 
5 pm 
9pm
DAY 3: 8  am
1 2  noon 
5 pm 
9pm
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Health Questionnaire
E x e r c is e  I n te r v e n t io n  f o r  M u l t ip le  S c le r o s is  ( E x IM S )
STH Study Number: 
Participant ID:
15153 Date:
Time point:
Sheffield Teaching Hospitals IfllUfa MvN, ^< 11 - - ' /
NHS Foundation Trust Multiple Sclerosis Sodety
Sheffield
H a lla m  University
Health and Daily Activities
1. In general, would you say your health is:
(circle one number)
Excellent 1
Very Good 2
Good 3
Fair 4
Poor 5
2. Compared to one year ago, how would you rate your health in general now?
(circle one number)
Much better now than one year ago 1
Somewhat better now than one year ago 2
About the same 3
Somewhat worse now than one year ago 4
Much worse now than one year ago 5
3-12. The following questions are about activities you might do during a typical day. 
Does vour health limit you in these activities? If so, how much?
__________________________________________ (Circle 1 , 2  or 3 on each line)
Yes, Yes, 
limited a limited a 
lot little
No, not 
limited at 
all
3. Viaorous activities, such as runnina. liftina 
heavy objects, participating in strenuous sports 1 2 3
4. Moderate activities, such as movina a table, 
pushing a vacuum cleaner, bowling, or playing
golf 1 2 3
5. Lifting or carrying groceries 1 2 3
6 . Climbina severalfliahts of stairs 1 2 3
7. Climbing one flight of stairs 1 2 3
8 . Bending, kneeling or stooping 1 2 3
9. Walk more than a mile 1 2 3
10. Walkina several blocks 1 2 3
11. Walkina one block 1 2 3
12. Bathing and dressing yourself 1 2 3
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13-16. During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of your physical health?
(Circle one number on each line)
YES NO
13. Cut down on the amount of time vou could soend on work or 
other activities 1 2
14. Accomplished less than vou would like 1 2
15. Were limited in the kind of work or other activities 1 2
16. Had difficulty oerformina the work or other activities 1 2
17-19. Durina the past 4 weeks, have vou had anv of the followina problems
with vour work or other reaular dailv activities as a result of anv emotional problems
(such as feeling depressed or anxious).
(Circle one number on each line).
YES NO
i 17. Cut down on the amount of time vou could soend on work or 
other activities 1 2
18 . Accomplished less than vou would like 1 2
19. Didn’t do work or other activities as carefully as usual 1 2
20. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbours or 
groups?
(circle one number)
Not at all 1
Slightly 2
Moderately 3
Quite a bit 4
j Extremely 5
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PAIN
21. How much bodily pain have you had during the past 4 weeks?
(circle one number)
None 1
Very mild 2
Mild 3
Moderate 4
Severe 5
Very Severe 6
22. Durina the past 4 weeks, how much did pain inter
(including both work outside the home and housework)?
(circle one number)
Not at all 1
A little bit 2
Moderately 3
Quite a bit 4
Extremely 5
23-32. These questions are about how you feel and how things have been with you 
during the past 4 weeks. For each question, please give the one answer that comes 
closest to the way you have been feeling. How much of the time during the past 4 
weeks......
Allot
the
time
Most 
of the 
time
A good 
bit of 
the 
time
Some 
of the 
time
A little 
of the 
time
None 
of the 
time
23. Did you feel full of pep? 1 2 3 4 5 6
24. Have you been a very nervous person? 1 2 3 4 5 6
25. Have you felt so down in the dumps that 1 O q A C
nothing could cheer you up? c. u o u
26. Have you felt calm and peaceful? 1 2 3 4 5 6
27. Did you have a lot of energy? 1 2 3 4 5 6
28. Have you felt downhearted and blue? 1 2 3 4 5 6
29. Did you feel worn out? 1 2 3 4 5 6
30. Have you been a happy person? 1 2 3 4 5 6
31. Did you feel tired? 1 2 3 4 5 6
32. Did you feel rested on waking in the morning 1 2 3 4 5 6
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33. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with you social activities (like visiting with friends, 
relatives, etc)?_______________________________
(circle one number)
All of the time 1
Most of the time 2
Some of the time 3
A little of the time 4
None of the time 5
HEALTH IN GENERAL
34-37. How TRUE or FALSE is each of the following statements for you.
(Circle one number on each line)
Definitely Mostly Not sure Mostly Definitely
true true false false
34. I seem to get sick a little i O q A c
easier than other people 1 c . O 4 O
35. I am as healthy as 1 p r> A K
anybody I know l o *+ vJ
36. I expect my health to get
1 2 3 4 5worse
37. My health is excellent 1 2 3 4 5
Health Distress
How much of the time during the past 4 weeks
(Circle one number on each line)
All of 
the 
time
Most 
of the 
time
A 
good 
bit of 
the 
time
Some 
of the 
time
A 
little 
of the 
tine
None 
of the 
time
38. Were you discouraged by 
your health problems?
1 2 3 4 5 6
39. Were you frustrated about 
your health?
1 2 3 4 5 6
40. Was your health a worry in 
your life?
1 2 3 4 5 6
41. Did you feel weighed down 
by your health problems?
1 2 3 4 5 6
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Cognitive function
How much of the time during the past 4 weeks....
________________________________________(Circle one number on each line)
All of 
the 
time
Most 
of the 
time
A 
good 
bit of 
the 
time
Some 
of the 
time
A 
little 
of the 
time
None 
of the 
time
42. Have you had difficulty 1 2 3 4 5 6
concentrating and thinking? 
43. Did you have trouble 1 2 3 4 5 6
keeping your attention on an 
activity for long?
44. Have you had trouble with 1 2 3 4 5 6
your memory?
45. Have others, such as family 1 2 3 4 5 6
members or friends, noticed that 
you have trouble with your 
memory or problems with your 
concentration?
Sexual function
46-49. The next set of questions are about your sexual function and your satisfaction 
with your sexual function. Please answer as accurately as possible about your function 
during the last 4 weeks only.
How much of a problem was each of the following for you during the past 4 weeks?
(Circle one number on each line)
MEN
Not a 
problem
A little 
of a 
problem
Somewhat 
of a 
problem
Very 
much of 
a
problem
46. Lack of sexual interest 1 2 3 4
47. Difficulty getting or keeping an 
erection 1 2 3 4
48. Difficulty having orgasm 1 2 3 4
49. Ability to satisfy sexual partner 1 2 3 4
(Circle one number on each line)
WOMEN
Not a 
problem
A little 
of a 
problem
Somewhat 
of a 
problem
Very 
much of 
a
problem
46. Lack of sexual interest 1 2 3 4
47. Inadequate lubrication 1 2 3 4
48. Difficulty having orgasm 1 2 3 4
49. Ability to satisfy sexual partner 1 2 3 4
50. Overall, how satisfied were you with your sexual function during the past 4 
weeks?
292
(circle one number)
Very Satisfied 
Somewhat Satisfied 
Neither satisfied or dissatisfied 
Somewhat dissatisfied 
Very Satisfied
51. During the past 4 weeks, to what extent have problems with your bowel or 
bladder function interfered with your normal social activities with family, friends, 
neighbours or groups?
(circle one number)
Not at all 
Slightly 
Moderately 
Quite a bit 
Extremely
52. During the past 4 weeks, how much did pain interfere with your enjoyment of 
life?
(circle one number)
Not at all 1
Slightly 2
Moderately 3
Quite a bit 4
Extremely 5
1
2
3
4
5
1
2
3
4
5
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QUALTIY OF LIFE
©
53. Overall, how would your rate your quality-of-life? 
Circle one number on the scale below:
© ©
10 9
Best 
Possible 
Quality-of- 
Life
1 0  
Worst 
Possible 
Quality-of-Life
As bad as or 
worse than 
being dead
54. Which best describes how you feel about your life as a whole?
(circle one number)
Terrible 1
Unhappy 2
Mostly dissatisfied 3
Mixed - about equally satisfied and dissatisfied 4
Mostly satisfied 5
Pleased 6
Delighted 7
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Fatigue
INSTRUCTIONS
Fatigue is a feeling of physical tiredness and lack of energy that many people 
experience from time to time. But people who have medical conditions like MS 
experience stronger feelings of fatigue more often and with greater impact than others.
Following is a list of statements that describe the effects of fatigue. Please read each 
statement carefully, then circle the one number that best indicates how often 
fatigue has affected you in this way during the past 4 weeks. Please answer every 
question. If you are not sure which answer to select, chose the one that comes closest 
to describing you.__________________ ________________________________
Because of my fatigue during the past 4 weeks I have
«>.
(0
Ne
ve
r
Ra
re
ly
So
m
et
im
es
Of
te
n
<4-*(0o
E
<
1 . been less alert 0 1 2 3 4
2 . had difficulty paying attention for long periods of time 0 1 2 3 4
3. been unable to think clearly 0 1 2 3 4
4. been clumsy and uncoordinated 0 1 2 3 4
5. been forgetful 0 1 2 3 4
6 . had to pace myself in physical activities 0 1 2 3 4
7. been less motivated to do anything that requires physical effort 0 1 2 3 4
8 . been less motivated to participate in social activities 0 1 2 3 4
9. been limited in my ability to do things away from home 0 1 2 3 4
1 0 . had trouble maintaining physical effort for long periods 0 1 2 3 4
1 1 . had difficulty making decisions 0 1 2 3 4
1 2 . been less motivated to do anything that requires thinking 0 1 2 3 4
13. been feeling as though my muscles are week 0 1 2 3 4
14. been physically uncomfortable 0 1 2 3 4
15. had trouble finishing tasks that require thinking
16. had difficulty organising my thoughts when doing things at 
home/work
0
0
1
1
2
2
3
3
4
4
17. been less able to complete tasks that require physical effort 0 2 3 4
18. been thinking more slowly 0 1 2 3 4
19. had trouble concentrating 0 1 2 3 4
2 0 . limited my physical activity 0 1 2 3 4
2 1 . needed to rest more often or for longer periods 0 1 2 3 4
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Physical Activity
FREE TIME ACTIVITY
1. During a typical 7-Day period (a week), how many times on the average do you 
do the following kinds of exercise for more than 15 minutes during your free time?
Please place a number in each box
a) STRENUOUS EXERCISE (heart beats rapidly)
(e.g. jogging, vigorous swimming, netball, aerobics, circuits) ___
b) MODERATE EXERCISE (not exhausting, but tiring)
(e.g. fast walking, tennis, cycling, easy swimming, dancing)
c) MILD (minimal effort)
(e.g. yoga, archery, bowling, golf, easy walking) ___
2. During a typical 7-Day period (a week), in your leisure time, how often do you 
engage in any regular activity long enough to work up a sweat (heart beats rapidly)?
Often Q ] Sometimes I [ Never/Rarely | |
EVERYDAY ACTIVITY
We are interested in finding out about the kinds of physical activities that people do as 
part of their everyday lives. The questions will ask you about the time you spent being 
physically active in the last 7 days. Please answer each question even if you do not 
consider yourself to be an active person. Please think about the activities you do at 
work, as part of your house and yard/garden work, to get from place to place, and in 
your spare time for recreation, exercise or sport.
Think about all the vigorous activities that you did in the last 7 days. Vigorous 
physical activities refer to activities that take hard physical effort and make you breathe 
much harder than normal. Think only about those physical activities that you did for at 
least 1 0  minutes at a time.
1. During the last 7 days, on how many days did you 
do vigorous physical activities like heavy lifting, 
digging, aerobics, or fast bicycling?
days per week
□ no vigorous activity ^  
Skip to question 3
2. How much time did you usually spend doing 
vigorous physical activities on one of those days?
hours per day 
minutes per day
□ Don’t know/Not sure
Think about all the moderate activities that you did in the last 7 days. Moderate 
activities refer to activities that take moderate physical effort and make you breathe
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somewhat harder than normal. Think only about those physical activities that you did 
for at least 1 0  minutes at a time.
3. During the last 7 days, on how many days did you 
do moderate physical activities like carrying light 
loads, bicycling at a regular pace, or doubles tennis? 
Do not include walking.
days per week
□ No moderate physical 
activities^ Skip to question 
5
4. How much time did you usually spend doing 
moderate physical activities on one of those days?
hours per day 
minutes per day
□ Don’t know/Not sure
Think about the time you spent walking in the last 7 days. This includes at work and 
at home, walking to travel from place to place, and any other walking that you might do 
solely for recreation, sport, exercise, or leisure.
5. During the last 7 days, on how many days did you 
walk for at least 1 0  minutes at a time? days per week
□ No walking 
^  Skip to question 7
6 . How much time did you usually spend walking on 
one of those days?
hours per day
minutes per day
□ Don’t know/Not sure
The last question is about the time you spent sitting on weekdays during the last 7 
days. Include time spent at work, at home, while doing course work and during leisure 
time. This may include time spent sitting at a desk, visiting friends, reading, or sitting or 
lying down to watch television.
7. During the last 7 days, how much time did you 
spend sitting on a week day?
hours per day 
minutes per day
□ Don’t know/Not sure
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Health and Daily Activities
INSTRUCTIONS
This survey asks about your health and daily activities. Answer every question by 
circling the appropriate number. If you are unsure about how to answer a question, 
please give the best answer you can and write a comment or explanation in the 
margin.
Please feel free to ask someone to assist you if you need help reading or marking the 
form.
Please indicate which statements best describe your own health state today. 
________________________________________________ (circle one number)
Mobility
1 have no problems in walking about 1
1 have some problems in walking about 2
1 am confined to bed 3
Self-Care
1 have no problems with self-care 1
1 have some problems washing or dressing myself 2
1 am unable to wash or dress myself 3
Usual Activities (e.g. work, study, housework, family or leisure activities)
! 1 have no problems with performing my usual activities 1
1 have some problems with performing my usual activities 2
1 am unable to perform my usual activities 3
Pain/Discomfort
1 have no pain discomfort 1
1 have moderate pain discomfort 2
1 have extreme pain or discomfort 3
Anxiety/Depression
1 am not anxious or depressed 1
1 am moderately anxious or depressed 2
1 am extremely anxious or depressed 3
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Your own health state today
To help people say how good or bad a health 
state is, we have drawn a scale (rather like a 
thermometer) on which the best state you 
can imagine is marked 1 0 0  and the worst 
state you can imagine is marked 0 .
We would like you to indicate on this scale 
how good or bad your own health is today, in 
your opinion. Please do this by drawing a line 
on the scale at whichever point indicates how 
good or bad your health state is today.
Best 
imaginable 
health state
1 0 0
9-^0
8 " 0
7” 0
6 » 0
£ > 0
4 ” 0
3” 0
2 l i 0
1 ^ 0
0
Worst 
imaginable 
health state
This is the end of the questionnaire, thank you for participating.
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Appendix 8.10 - Data collection sheet (supervised exercise sessions)
ExIMS - Supervised Exercise Session 
Data Collection Sheet
STH Study Number: 15153__________________  Week:
Patient ID Number:
1. SUPERVISED SESSION DATE................ TIME
Duration Mode Intensity HR (bpm) RPE
Additional Work Done (i.e. strenath, function, balance, R of M):
Additional Comments:
2. SUPERVISED SESSION DATE................ TIME
Duration Mode Intensity HR (bpm) RPE
Additional Work Done (i.e. strenath, function, balance, R of M):
Additional Comments:
Signature of Person Completing Form: 
Name of Person Completing Form:
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Appendix 8.11 - Data collection sheet (home exercise session)
ExIMS - Home Exercise Session 
Data Collection Sheet (Weeks 1-6)
STH Study Number: -j 5-| 5 3 Week:
Patient ID Number:
1. HOME SESSION DATE.................  TIME
Suggested Exercise Achieved Exercise
Activity
(walking, 
swimming etc)
Intensity
(RPE Scale)
Time
(minutes)
Additional
Comments
Signature of person 
completing the form
Name of person 
completing the form
Intensity - Borg's RPE Scale
6
7 Very, very light
8
9 Very light
10
11 Fairly Light
12
13 Somewhat hard
14
15 Hard
16
17 Very hard
19 Very, very hard
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Appendix 8.12 - Action Plan
ExIM S - Final Exercise Session (W k11)
STH Study Number: 15153
Patient ID Number:
1 a. Review Goals (did you achieve them? If yes well done, if not why not, what can 
we do to help?)
b. What is your long-term goal over the next 6-months (SMART)?
c. What short term goals are going to enable you to reach this goal (SMART)?
2 a. What do you see as potential barriers to continuing to be physical activity 
(SWOT-strengths, weaknesses, opportunities and threats)?
b. How might you avoid or overcome these?
3 a. Exercise Achievements. What have I achieved so far, what have I learnt, is there 
anything that I still would like to know?
4. Action Plan for Home (Session menu, tailored plan, progression and relapse 
strategy)
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Exercise and MS - Home Plan
Aerobic exercise Session Plan: 3 x week
Gentle Aerobic Warm-up
• Light walk/cycle to gradually increase your heart rate (RPE ~10-11)
Light Stretching
• Stretching of muscles to be used in the session (hold each stretch for ~5- 
6s)
20-30 minute's aerobic exercise at a mild to moderate intensity (RPE Scale 
~ 11-13)
Gentle walk/cycle to gradually decrease your heart rate (RPE ~10-11)
Carry out any symptom specific physio exercises now that the muscles and 
body are nice and warm
Stretching of muscles used in the session (hold each stretch for ~5-6s)
Aerobic Exercise Session
Gentle Aerobic Cool-down
Physiotherapy Exercises
Light Stretching
• Remember exercises should not be painful.
• The amount and intensity of the exercise 
may need to be adjusted depending on how 
you feel on the day.
• If you have any significant time away from 
exercise, remember you will need to start 
slowly and gradually build back-up.
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Intensity - Borg's RPE Scale
6
7 Very, very light
8
9 Very light
10
11 Fairly Light
12
13 Somewhat hard
14
15 Hard
16
17 Very hard
Exercise Goals 
Example Exercise Sessions
Ideally exercise 4x week, but always at least 2 
Combinations of Yoga/swimming/walking/gym
Maintain and further improve fitness 
Lose more weight 
Maybe start running
•W arm -up: 10-min Treadmill (Hill profile, 3.3mph), stretching 
•Session - Rower (1000m, 5-6 min), 10-min bike 
•Ba ll W ork
•Cool down: 10-min recumbant bike, stretching
20-30 minutes (20-30 lengths)
•30m in  - lh r
Short-Term
Long-Term
1. Gym (SHU) or private
3. W alking/bike ride
2. Swimming
Physiotherapy Exercises —
V™ .__________________ ■______________ ___ _______________________ _ _______________________ _ ___________
• Ball work - sit-ups, roll-outs, back raises, tw ists xlO
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Appendix 8.13 - Exercise information Sheet
M u l t i p l e  S c l e r o s i s  
a n d  E x e r c i s e :
A d v i c e  L e a f l e t
The information provided in this leaflet is designed to be used in 
conjunction with the MS and exercise intervention research taking 
place at Sheffield Hallam University and is to be used alongside the 
individual exercise advice provided by the project team.
M
Multiple Sderosis Society
3C
Sheffield Teaching Hospitals fM f£
NHS Foundation Trust
B e n e f i t s  o f  E x e r c i s e
Being physically active can improve both your physical and mental 
health and reduce your risk of suffering from health problems such 
as; cardiovascular disease, stress, obesity, diabetes, some cancers, 
osteoporosis, high cholesterol and high blood pressure.
In addition, regular appropriate exercise can have a positive impact 
on living with MS, helping you to stay mobile and manage your 
symptoms better. There is no evidence that exercise makes your 
MS worse or that it increases the number of relapses.
Research has shown that regular aerobic exercise for people with 
mild to moderate MS can improve;
•  Strength
• Stamina (aerobic capacity)
•  Mobility (walking/balance)
• Mood state (anxiety/depression)
•  Quality of life
•  Fatigue
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C h o o s i n g  P h y s i c a l  A c t i v i t y ?
There are many types of physical activity to choose from. The most 
appropriate one's for you will depend on your symptoms and may 
vary over time and from day to day.
For example if you suffer from balance problems, spasticity or jo int 
stiffness you might benefit more from activities such as Yoga or 
Pilates, whilst if you suffer from fatigue, research suggests that 
aerobic activities such as brisk walking may actually effectively 
reduce your fatigue.
Physical activity does not have to mean sport or exercise in a gym, 
just being more activity in your daily life, by using the stairs more or 
cleaning the car all counts.
G e t t i n g  S t a r t e d
When starting to increase your physical activity levels th ink about 
the type of exercise that you would like to do, what you would enjoy 
and what fits into your current lifestyle.
The type, amount and intensity of the exercise recommended will 
depend on your current level of fitness, symptoms and preferences.
Even small increases in physical activity could benefit your physical 
and mental health.
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E x e r c i s e  T y p e
Aerobic exercises include activities such as 
brisk walking, swimming and cycling that use 
large muscle groups for a reasonable length of 
time. These exercises work the heart and the 
lungs and will improve your stamina.
J
Strength exercises include resistance type 
exercises aimed at strengthening specific 
muscle groups and/or improving posture. 
These may include lifting small weights, using 
your own body weight or pulling against 
resistance bands.
Flexibility exercises should be done as a 
warm-up and cool down before aerobic and 
strength exercise, but can also be beneficial on 
their own for increasing range of motion.
J
I
Water-based activity reduces the strain on the 
body, supporting the body and reducing your 
risk of falling. If you are heat sensitive it may 
be good to check the temperature of the water 
before you go in.
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E x e r c i s e  R e c o m m e n d a t i o n s
• How much exercise and at what intensity?
o 2-3 aerobic sessions a week, for 20-30 minutes, at 
m ild/moderate intensity is suitable for people with mild to 
moderate MS.
o Remember even if you can only manage a few minutes 
initially, something is better than nothing, just build up 
gradually.
• W hat is moderate activity and how is it monitored? 
o Moderate intensity can be described as;
'an aerobic activity that noticeably increases you r heart 
rate and breathing rate. You m ay sweat, bu t you are still 
able to ho ld a conversation, but you can't sing'.
o  The intensity of your exercise can also be monitored by 
taking your heart rate, or by monitoring your rating of 
perceived exertion (RPE) using a scale (see diagram 
opposite). The exercise should feel fairly light to 
somewhat hard on this scale (green portion).
• Exercise Progression
o To improve fitness you need to work your body above 
the level that it is used to. 
o To progress you need to gradually increase the amount, 
duration or intensity of the physical activity that you are 
doing.
o Remember you must give your body the time to adapt to 
being more physically active, before trying to progress 
further.
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R P E  S c a l e
6
7  V e r y ,  V e r y  L i g h t  -  R e s t
8
9  V e r y  L i g h t  -  G e n t l e  W a l k
1 0
1 1  F a i r l y  L i g h t
1 2
1 3  S o m e w h a t  H a r d
1 4
1 5  H a r d
1 6
| 1 7  V e r y  H a r d
| 1 8
1 9  V e r y ,  V e r y  H a r d
2 0
Borg Rating of Perceived Exertion Scale, 1998
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E x e r c i s e  S a f e t y
Exercise is safe for people with MS providing you take things slowly 
and follow some simple guidelines;
W ear a p p ro p ria te  c lo th in g  and foo tw ea r: If cycling use a helmet, 
reflective clothing and lights at night.
C hose a safe  en v iro n m e n t: W hen walking avoid being alone at 
night and keep to well lit areas.
A dap t e xe rc ise s  depend ing  on y o u r sym p to m s : If your balance 
is affected you may want to consider using gym equipment, such as 
a treadmill with a hand rail, or a stationary cycle.
S ta rt s lo w ly  and g ra d u a lly  b u ild -u p : Splitting exercise into short 
bouts of m ild/moderate exercise with rest periods can help you to 
manage more (and still gives you benefit).
L is ten  to  y o u r body: Don't try to do too much
o Learn your limits and stop before you get too tired 
o If you feel pain, dizziness or discomfort, stop and seek advice 
o If you are unwell or have a fever don't exercise 
o Don't exercise during an acute relapse and take advice from a 
specialist before starting again. Remember start again slowly
Be fle x ib le : If you are having a bad day, reduce the am ount of 
exercise that you had planned, or re-schedule.
W arm -up and co o l-d o w n : This will help guard against injury and 
prevent existing muscle problems getting worse.
o Start aerobic sessions slowly, gradually increasing your heart 
rate
o Gently stretch muscles being used both before and after the 
session
Keep w e ll hydra ted
o When exercising you will need to drink more, particularly if 
exercising in the heat
311
o Drinking cool water may help to keep body temperature down
C o nsu lt yo u r GP: If you have any other health issues, such as 
heart conditions or asthma, consult your GP before starting on an 
exercise programme.
E x e r c i s e  a n d  F a t i g u e
Fatigue is one of the most common symptoms for people with MS. 
Feeling tired can often put you off starting an exercise programme. 
However, research has shown that exercise can be a good thing, 
increasing your stamina and reducing muscle weakness.
W hen starting an exercise programme you may feel more tired 
initially. However, these affects can be minimised by starting at an 
appropriate level and building up slowly.
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E x e r c i s e  a n d  H e a t  S e n s i t i v i t y
People with MS can suffer from heat sensitivity. This means that 
during and immediately after exercise when your body temperature 
has been increased your symptoms may feel worse. However, this 
effect is temporary and as the body cools down again your 
symptoms will return to normal. This should not be a reason to avoid 
exercise, but trying to keep cool when doing so may help.
Tips for keeping cool
•  Drink cool fluids during and after exercise
• Exercise at a cooler time of day or in a well ventilated space (a 
fan may help)
• W ear appropriate clothing for the conditions
• Consider interval training (alternating short bouts of activity 
with rest to prevent your body getting too warm)
• Use cooling vests or caps
• Use wipes to cool your skin or take a cool shower after 
exercise
• Exercise at a mild to moderate intensity
Contact Details
Anouska McConnell 
0114 225 5633 
a.m cconnell@ shu.ac.uk
Centre for Sport 
and Exercise Science
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Appendix 8.14 - Effect Sizes for Main Study Outcomes
OUTCOME 3-Months Follow-up 6-months Follow-up
Effect Lower Upper Effect Lower Upper
Size 95% limit 95% limit Size 95% limit 95% limit
Clinical Measurements
EDSS -0.08 -0.28 0.12 -0.09 -0.30 0.11
Systolic BP -0.08 -0.27 0.12 0.01 -0.18 0.20
Diastolic BP -0.11 -0.30 0.09 -0.20 -0.39 -0.01
Resting Heart Rate 0.19 -0.00 0.38 0.11 -0.08 0.30
Weight 0.06 -0.13 0.25 0.02 -0.18 0.21
BMI 0.06 -0.13 0.26 0.08 -0.11 0.28
Waist -0.18 -0.37 0.01 -0.22 -0.41 -0.03
Hip -0.21 -0.41 -0.02 -0.10 -0.29 0.09
Waist:Hip -0.03 -0.23 0.16 -0.16 -0.36 0.03
Physical Activity - Godin/IPAQ
Godin 0.25 0.05 0.46 0.18 -0.02 0.39
Vigorous MET hrs/wk 0.12 -0.09 0.32 -0.04 -0.25 0.17
Moderate MET hrs/wk 0.04 -016 0.25 0.09 -0.13 0.30
Walking MET hrs/wk 0.17 -0.03 037 -0.33 -0.55 -0.12
Total MET hrs/wk 0.17 -0.03 0.37 -0.15 -0.36 0.06
Sitting time hrs/day -0.02 -0.17 0.13 0.06 -0.15 0.27
Physical Activity - Accelerometry
Vertical 0.20 -0.08 0.39 0.01 -0.19 0.22
Horizontal 0.12 0.07 0.31 -0.12 -0.32 0.09
Step Count 0.26 -0.65 0.46 -0.01 -0.21 0.20
Physical Fitness
6MWT 0.13 -0.06 0.33 0.14 -0.07 0.34
Fatigue - MFIS
Physical -0.45 -0.65 -0.26 -0.13 -0.33 0.08
Cognitive -0.39 -0.58 -0.19 -0.15 -0.35 0.05
Psychosocial -0.45 -0.64 -0.26 -0.10 -0.30 0.11
Total MFIS -0.50 -0.69 -0.30 -0.16 -0.36 0.04
MS Functional Composite
25ft walk -0.17 -0.36 0.03 0.06 -0.15 0.26
9-hole peg test DH -0.11 -0.31 0.08 -0.19 -0.40 0.01
9-hole peg test NDH -0.10 -0.30 0.09 -0.13 -0.33 0.07
PASAT -0.14 -0.34 0.06 0.17 -0.03 0.38
Quality of Life - MSQOL54
Physical Health 0.33 0.14 0.53 0.13 -0.07 0.33
Role Physical 0.16 -0.04 0.35 -0.02 -0.22 0.19
Role Emotional 0.12 -0.08 0.32 0.08 -0.13 0.28
Pain 0.22 -0.02 0.41 0.04 -0.16 0.24
Emotional Wellbeing 0.37 0.18 0.57 0.26 0.05 0.46
Energy 0.56 0.36 0.75 0.11 -0.09 0.32
Health Perceptions 0.39 0.19 0.58 -0.05 -0.26 0.15
Social Function 0.37 0.18 0.57 0.30 0.09 0.50
Cognitive Function 0.19 -0.01 0.39 0.04 -0.16 0.25
Health Distress 0.46 0.26 0.65 0.05 -0.16 0.25
Sexual Function 0.25 0.04 0.45 0.13 -0.09 0.35
Change in Health 0.51 0.32 0.71 0.09 -0.11 0.29
Sexual Satisfaction 0.26 0.06 0.47 0.01 -0.21 0.22
Overall QoL 0.54 0.35 0.74 0.34 0.13 0.54
Quality of Life - EQ5D
EQ5D 0.42 0.23 0.62 0.09 -0.11 0.30
314
Appendix 8.15
Cost effectiveness of a pragmatic exercise intervention (EXIMS) for people 
with multiple sclerosis: economic evaluation of a randomised controlled 
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1.1 Abstract
Background: Exercise is a safe, non-pharmacological adjunctive treatment for 
people with multiple sclerosis but cost-effective approaches to implementing 
exercise within health care settings are needed.
Objective: The objective of this paper is to assess the cost effectiveness of a 
pragmatic exercise intervention in conjunction with usual care compared to 
usual care only in people with mild to moderate multiple sclerosis.
Methods: A cost-utility analysis of a pragmatic randomised controlled trial over 
nine months of follow-up was conducted. A total of 120 people with multiple 
sclerosis were randomised (1:1) to the intervention or usual care. Exercising 
participants received 18 supervised and 18 home exercise sessions over 12 
weeks. The primary outcome for the cost utility analysis was the incremental 
cost per quality-adjusted life year (QALY) gained, calculated using utilities 
measured by the EQ-5D questionnaire.
Results: The incremental cost per QALY of the intervention was £10,137 per 
QALY gained compared to usual care. The probability of being cost effective at 
a £20,000 per QALY threshold was 0.75, rising to 0.78 at a £30,000 per QALY 
threshold.
Conclusion: The pragmatic exercise intervention is highly likely to be cost 
effective at current established thresholds, and there is scope for it to be 
tailored to particular sub-groups of patients or services to reduce its cost impact.
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1.2 Introduction
Exercise is a safe, non-pharmacological treatment strategy for people with
%
multiple sclerosis (PwMS) that can bring many health benefits, including 
improvements in muscle power, physical and psychosocial functioning, fatigue 
symptoms and quality of life (1_3) A major challenge, however, is to develop 
pragmatic and cost-effective interventions that can engage PwMS in exercise 
and have a long-lasting impact on physical activity behaviour. Ensuring that an 
intervention is both comprehensive and guided, but also pragmatic in terms of 
delivery and resource requirements, is a challenge that needs to be addressed 
so that health resources are appropriately utilised.
To date, cost-effective ness analyses, aimed at comparing the costs and health 
benefits of exercise interventions for PwMS, are lacking. However, evidence to 
suggest that an exercise intervention provides health benefits at an acceptable 
cost may aid in the decision to implement new services. We recently undertook 
a parallel-arm, randomised controlled trial that investigated the effects of a 
pragmatic Exercise Intervention for people with MS (EXIMS) on a range of 
important health outcomes. The exercise intervention increased self-reported 
physical activity, improved fatigue symptoms and led to a sustained 
enhancement of health-related quality of life (HRQoL) [Epub ahead of print; 
10.1177/1352458513519354]. Using a National Health Service (NHS) and 
societal perspective, we also undertook an economic evaluation to estimate the 
cost and cost effectiveness of the pragmatic exercise intervention in conjunction 
with usual care, in comparison with usual care alone for PwMS. The results of 
this economic evaluation are reported here.
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1.3 Materials and Methods
1.3.1 Randomised controlled trial
Details of the randomised controlled trial have been published elsewhere.4 
Briefly, 120 PwMS were randomised (1:1) to a pragmatic exercise intervention 
(EXIMS) plus usual care group, or usual care only. Participants in the 
intervention group undertook a 12-week programme of exercise. During weeks 
1-6, participants attended two supervised sessions per week at a university 
exercise facility close to the hospital and engaged in one additional self-directed 
exercise session in their home environment. During weeks 7-12, participants 
attended the centre once per week and completed two additional self-directed 
exercise sessions in their home environment. EXIMS also incorporated 
cognitive-behavioural techniques (e.g. goal setting, finding social support, 
understanding the costs/benefits of exercise, etc.) to promote long-term 
participation in physical activity. The study was approved by the South 
Yorkshire Research Ethics Committee and conducted according to the 
principles of the Declaration of Helsinki. Written informed consent was obtained 
from participants before entering the study.
1.3.2 Economic evaluation
The primary analysis examined intervention and NHS care costs up to nine 
months’ post-randomisation. Other analyses included wider costs such as 
patient costs and productivity losses. Patient and productivity costs were 
excluded from the primary analysis as they do not fall on the budget of a health 
service payer.
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1.3.3 Resource use
Data collected were NHS and Personal Social Services (PSS) resources, 
personal costs incurred by participants and lost productivity due to time off 
work. A questionnaire was used to report MS-related NHS contact with primary 
and secondary care services. We also asked participants to report any 
personally incurred expenditure due to their condition or treatment, as well as 
any private therapies and complementary and alternative medicines (CAMs). 
Participants were asked if they had received assistance from social care staff 
and if they had taken time off work because of their MS or their treatment for 
MS. Secondly, the NHS medical records for all participants were cross-checked 
for secondary consultations with MS consultants and nurses. These data were 
checked against the patient questionnaire to avoid double-counting of events. 
Accident and emergency (A&E) attendances and inpatient hospitalisations were 
extracted from NHS medical records. Finally, the number of prescribed exercise 
sessions completed by each patient in the intervention arm (out of a possible 18 
sessions) was recorded by the exercise specialist who led the intervention.
1.3.4 Costs
Unit costs for each of the resources used are presented in Table 1.1. Three 
broad groups of costs were estimated: intervention costs, NHS costs, and 
personal costs. An estimate of the cost of the group exercise programme was 
an aggregation of staff costs, equipment costs and facility overheads. Staff 
costs were estimated using NHS physiotherapists and exercise specialists,5 and 
weighted by the amount of time each staff member spent setting up and 
delivering the sessions. Equipment costs were estimated using retail prices for
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each piece of exercise equipment, and annuitized for its life expectancy as 
judged by exercise experts on the research team. In an NHS setting, it was 
judged that the sessions would be delivered in a physiotherapy department. 
Overhead costs for a physiotherapy department were used from the published 
Unit Costs of Health and Social Care5 and composed of management, non-staff 
and capital overheads. It was assumed that there were no costs associated with 
prescribing the home exercise sessions, as this was undertaken during the 
supervised exercise sessions.
Table 1.1. Cost of the intervention.
Resource use Unit cost (£) -  2011 unless specified Source
Intervention costs
Staff 18.38 per session per patient PSSRU Curtiis. 20I Is
Equipment 3.31 per session per patient Microcosted estimate. Retail prices, annuitized
Overheads 0.82 per session per patient PSSRU Curtiis. 2 0 I I5
Intervention cost (2012 prices) 22.52 (per session per patient)
408 per patient-18 sessions 
12 16 per programme for three patients
NHS costs
GP appointment 36 PSSRU Curtiis. 201 Is
Neurology outpatient visit 2I4 2011 Reference costs
NHS community health visit £42 PSSRU Curtiis. 20I I5
Social care visit 25 PSSRU Curtiis. 20115
Neurology inpatient visit 144 2011 Reference costs
Hospitalisation 463 2011 Reference costs
Accident and emergency visit 55 PSSRU Curtiis. 20I Is
Personal costs
Time off work 13.11 (male), 11.9 1 (female), per hour Annual Survey of Hours and earnings (ONS, 20! I)
GP: general practitioner; NHS: National Health Service; ONS: Office for National Statistics.
NHS costs were provided by national published unit cost and reference cost 
sources. The cost of an A&E visit was estimated using a published figure for an 
A&E visit with no resulting hospital admission. If a patient experienced a 
hospitalisation, a daily unit cost was estimated based on a neurology inpatient 
hospitalisation (£2235 average cost for a 4.82-day-long stay). Personal costs
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included any personal expenses reported by the patient, as well as any time off 
work. The human capital approach was used to estimate the productivity loss.6 
Office for National Statistics (ONS) sources were used to estimate the hourly 
rate per male and per female.
1.3.5 Cost-utility analyses
For the cost-utility analyses, health benefits were measured in terms of quality- 
adjusted life years (QALYs) using EQ-5D HRQoL values.7 QALYs were 
calculated using the trapezium rule to estimate the area under the curve. As an 
alternative HRQoL measure, we used SF-6D utilities by extracting the SF-36 
items from the Multiple Sclerosis Quality of Life-54 (MSQOL-54) instrument and 
applying the SF-6D algorithm.8 The EQ-5D and MSQOL-54 scores were 
measured at baseline, three months and nine months. In the primary analysis, 
only NHS costs were included. Personal and societal costs were included in a 
sensitivity analysis. All analyses were conducted using STATA© 12 and 
Microsoft Excel© 2010.
1.3.6 Statistical analysis
All comparisons of costs and effects were performed at the end of the nine-
month randomisation period. It was not necessary to discount costs and
outcomes because of the nine-month time horizon. Mean costs and mean
QALYs were estimated separately. An ordinary least squares (OLS) regression
was applied to control the estimated QALYs for baseline level of utility. Mean
differences between both groups are presented with their bootstrapped 95%
confidence intervals (CIs). An incremental analysis was undertaken by dividing
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the mean incremental costs by the mean incremental QALYs to produce an 
incremental cost effectiveness ratio (ICER). This can be interpreted as the 
additional cost per QALY gained for the exercise intervention. Uncertainty in the 
ICER was parameterised by bootstrapping 5000 replications of each ratio 
(replicated ICERs). The uncertainty was visualised in two ways: firstly with each 
replicate of costs and QALYs plotted on a two-dimensional cost-effectiveness 
plane, and secondly with the probability of cost effectiveness at a range of 
thresholds plotted on a cost-effectiveness acceptability curve.9,10 We also 
estimated the net monetary benefit gained from adopting the intervention for 
given values of cost per QALY that society might be willing to pay (£20,000 and 
£30,000),11 and the probability that the net monetary benefit is positive using 
these values.
1.3.7 Sensitivity analysis
The robustness of the results was examined in a series of scenario analyses.
Firstly, the delivery of the intervention in private gyms or by third-party providers
was costed and included as a sensitivity analysis. Secondly, personal costs and
time off work were included to expand the analysis to a societal perspective.
Thirdly, a priori sub-groups were defined by defining clinically meaningful
patient sub-populations. The Expanded Disability Status Scale (EDSS) clinical
measure of disability in people with MS was used to classify participants as
EDSS ^ 3.5 (mild disability) and 3.5 < EDSS ^ 6.5 (moderate disability). The
baseline Godin Leisure Time Exercise Questionnaire (GLTEQ) measure of
physical activity was used to classify participants as GLTEQ < 14 (insufficiently
active) and GLTEQ > 1 4  (moderately active). The cost-utility analysis was
conducted for all four sub-groups. Fourthly, there are numerous generic
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preference-based measures of HRQoL, and although the EQ-5D is 
recommended in the United Kingdom (UK) for cost-utility analyses,11 the SF-6D 
values were used in a scenario analysis to evaluate the uncertainty regarding 
the estimates of change in QALYs.
1.4 Results
A total of 120 PwMS were randomised into the two groups (N=60 participants in 
each group). The two groups had similar demographic, anthropometric and MS 
disease characteristics at baseline (Table 1.2). A total of 21 (17.5%) participants 
withdrew from the trial, and 27 (22.5%) participants were not a complete case 
(resource use questionnaire data missing from 17 (14%) and EQ-5D follow-up 
data missing from 27 (22.5%)). Where complete case data were missing, 
multiple imputation methods using the multiple imputation (Ml) command in 
STATA© were used to impute missing values for costs and missing domains for 
EQ-5D. Ml is a method by which each missing datum case is replaced by a set 
of plausible estimates, based on predictors (sex, age, baseline EDSS and 
baseline EQ-5D domains). The process is repeated using different estimates 
and then the results are combined using Rubin’s rule.12
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Table 1.2. Baseline characteristics of participants allocated to usual care only or 
usual care plus EXIMS. Values are numbers (percentages) or mean ± SD.
Characteristics Usual care (n=60) EXIMS (n=60)
Age (years) 46.0 ± 8.4 45.7 ±9.1
Female 43 (71.7%) 43 (71.7%)
White 57 (95%) 54 (90%)
Married or cohabiting 46 (77%) 48 (80%)
Educated to A level or beyond 39 (65%) 41 (68%)
Employed full time 16(27%) 9(15%)
Employed part time 14(23%) 17(28%)
Time since MS diagnosis (years) 9.2 ± 7.9 8.4 ± 7.4
EDSS score subgroup 3.8 ± 1.5 3.8 ± 1.5
0-3.S 28 (47%) 29 (48%)
4.5-6.5 32 (53%) 31 (52%)
Mean score 3.8 ± 1.5 3.8 ± 1.5
MS subtype
Relapsing-remitting 47 (78%) 51 (85%)
Secondary progressive II  (18%) 7(12%)
Primary progressive 2 (3%) 2 (3%)
Anthropometric variables
Height (m) 1.68 ±0.07 1.68 ±0.08
Body mass (kg) 76.4 ± 15.5 79.4 ± 17.8
BMI (kg/m2) 27.1 ±5.8 28.0 ± 5.4
EXIMS: EXercise Intervention for people with MS; MS: multiple sclerosis; EDSS: Expanded Disability Status Scale; BMI: body mass Index,
1.4.1 Resource use
NHS and PSS resource use is shown in Table 1.3. The mean number of 
contacts was higher in the usual care control group compared to the exercise 
group, although variability in the estimates is too large to draw reliable 
conclusions about a difference in them. The number of outpatient, general 
practitioner (GP) visits, A&E visits and inpatient stays was small for both 
groups. Community visits and social care contact was not utilised by the 
majority of either group; however, the mean estimate of social care contact is 
heavily skewed because of a few patients requiring high levels of contact. Of 
the 60 participants allocated to receive the exercise intervention, six (10%) did 
not use the service at all, and 24 (40%) used the full allocation of 18 sessions.
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Table 1.3. NHS and PSS resource use by allocation group.
Usual care EXIMS
n % n %
O utpatien t visits
Missing values 13 21.7% 12 20.0%
0 12 20.0% 16 26.7%
I 14 23.3% IS 25.0%
2 9 15.0% 7 11.7%
3 I 1.7% 4 6.7%
4+ II 18.3% 6 10.0%
Total 60 100.0% 60 100.0%
Mean (SD) 2.0 (2.2) 1.4 ( 1.4)
Median (IQR) 1 (0- 2) 1 (0-2)
GP visits
Missing values 13 21.7% 12 20.0%
0 22 36.7% 28 46.7%
I II 18.3% 9 15.0%
2 7 11.7% 2 3.3%
3 4 6.7% 1 1.7%
4+ 3 5.0% 8 13.3%
Total 60 100.0% 60 100.0%
Mean (SD) 1.4 (2.6) 1.3 (2.3)
Median (IQR) 1 (0-2) 0 (0- 1)
C om m unity  visits
Missing values 13 21.7% 12 20.0%
0 34 56.7% 34 56.7%
I 3 5.0% 5 8.3%
2 3 5.0% 4 6.7%
3 2 3.3% 3 5.0%
4+ 5 8.3% 2 3.3%
Total 60 100.0% 60 100.0%
Mean (SD) 1.3 (3.2) 0.7 (1.5)
Median (IQR) 0 (0- 1) 0 (0- 1)
Social care hours
Missing values 13 21.7% 12 20.0%
0 42 70.0% 45 75.0%
I-20 I 1.7% 0 0.0%
2I - 4Q 0 0.0% 1 1.7%
41-60 0 0.0% 0 0.0%
61 + 4 6.7% 2 3.3%
Total 60 100.0% 60 100.0%
Mean (SD) 15.6 (57.8) 10.8(51.5)
Median (IQR) 0(0-0) 0(0-0)
Inpatient hospitalisations
Missing values 0 0.0% 0 0.0%
0 60 100.0% 56 93.3%
I-5 nights 0 0.0% 1 1.7%
5 nights+ 0 0.0% 3 5.0%
Total 60 100.0% 60 100.0%
Mean (SD) 0.0 (0.0) 0.78(3.61)
Median (IQR) 0(0-0) 0 (0-0)
A&E visits
Missing values 0 0.0% 0 20.0%.
0 59 70.0% 56 75.0%
I I 1.7% 4 0.0%
Total 60 100.0% 60 100.0%
Mean (SD) 0.02 (0.13) 0.07 (0.25)
Median (IQR) 0(0-0) 0(0-0)
Exercise in tervention (sessions)
Missing values 1 1.7%
0 6 10.0%
I-6 0 0.0%
7- I 2 5 8.3%
13- 17 25 41.7%
18 23 38.3%
Total 60 100.0%
Mean (SD) 14.6 (5.5)
Median (IQR) 17(14- 18)
NHS: National Health Service; PSS: Personal Social Services; IQ R: inter­
quartile range; EXIMS: Exercise intervention fo r people w ith multiple 
sclerosis; GP; general practitioner; SD: standard deviation.
325
1. 4.2 Cost-utility analyses
The average intervention cost per participant was £375 in the exercise group. 
There was a small increase in the wider NHS and PSS costs in the exercise 
group compared to the usual care control group (Table 1.4), which when 
combined with the exercise intervention cost resulted in a mean additional cost 
to the NHS and PSS of £466 (Cl: -£273 to £1310) compared to the usual care 
control group. At the end of the follow-up period, PwMS who were randomised 
to the exercise group experienced 0.538 QALYs compared with 0.492 QALYs 
for patients in the usual care control group, indicating no significant difference in 
health benefit (difference 0.046, -0.022 to 0.115). Although the point estimates 
in difference in costs and QALYs were not statistically significant, they suggest 
that the EXIMS intervention may be more beneficial in providing QALYs but also 
more expensive. The ICER which relates increased costs to a gain in QALYs 
was £10,137 per QALY gained (£466/0.046). This indicates that each QALY 
gained by providing exercise to PwMS will cost the NHS £10,137. The EQ-5D 
scores for the control and intervention group at each assessment point are 
reported in Table 1.5. The probability of being cost effective at £20,000 per 
QALY is 0.70, and 0.78 if the threshold is £30,000 per QALY. Figure 1.1 plots 
the 5000 replicated cost and QALY pairs (generated using bootstrap methods), 
together with two threshold lines at £20,000 and £30,000 per QALY. The figure 
shows that 11% of replicates suggest that the pragmatic exercise intervention 
generates health benefits at lower cost (intervention dominates usual care). 
Figure 1.2 provides a cost-effectiveness curve, which indicates the probability of 
the intervention being cost effective for a range of maximum acceptable ICERs 
(MAICERs).
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Table 1.4. Cost-utility analysis.
Usual care n=60 
Mean (SD)
EXIMS n=60 
Mean (SD)
Difference (95% Cl)
Intervention cost - - 375 7 375 (360 to 388)
Outpatient costs 437 67 290 42 -146 (-306 to 7)
Primary care costs 50 14 46 12 —4 (—40 to 30)
Community care costs 57 19 30 9 -26 (-69 to 13)
Social care costs 389 2I0 270 184 -119 (-677 to 426)
Hospitalisation costs - - 392 265 392 (-321 to 1780)
A&E costs I I 3 2 2 (-2 to 7)
TOTAL cost (£) 932 225 1398 337 466 (-273 to 1310)
QALYs 0.492 0.028 0.538 0.021 0.046 (-0.022 to 0.115)
ICER, cost per QALY gained £10,137
N et monetary benefit (probability > 0)
Willingness to pay (k) -  £20,000 per QALY £453 0.75
Willingness to pay (X) = £30,000 per QALY £913 0.78
EXIMS: Exercise intervention for people with multiple sclerosis; SD: standard deviation; Cl: confidence interval; A&E: accident and emergency; 
QALY: quality-adjusted life year; ICER: incremental cost effectiveness ratio.
Table 1.5. EQ-5D scores.
Baseline 12 Weeks’ post-baseline Six months’ post-baseline
Usual care Intervention Difference Usual care Intervention Difference Usual care Intervention Difference
Mean 0.642 0.634 -0.008 0.684 0.744 0.060 0.734 0.739 0.005
SD 0.255 0.279 0.024 0.263 0.204 -0.059 0.252 0.249 -0.003
Minimum -0.016 -0.181 -0.165 -0.016 -0.016 0.000 -0.016 -0.181 -0.165
Lower quartile 0.587 0.516 -0.071 0.587 0.656 0.069 0.656 0.656 0.000
Median 0.717 0.725 0.009 0.727 0.727 0.000 0.727 0.727 0.000
Upper quartile 0.796 0.779 -0.017 0.850 0.919 0.069 0.919 0.919 0.000
Maximum 1.000 1.000 0.000 1.000 1.000 0.000 1.000 1.000 0.000
SD: standard deviation.
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Table 1.6. Scenario analysis results
Scenario i : Stratified 
by EDSS score
Control Intervention ICER Willingness to  pay
Costs (£) QALYs Costs (£) QALYs £20,000 per QALY £30,000 per QALY
EDSS < 4.0 434 0.592 1153 0.588 Dominated - 794(0.18) -832 (0.25)
EDSS > 4.0 1378 0.406 1726 0.474 £5092 1017(0.80) 1699 (0.84)
Scenario 2: Stratified Control Intervention ICER Willingness to  pay
by GLTEQ score
GLTEQ > 14 839 0.504 1253 0.548 £9558 £453 (0.65) £886 (0.72)
GLTEQ < 14 1155 0.464 1766 0.517 £11,470 £454 (0.63) £987 (0.70)
Scenario 3: Societal Control Intervention ICER Willingness to  pay
perspective 1660 0.492 2804 0.538 £24,897 -£225 (0.43) £235 (0.58)
Scenario 4: Private Control Intervention ICER Willingness to  pay
provision (£495 932 0.492 1481 0.538 £11,938 £371 (0.67) £830 (0.76)
per patient per
programme)
Scenario 5: SF-6D Control Intervention ICER Willingness to  pay
utility  scores 932 0.449 1398 0.473 £19,783 £5 (0.50) £241 (0.63)
EDSS: Expanded Disability Status Scale; QALYs: quality-adjusted life years: GLTEQ: Godin Leisure Time Exercise Questionnaire; ICER: incremental 
cost effectiveness ratio.
1.4.3 Scenario analysis
The results of the scenario analyses are shown in Table 1.6. Two sub-group 
analyses were undertaken, splitting the trial participants by disease severity 
(EDSS < 4.0 (control n = 22, intervention n = 20) and EDSS > 4.0 (control n = 
38, intervention n = 40)), and by level of physical functioning (GLTEQ >14  
(control n = 35, intervention n = 34) and GLTEQ < 14 (control n= 25, 
intervention n = 26)). In the less severe disease activity group (EDSS < 4-0), the 
intervention was more expensive and generated less QALYs (dominated). In 
the more severe disease activity group (EDSS > 4.0), the intervention was more 
costly (+£348) and more effective (+0.068 QALYs), resulting in an ICER of 
£5092 per QALY gained. These results suggest a clear difference in the cost 
effectiveness of the intervention when comparing these two patient sub-groups.
Likewise, in the more physically active sub-group (GLTEQ > 14), the
intervention was more costly (+£414) and more effective (+0.044 QALYs),
resulting in an ICER of £9558 per QALY gained. In the less physical active sub­
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group (GLTEQ < 14), the intervention was more effective (+0.053 QALYs) and 
more costly (+£611), resulting in an ICER of £11,470. These results do not 
suggest that it is possible to define a more cost-effective subgroup of PwMS 
based on their baseline GLTEQ score.
A scenario analysis with a societal perspective was undertaken. Personal costs, 
as well as time-off-work productivity costs were included. This saw an increase 
in costs in both trial groups, with the exercise group more costly compared to 
the usual care control group (+£1144), and a resulting ICER of £24,897 per 
QALY gained.
A scenario analysis was undertaken with an alternative intervention cost. In the 
basecase analysis, the cost of £408 per patient per programme was derived 
using NHS facilities. An alternative option for providing the service is via private 
facilities and third-sector providers. An estimate of the cost of private provision 
from two local gyms was obtained resulting in an approximate estimate of £495 
per patient per programme. As expected, the cost of the intervention group 
increased, resulting in an ICER of £11,938 per QALY gained compared to the 
control group.
Finally, to assess sensitivity in the measure of HRQoL, the SF-6D was used. 
The analysis was robust, with the intervention continuing to provide more 
QALYs (+0.024 QALYs). The ICER for the intervention when using the SF-6D 
was £19,783 per QALY gained compared to the usual care control group.
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1.5 Discussion
In this economic evaluation, the exercise intervention appeared to be both more 
effective and more expensive than usual care alone; however, the differences in 
costs and benefits between the treatment groups were mostly small and not 
significant after nine months. The ICERs remained well below the generally 
accepted standard of £20,000 per QALY gained, with the intervention having a 
high probability of being cost effective. Therefore the intervention may be 
regarded as potentially cost effective for PwMS. The low amount of uncertainty 
relating to the cost-effectiveness results, as highlighted by the high probability of 
exercise being cost effective, seems counterintuitive in the face of non- 
statistically significant cost and QALY differences. However, this is due to the 
purpose of the analysis being to compare against a positive ratio of incremental 
costs and effects (typically set at £20,000 per QALY), rather than tests of no­
difference in effects.13
As is common with economic evaluations conducted alongside clinical trials, the 
accuracy of the resource use data may limit the usefulness of the results. There 
is a debate in the literature regarding the appropriateness of methods to collect 
resource use data in trial participants.14,15 Because of the finite resources for 
conducting this clinical trial, a pragmatic method was chosen, with participants 
asked to complete questionnaires with a three-month recall period. This method 
can lead to inaccurate results, as well as incomplete data. The questionnaire 
was also used to ask participants about any personal expenditure due to MS, 
and any time off work they had in the previous three months. Only a few 
participants reported any personal expense or time off work, which lead to 
skewed and uncertain estimates of cost effectiveness for the analysis with a 
societal perspective.
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The costing of the intervention is potentially limited because of the variation in 
options for implementation of the service. Micro-costing for NHS provision was 
undertaken because the service does not fit within current NHS tariffs. The 
micro-costing approach uses national average data and may not be an accurate 
reflection of the true cost to the NHS if the service was commissioned. 
Alternatively, the service could be provided privately, and the cost estimates 
included in the scenario analysis for this option use Sheffield UK prices in terms 
of staff and local gym hire. If local gyms were to be used, the suitability and 
convenience for PwMS is important and staff would have to be appropriately 
trained to deliver the intervention. The scenario analysis undertaken found that 
the cost-effectiveness results were generally robust to changes in the cost of 
the EXIMS intervention.
This analysis only assessed the cost effectiveness of the EXIMS intervention 
across nine months. Because the intervention costs are borne up front, if results 
were to be extrapolated, the intervention would become even more cost 
effective, even if the effects diminished over time. In this respect, the analysis is 
a conservative estimate of cost effectiveness and the long-term benefits of the 
intervention have not been fully explored. Furthermore, the sub-group analyses 
highlighted that in less-active participants, and in more severely affected PwMS, 
the intervention is likely to be most cost effective, and potentially cost saving. In 
these sub-groups, the cost may be offset by a reduction in the substantial NHS 
and PSS resources that these participants require.
In conclusion, the results of this study suggest that this pragmatic exercise
intervention could feasibly be provided by the NHS for PwMS and has a high
probability of being cost effective. The results are generally robust to whether
EXIMS is provided by the NHS or provided privately. Although the long-term
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health impact of EXIMS has not been established, a more active lifestyle and 
the confidence to undertake home-based exercise are likely to lead to improved 
fatigue management, HRQoL benefits and potential cost benefits for the NHS.
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